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Abstract 
CV -N is an 11 kDa, anti-HIV protein that binds strongly to the envelope glycoprotein, 
gp120, expressed on the outer surface of the free virion and also on HIV-infected cells. As 
such, it represents an important lead for development of anti-HIV therapeutics. Marine 
toxins such as the halichondrins have potent in vivo cytotoxicities and are lethal to cells. 
, 
The combination of this potency of the marine toxins with the unique targeting capability 
of CV -N has been harnessed to produce conjugates that have the potential to selectively 
target and eliminate HIV-infected cells. 
Three forms of the protein were developed; the native protein itself, a derivative 
recombinantly produced inE. coli with an extra cysteine at the C-terminal (CV-N-Cys) and 
CV-N with the lysine side chain amines converted into thiols (thiolated-CV-N). 
To facilitate release of the toxin within infected cells an enzymatically-cleavable pH-
dependent biolinker was incorporated separating the toxin from the protein. The 
chemistry required for incorporation of protein, biolinker, and toxin, was established 
through synthesis of fluorescently labelled conjugates capable of reaction with CV-N. 
Biological testing of these derivatives showed no interference with the anti-HIV activity of 
the CV-N when conjugated in these model compounds. Synthetic strategies were 
developed to produce two derivatives of norhomohalichondrin B amine, both containing 
the cleavable biolinker, but with activation from succinimidyl esters and maleimido groups 
respectively. 
Native CV-N was reacted with the succinimidyl ester derived toxin construct to produce a 
CV-N-biolinker-toxin conjugate. The maleimido derivative toxin construct was reacted 
with both CV -N-Cys and thiolated-CV -N to produce closely related CV -N-toxin 
conjugates. Investigations into the binding properties and cell toxicities of these conjugates 
is currently underway. 
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Chapter 1 
INTRODUCTION 
1.1 HIV 
1.1.1 HIV, AIDS - A Global Perspective 
As of December 2000 the World Health Organisation (WHO) put the number of people 
infected with the HIV virus at 36.1 million. This is more than 50% higher than the 1991 
projection using the data available at the time. The following snapshots of the effect of the 
virus demonstrate the impact this epidemic has had around the world. l 
III Since the beginning of the epidemic 21.8 million people have already died, 4.5 
million of them children under 15 years of age. 
III In the year 2000, 5.3 million people became newly infected while 3 million died. 
III In all parts of the world except sub-Saharan Africa, there are more men infected 
with HIV than women. 
III During 2000, more new infections have been registered in the Russian Federation 
than in all previous years of the epidemic combined. The total number of people 
living with HIV I AIDS in Eastern Europe and countries of the former Soviet Union 
was 420,000 in 1999 but after 2000 is estimated to be 700,000. Intravenous drug 
use is the prevalent method of transmission in this region. 
It For the fIrst time the number of new infections in sub-Saharan Africa has declined 
with 3.8 million infected in 2000 compared to 4 million the year before. However, 
this region contributes 25.3 million of the global 36.1 million people infected. The 
prevalence rate for adults 15-49 years old living with HIV/AIDS in this area is 
8.8%. 
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&I In South Africa this epidemic is projected to reduce economic growth by 0.3-0.4% 
annually and by 2010 the GDP will be 17% lower than it should have been, wiping 
US$ 22 billion off the country's economy. 
• III Abidjan AIDS costs represented between 0.8% and 3% of the wage bill in 1997. 
A survey of five Ethiopian firms in the mid 1990's found AIDS responsible for 
more than half the burden of sickness over a five-year period. In Tanzania a similar 
survey showed a three-fold increase in medical costs per employee while burial 
costs for the companies increased five-fold. 
• While the prevalence rate for East Asia and the Pacific is only 0.07% there is ample 
room for growth. The use of illicit drugs and the sex trade are extensive, as is the 
migration and mobility within and across borders. China, which virtually wiped out 
sexually transmitted diseases in the 1960's, is now seeing a steep rise that could 
translate into higher HIV levels in future years. The hundred million or more 
people on the move within the country may exacerbate this situation. 
It The Caribbean has the highest rate of infection outside of Africa with a 2.3% 
incidence. 
&I For Western Europe and North America the new infection rate has stalled while the 
prevalence rate has risen slightly in both regions mainly due to anti-retroviral 
therapies that are keeping HIV infected people alive longer. In an era where few 
young gay men have seen friends die of AIDS, and some mistakenly view anti-
retrovirals as a cure, there is growing complacency about the HIV risk. 
An analysis of the above facts reveals that the devastation wrought by HIV is very real, 
whether measured by the future prospects of a child or the bottom line of a company's 
ledger. Hundreds of millions of research dollars around the world continue to be spent on 
developing therapies to control the virus and on vaccines to prevent infection. The aim of 
this thesis is to contribute to this global effort so the 21 st century may provide solutions to 
this devastating epidemic that has plagued the latter half of the 20th century. 
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1.1.2 The HIV Virus 
The human immunodeficiency virus (HIV) is a member of the lentivirus genus of the 
Retroviridae family. A major feature characterising the Retroviridae family, is that rather 
than house DNA as their store of genetic material, retroviruses utilise RNA as their source 
of genetic information. Lentiviruses have certain characteristics that distinguish them from 
other retroviruses. The most prominent morphological difference is the cylindrical or cone 
shaped nucleoid in the mature virion. Other differences include the encoding of several 
extra genes not present in other retroviral genomes and a biphasic course of viral gene 
expression. One of the first viruses found in nature was a lentivirus, the equine infectious 
anaemia virus, which was discovered in 1904.2 Lentiviruses infect a diverse group of 
animals including horses, sheep, goats, cows, cats, and primates.3, 4 Within this group of 
animals the lentiviruses cause a wide variety of diseases. HIV-I and HIV-2 are the only 
known human lentiviruses. Of the two subtypes, HIV -1 is the predominant form of the 
virus found throughout the world, while HIV-2 has been primarily isolated from West 
Africa, the Caribbean and South America. Both agents are associated with the 
development of progressive immunologic deterioration, but HIV-2 tends to have a longer 
incubation period5 and is not as easily transmitted perinatally as HIV-L6 
The earliest documented case of AIDS known to have been caused by the HIV virus was in 
1959 in a man from Kinshasa, Democratic Republic of Congo. However, it was not till the 
early 1980's that doctors in Los Angeles and New York were beginning to notice a pattern 
of rare pneumonia, cancer and other unfamiliar illnesses amongst young gay male 
patients.7•9 It was noted that all of the illnesses documented were rare in people who have 
healthy immune systems. The search for the cause of AIDS focused on a wide variety of 
viruses including retroviruses but also herpesviruses and parvoviruses that were known to 
cause immune deficiency.lO, 11 Even after the discovery of HIV in 1983 it still took a year 
for its classification as a lentivirus. 12-15 
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1.1.3 HIV Virion Structure 
Each HIV Vlflon is approximately 100 run in diameter. Externally the surface usually 
consists of 72 knobs containing trimers of the envelope glycoproteins. 16 There are two 
extensively investigated surface glycoproteins, gp 120 and gp41. These are derived from a 
single precursor of MW 160,000 that is cleaved inside the infected cell into the gp 120 
external surface envelope protein and the gp41 transmembrane protein. As mentioned, on 
the surface of the virion these are present in a trimeric form of gpl20 with a single gp41 
b~;JI''''''----- gp120 binds to ~j surface of host 
cell 
--- gp41 
malrix proteins 
viral envelope 
---- derived from 
tlost cell membrane 
viral core containing 
genetic material 
and enzymes 
Russell Kightley Media 
Figure 1.1 Stylised HIV virion structure 
molecule buried between the three gpl20 proteins. The gp120 protein is comprised of five 
variable regions (VI-V5) that are exposed on its surface and are interspersed with five 
conserved regions. Gp 120 remains attached to gp41 through a series of non-covalent 
interactions located in both the N- and C-tennini. The inner portion of the viral membrane 
is surrounded by a myristoylated p 17 core (Gag) protein that provides the matrix for the 
viral structure. 17, 18 Within this is the p25 (or p24) capsid (Gag) protein that contains two 
identical RNA strands with which the DNA polymerase (P64/p51, also called Pol or 
reverse transcriptase) and nucleocapsid proteins (p9, p6) are closely associated. Overall the 
Chapter 1 - Introduction 5 
virion has approximately 100 times more p25 than gp120, and 10 times more p25 than 
polymerase. l9 
1.1.4 Origins of 
It is generally agreed by most (but not all) that HIV-l and HIV-2 represent novel, zoonotic 
introductions to the human populations within the last 100 years.20 The most closely 
related animal lentivirus to HIV-l is SIVcpz of chimpanzees. Of the SIVcpz genomes 
sequenced, the subspecies Pan troglodytes troglodytes is the closest to HIV-l in genetic 
makeup?l Within the human population there are three major groups ofHIV-l, coded M, 
N, and O. The group M represents all the clades (subtypes) from A to H that have spread 
to cause the worldwide pandemic.22 The related subgroups 0 and N are by contrast largely 
confined to Cameroon, Gabon and neighbouring countries which happen to be the same 
areas as the natural habitat of P. t. troglodytes.23 A comparison of the gene sequences of 
groups M, N, and 0, show that they are as distinct from each other as they are from 
SIVcpz. (Figure 1.2)21 This would tend to suggest that they have derived from three 
CPZ.ANT 
o ICM.MVP51 
LCM.ANT70 
N @M.VBF30 
CPZ.US CPZ.GAB 
1 0% difference 
AE A 
Figure 1.2 Genetic variability of HIV -1 subtypes 
M 
separate introductions from chimpanzees to humans, but only one has become pandemic.24 
The less common HIV-2 can also be subdivided into a number of major groups which 
appear to represent separate zoonoses from a different primate host, the West African sooty 
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mangabey which is infected with SIV smm. There are many African monkeys that can 
harbour SIV strains but so far little evidence that they have crossed to humans. For 
example, despite 35 years use of unscreened green monkey kidneys to propagate poliovirus 
for the live attenuated vaccine, SIVagm has not crossed to humans. There is a hypothesis 
that HIV emerged from contaminated polio vaccine but the link appears very tenuous?5 
1.1.5 Pathogenesis of HIV 
The major reason why HIV is so problematic is that the target is the CD4 antigen which is 
present on several important cell types, particularly the CD4+ lymphocytes (also known as 
T-helper cells or T4 or CD4 T-cells) that are crucial to the body for a variety of host-
immune responses. Over time the virus leaves the immune system with a number of CD4+ 
lymphocyte cells that do not function effectively. Depletion of these cells leads to a 
progressive immunoincompetence which has the dual effect of not only impairing the 
host's ability to inhibit HIV replication but also allows the emergence of opportunistic 
infections which characterise the onset of AIDS. An average person will have a T4 cell 
count of between 400 and 1200 in 1 mL of blood. Once the count falls below 200, the risk 
of opportunistic infections greatly increases. Without treatment, the average time from 
becoming HIV -infected to developing immune deficiency (AIDS) is around 10 years. 
ACU E 
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Figure 1.3 CD4 T cell count vs HIV viral load 
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As well as measuring the levels of CD4+ lymphocytes in the blood there is an assay that 
measures the amount of HIV-l RNA present in the plasma. Currently, there are three 
commercially available varieties of this assay technique. These are the reverse 
transcriptase-polymerase chain reaction (RT-PCR), the branched DNA (bDNA), and the 
nucleic acid sequence-based amplification (NASBA)?6 The relationship between average 
viral load and the time from seroconversion to death is remarkably constant.27 A study of 
infected individuals with identical CD4+ lymphocyte cell counts found that those with a 
high HIV-I RNA plasma level died more rapidly (mean of 6.8 years) than those with a low 
level (time to death> 10 years).28 However, it has been estimated that only 2% of HIV is 
circulating in the blood. 
During all phases of infection the average daily production of new HIV -1 virions is on the 
order of 1 x 1010 partic1es.29 This high level of output of virions contrasts with the 
estimated 1-2 x 109 CD4+ lymphocyte cells eliminated per day. 30, 31 This in effect 
translates to 1% of the body's complement ofCD4+ lymphocyte cells being destroyed and 
replaced every day over a period of many years. Another cell type that expresses CD4 
antigens is the tissue macrophage, derived from monocytes circulating in the blood. These 
macrophages act as antigen-presenting cells and function as scavengers, but once infected 
act as an important reservoir of virus in the body.32 It is the infection of these 
macrophage(s) that most probably accounts for the wasting syndrome in AIDS due to 
aberrant signalling of short range molecules such as cytokines and chemokines that traffic 
between different blood and tissue cells. Dendritic cells, which are derived from 
monocytes, also have CD4 antigens and so also become infected with HIV. After initial 
infection it is the dendritic cells that carry HIV to the lymph nodes where CD4+ 
lymphocytes become infected.32 Using quantitative image analysis, a virus pool of 10-40 
times larger than the pool of infected CD4+ lymphocytes has been estimated to be trapped 
on the surface of follicular dendritic cells (FDC).33 This pool may be important for the 
spread and perpetuation of the viral infection within lymphoid tissue. 
While the CD4 receptor is important for HIV attachment to the cell surface it was 
recognised early on that although it is necessary, it is not sufficient for cellular entry.34 
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After much research by many groups, there fmally emerged not one but two co-receptors 
that mediate fusion between virion and cell. They are CXCR435 (also known as fusin) and 
CCR5 (also known as CC_KR_5).36, 37 The CXCR4 receptor is utilised by syncytium-
inducing (SI) primary HIV -1 isolates and laboratory-adapted HIV -1 strains. This variety of 
virus is termed T-tropic or X4,38 and replicates well in primary T-cells and immortalised T-
cell lines. In contrast, most non-syncytium-inducing (NSI) HIV -1 primary isolates use the 
CCR5 chemokine receptor and replicate within both macrophages and primary T cells but 
not in immortalised cell lines. For this reason these are referred to as macrophage (M)-
tropic or R5 viruses. Most HIV strains of each subtype use CCR5 as their co-receptor but 
in about 50% of people that progress to AIDS the more virulent X4 strain emerges later in 
the course of the disease. This extra virulence is what probably hastens the depletion of 
CD4+ cells and emergence of AIDS symptoms. There are certain people that carry 
defective CCR5 receptors39, 40 and about 1 in 400 of the Caucasian population (but rare in 
Africans) are homozygous for the 32 base-pair deletion.41 Such people are highly resistant 
to infection and those who do become infected, do so through X4 strains that utilise the 
CXCR4 receptor.42 
1.1.6 Life Cycle of HIV 
The life cycle of HIV (Figure 1.4) begins at the surface of the host cell when the gp120 
glycoprotein coating the virus binds to the CD4 receptor that is present on many 
lymphocytes. This binding is also facilitated by non-specific interactions between 
envelope proteins and other cell surface molecules such as heparan, sulfate proteoglycan, 
galactosyl ceramide, mannose receptors and adhesion molecules.43 A very detailed 
understanding of just how gp 120 interacts with CD4 was afforded with the crystal structure 
of a trimolecular complex consisting of the core of gp 120, the V IIV2 domains of CD4 and 
the Fab fragment of a neutralising monoclonal antibody (mAb) designated 17b.44 An 
analysis of this crystal structure reveals that the core of gp 120 is composed of an inner and 
outer domain joined by a j3-sheet, referred to as the bridging sheet.44 The inner domain 
faces the axis of the trimer and presumably gp41, while the outer domain is exposed on the 
Chapter I - Introduction 
• 
... ~ ... . ' , 
.. . - . 
. . . 
D4 
Drugs under 
&tudywould 
block binding 
Some existing drugs 
Inhibit reverse 
transcriptase 
"".~~ REVER~E 
TRAtlSCRIPTASE 
Figure 1.4 HIV life cycle 
9 
." 
. . 
Bartlett, J. C. and Moore, R. D. 
surface.44 The CD4 receptor binds to gp120 in a recessed cavity constructed from elements 
of both major domains and the bridging sheet.44 This deep pocket, which is occupied by 
the aromatic side chain of Phe43 of CD4, is very important for gp120 binding.44 Unlike 
other portions of gp120 this cavity is highly conserved making inhibitors of this pocket a 
highly attractive target. Previous, less specific gp 120 inhibitors have shown poor potency 
against diverse clinical isolates, probably due to the vast genetic diversity present in the 
HIV envelope protein. 
The binding to CD4 induces a conformational change within gp120, allowing interaction 
with either of the two chemokine receptors (CCR5 or CXCR4) to form a trimolecular 
complex (CD4-gpI20-CCR5 /CXCR4). An excess of the ligands (natw-al or synthetic) for 
these receptors can competitively inhibit this step.45-48 AMD-3100, a bicyclam analogue, 
that inhibits the CXCR4 chemokine receptor is one of these promising ligands and has 
entered phase II trials in 2000 and will be launched in 2003 as a potential treatment for HIV 
infection if trials are successful.49 
After binding to the chemokine receptors, the gp 120 is thought to be stripped off the virion, 
exposing a hydrophobic domain at the N-terminus of gp41 which in tum mediates fusion of 
the virus and host cell membranes, therefore allowing the viral core access to the host cell 
cytoplasm. The genetic material of the HIV, which like all retroviruses is RNA, is now 
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released and undergoes reverse transcription into double stranded DNA. The enzyme that 
performs this transformation (reverse transcriptase) is the target of several anti-retroviral 
drugs that are now in clinical use. These reverse transcriptase inhibitors will be discussed 
later. Now that the genetic material has been converted into DNA it enters the nucleus of 
the host cell where it is spliced (integrated) into the genetic material of the cell by the 
enzyme integrase. Inhibitors of this enzyme are also being developed as anti-retroviral 
therapies.50 At this stage it is possible that the HIV may persist in a latent state for many 
years. These latently infected cells are the major barrier to eradication or cure of HIV. 
Activation of these cells using the integrated DNA, or provirus, leads to the transcription of 
viral DNA into messenger RNA (mRNA), which is then translated into viral proteins and 
RNA. The viral RNA and viral proteins now gather at the cell membrane and begin to 
form a new virus. Compounds are being developed that target the highly conserved HIV-l 
nuCleocapsid protein zinc fmgers involved in genome packaging and virus assembly.51, 52 
A third enzyme, HIV protease, cleaves some of the viral proteins into their functional 
forms. Protease inhibitors block this crucial maturation step of the life cycle. Following 
assembly at the cell surface, the new viral particle buds from the cell, ready to infect others. 
1.1.7 Current and Future Therapies 
There are currently fourteen compounds that have been approved for the treatment of HIV 
infections. Of the fourteen, six are nucleoside reverse transcriptase inhibitors (NRTl's) 
that are competitive inhibitors of the normal substrates (dNTP's) after their intracellular 
conversion to the 5' -triphosphate form. These are zidovudine (AZT) (1), lamivudine 
(3TC) (2), abacavir (ABC) (3), zalcitabine (ddC) (4), didanosine (ddI) (5), and stavudine 
(d4T) (6). There are three non-nucleoside reverse transcriptase inhibitors (NNRTI's) that 
interfere with reverse transcriptase at a non substrate binding, allosteric site. They are 
nevirapine (7), delavirdine (8) and efavirenz (9). The final class are the protease inhibitors 
(PI's) that prevent the cleavage of precursor to mature HIV proteins and therefore weal(en 
the infectivity of the virions produced when these inhibitors are present. The aspartyl 
protease responsible for the proteolytic cleavage has been examined at the atomic level53 
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and subsequent rational design of inhibitors tookplace.54 The five PI's are saquinavir (10), 
ritonavir (11), indinavir (12), nelfinavir (13) and amprenavir (14). All of the fourteen 
compounds are synthetic and not derived from natural sources. 
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Drug resistance became a problem when some of the earlier drugs, above, were taken 
singly. As HIV replicates itself, mutations occur in a small percentage of new virus 
particles formed. Out of the mutated viruses there may be some that are unaffected by the 
particular anti-retroviral in use. The original viruses will die off but the new drug resistant 
mutated form will continue to replicate and the viral load will again increase. Therefore a 
new strategy, HAART (Highly Active Anti-Retroviral Therapy), was developed to try and 
overcome the growing drug resistance. 55 Studies clearly showed that a combination of 
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three drugs ('triple cocktail') were much more effective than one drug used alone or two 
drug combinations.56, 57 This HAART strategy is now the standard treatment for HlV 
infection in the western world. It was thought that this therapy might have lead to a 'cure' 
if HlV could be completely eliminated but unfortunately viremia can be reactivated 
following cessation of treatment. 58 There is also the problem of imperfect adherence to the 
prescribed regimen of complex timetables and the often severe side effects of current 
therapies. This can lead to the increasing resistance of the virus particularly if only one 
drug is taken while another is not, due to deleterious side effects. 59 
Another characteristic, crucial to survival of the HlV -1 virus, that has been hinted at 
earlier, is the large reservoir of latently infected cells present in the body. Virus production 
is a dynamic process involving continuous rounds of infection of, and replication in, CD4+ 
T cells with a very rapid turnover of both virions and infected cells. With effective anti-
retroviral therapy this process is largely, but not completely interrupted and after several 
months plasma levels ofHlV RNA become undetectable in many patients. However, there 
are several potential reservoirs, both cellular and anatomically that may contribute to long-
term persistence of HlV _1. 60 These include areas of the central nervous system and the 
male urogenital tract. By far the most troublesome reservoir is that of the latently infected 
resting memory CD4+ T cells carrying integrated HIV-1 DNA.60 With a half-life of 44 
months, this reservoir would take over 60 years of continuous treatment with conventional 
anti-retrovirals to be eliminated. 58 With the side effects and toxicities of current 
therapeutics this is a completely unrealistic hope. 
A potential strategy for eliminating the virus along with the latently infected cells is to 
force the reservoir into a fully productive state, and to therefore be able to eliminate it with 
current drugs. This has already been investigated with the immune-activating compound 
interleukin-2.61 , 62 An alternative approach is to use a cytoreductive treatment such as 
cyclophosphamide that may reduce the size of the latent HIV -1 reservoir and thereby 
facilitate its elimination. 63 
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1.1.8 mv Vaccine Development 
Since 1987, more than 40 individual vaccines for HIV have been studied in clinical trials 
worldwide. The US has committed itself to developing such a vaccine by the year 2007. 
Currently, however, there are only a small handful of phase III efficacy trials that have been 
initiated so far. 
There are several major impediments to developing a successful vaccine for HIV-l. The 
first of these is the constant variability of the virus within the individual through constant 
mutation and recombination. Therefore, the significance of strain variation needs to be 
estimated in order to ensure the vaccine is capable of eliciting the correct response to the 
particular strain present. Secondly, the multiple virus subtypes make it difficult to design a 
vaccine that will target all of them. Investigations into the conserved regions of HIV genes 
to fmd proteins common to all or most subtypes will provide a better target, but if not 
found, then a vaccine 'triple cocktail' approach may be necessary. The easiest way to 
design an effective vaccine is to know what immune responses protect against it, and tailor 
a vaccine to turn on that specific response. This leads to the third problem as these so-
called "correlates of immunity" have not being precisely identified for HIV and with no 
known documented case of complete recovery there remains the distinct possibility that a 
natural protective state does not exist. There are, however, HIV positive people who 
remain clinically asymptomatic over a long-term period and more importantly, people who 
have been multiply exposed but still remain uninfected. Studies on the immune response 
of these individuals could prove particularly useful in fmding the correlates of immunity. 
Fourthly, as HIV can exist in the body as both a free virion and within an infected cell, any 
vaccine must activate both am1S of the immune system. The first arm is humoral immunity 
whereby B-cells make antibodies to defend against the free virus. The other arm is cellular 
immunity that uses T helper cells (CD4+ T cells) and T killer cells (Cytotoxic T 
Lymphocytes, CTL's) to organise the immune response and attack infected cells. The most 
difficult challenge for a successful HIV vaccine is that the target of HIV is the immune 
system itself, in particular the T helper cells that instead of organising a defence are being 
modified or destroyed. As over 80% of transmission of the HIV virus arises sexually,64 a 
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more daunting prospect is that a third type of immunity, mucosal immunity, may have to be 
stimulated. The immune cells lining the mucous membranes of the genital, respiratory, 
digestive, and reproductive tracts and those in the nearby lymph nodes are the body's first 
line of defence against infectious organisms. They produce different immune responses 
that are not well understood. The final hurdle to overcome is the lack of an ideal animal 
model in order to test vaccines against the introduction of a live virus. 
The most extensively studied vaccine candidate is the recombinant gp120 subunit vaccine 
AIDSV AX developed by VaxGen.65 They were the first to initiate a phase III trial for an 
AIDS vaccine in 1998 and followed this with a second phase III trial in Thailand in 1999.66 
Basically the recombinant gp120 (and also gp160) are used to evoke an immune response 
that will then trigger a larger attack on the free virus and infected cells.65 Comparable to 
this method is the use of peptide epitopes that mimic only part of the HIV envelope instead 
of using the whole. However, peptide vaccines generally have several problems to 
overcome such as low immunogenicity, difficulty in translating results from animals to 
humans, extensive genetic variability of HIV, and lack of important structural 
conformation of some neutralisation epitopes of HIV. Another approach to developing 
vaccines is to use DNA expression plasmids that encode HIV-l gene products that again, 
ultimately, are hoped to produce an immune response. After the first human trial67 by the 
Apollon company of HIV Gag/Pol DNA vaccines, additional trials are underway. Other 
companies such as Merck, Chiron and Pasteur Merieux Connaught are also at various 
stages of developing similar DNA type vaccines. Along similar lines to the DNA vaccines 
are live vector vaccines. These are harmless bacteria or viruses containing genes that will 
encode for HIV proteins. These proteins are presented to the immune system, just as 
proteins from a virus-infected cell would be. Therefore, these vector-based vaccines 
produce both a humoral and cellular immune response and have the added advantage of 
being able to elicit a mucosal immune response as this is the route of their infection. Such 
vaccines based on the canarypox virus have entered human clinical trials.68 The most 
controversial type of vaccine is the live-attenuated virus. While most licensed vaccines in 
use today are based on this concept there are serious safety issues with regards to HIV-l 
due to the potential for the vaccine to cause AIDS instead of prevent it. However, research 
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is ongoing to improve the safety of these types of HIV vaccines but no human trials are 
planned as yet. A slightly safer option is to use whole, killed HIV that is incapable of 
replication but which will elicit the required immune response. In much the same way as 
anti-retrovirals, what may turn out to be the best approach is combination vaccine therapies 
which are being researched with some current phase II trials underway using the gp 120 
protein plus the canarypox vectors.69 Using such combinations should hopefully stimulate 
both arms of the immune system and may have the benefit of not just having an additive 
but a synergistic effect. However, current approaches are mostly based on empiric 
observations and many complex clinical trial agreements would need to be established 
amongst the various manufacturers. 
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1.2 Cyanovirin-N 
1.2.1 Discovery and Isolation 
In 1992, Dr G. Patterson, University of Hawaii, as part of a larger NCI (National Cancer 
Institute) programme for the collection and screening of cyanobacteria, prepared an extract 
from a sample of the blue-green algae Nostoc ellipsosporum.70 As part of the NCT's 
program to screen and evaluate natural product leads for anti-HIV activity, this extract was 
selected by the Laboratory for Drug Discovery, Research and Development (LDDRD) for 
further investigation due to its strong HIV inhibition and from preliminary indications that 
the active component was a protein.71 Further anti-HIV testing and screening using an 
XTT assay showed significant activity that was not due to any known anti-HIV compounds 
such as sulfolipids or sulfated polysaccharides.71 After dereplication and purification by 
reverse phase CI8 HPLC an active protein was isolated.7] The amino acid sequence of the 
protein was deduced from a combination of Edman degradation of both the intact protein 
and numerous overlapping fragments derived from endoproteinase digestion.7l • 72 The 
sequence obtained from these experiments matched an amino acid analysis of the protein. 71 
Finally, mass spectrometry (ESIMS) showed a molecular ion in agreement with the 
calculated mass/charge ratio for the calculated molecular weight. The 101 amino acid 
protein with a molecular weight of 11,009 Da was named cyanovirin-N (CV-N) (15).7] 
The sequence of CV -N (15) was compared to known proteins and gene products on various 
databases with no homologies beyond 8 continuous amino acids nor >20% total sequence 
homology for any known products. 71,72 
1.2.2 Chemistry and Biochemical Testing 
CV -N (15) is a particularly stable protein and can withstand multiple freeze-thaw cycles, 
organic solvents, 8M guanidine HCI, 0.5% SDS (detergent), 0.5% H20 2 or boiling (15min 
in H20) with no significant loss of anti-HIV activity.71 There are four cysteine residues in 
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CV-N (15) involved in two cross-linked disulfide bonds and only when these are reduced 
and alkylated with vinyl pyridine is the activity eliminated.?1 One of the more exciting 
aspects of CV-N (15) is the range of its anti-retroviral activity. CV-N (15) showed potent 
inhibition with all tested laboratory strains of HlV-l, HIV-2 and SlY. Also, CV-N (15) 
showed analogous antiviral activity against T-tropic, M-tropic and dual tropic HlV-l 
primary isolates.?l The specificity of CV-N (15) was also demonstrated by its lack of 
activity with a series of unrelated human viruses such as herpesvirus type l, 
cytomegalovirus and adenovirus type 5.71 
In experiments with HIV-lRF in CEM-SS cells it was found that CV-N (15) had a 
remarkable concentration-dependent inhibition of virus-induced cell killing that gave 
comparative decreases in the supernatant reverse transcriptase (RT) and viral core antigen 
(P24) levels.?1 In contrast, there was no observable toxicity or growth irIhibition of control 
cells at even the highest concentrations of CV -N (15) used?1 Also noted was the fact that 
for maximal anti-HlV activity, CV -N (15) had to be added before, or just after, addition of 
the virus. A delay of just 3 hours before addition of the CV-N (15) led to little or no 
activity. ?l 
Further experiments with co-cultivation of both chronically infected and uninfected CEM-
SS cells demonstrated that CV-N (15) was acting on both infected cell and virion. 
However, CV -N (15) was not preventing replication of the virus if a cell had already 
become infected prior to CV-N (15) dosing.?1 Boyd et al.?1 also showed that pre-
incubation of uninfected cells with CV -N (15) followed by washing still led to viral 
infectivity pointing towards CV-N (15) acting as a virucide.?1 This means it was acting 
directly on some constituent of the virus and preventing it from infecting otherwise 
susceptible cells. This combined evidence indicated that the target of CV -N (15) might be 
the gp120 envelope protein ofHIV exposed on both virion and infected cells. The timing 
suggested an interruption of the attachment and fusion process of both cell-cell and virus-
cell transmission. To back up this hypothesis, CV-N (15) was shown to bind to free gpl20 
irreversibly to form some kind of complex, which in its entirety proved to have no anti-
HlVactivity.?1 Of the initial experiments performed with CV-N (15), the most interesting 
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were ELISA (Enzyme Linked Immunosorbent Assay) experiments demonstrating that the 
binding site of CV-N (15) to gp120 appeared distinct from that of monoclonal antibodies 
directed to the immunodominant V3 loop and, just as importantly, distinct from the CD4 
binding site of gp120.n The failure of CV-N (15) to block gp120 binding to CD4, plus the 
previous experiments all pointed towards CV-N (15) acting after the initial binding of virus 
to cell, but before viral entry into the cell. 
A study by Mariner et aI?3 in 1998 set out to investigate more fully the interactions 
between virus-associated gp120 and its relationship with CD4.73 They demonstrated that 
CV-N (15) fails to block both soluble CD4 receptor (sCD4) binding to viral lysates 
(infected cells) and also binding of virions to cells. They concluded that CV-N (15) may 
bind to unique regions of gp120 which do not hinder its binding to CD4 receptors but 
prevent further fusion and viral entry. 73 However, the experiments did not prove that the 
binding activities measured, were in fact representative of the actual gp120-CD4 
interactions. In an additional experiment, virions were treated to lOO,OOOx ECso of CV-N 
(15) with no observed change in virion morphological structure, unlike treatment with 
sCD4, which decreases the density of envelope spikes.73 
Further work by Esser et aI.74 published a year later provided additional, more specific 
information about where CV-N (15) was (or was not) binding.74 It was shown that CV-N 
(15) had no inhibitory effects on several monoclonal antibodies (MAb's) directed to the 
CD4 binding site on gp120.74 Flow cytometry experiments indicated that CV-N (15) 
blocked binding of HIV virions at the Leu3A neutralising epitope on CD4, and furthermore 
blocked the Leu3A sensitive (CD4-dependent) component of virion binding to CD4+ 
cells.74 These results seemed to imply that CV-N (15) was interfering with gp120-CD4 
binding but this interpretation contrasts with another experiment by Esser et aI.74 that 
demonstrated that CV-N (15) did not impair sCD4 induced enhancement of exposure of 
certain gp120 epitopes. Therefore, according to this experiment, CV-N (15) did not affect 
sCD4 triggered conformational changes in gp120. The fmal experiment of this paper 
involved examining the effect ofCV-N (15) treated virions on the glycosylation-dependent, 
neutralising epitope by MAb 2G12.74 It was shown that CV-N (15) inhibited this epitope 
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region on gp 120, which is characterised by high-mannose sugars. The 2G 12 epitope 
overlies the stem of the V3 loop of gp 120 and comprises domains from the C2, C3, C4 and 
V4 regions.75, 76 It is also opposite, and 2sA away from the CD4 binding site. 76 The 
partial gp120 crystal structure indicates that there is a large, heavily glycosylated, 
immunologically silent region which may allow CV-N (15) to not only bind at or near the 
2G12 site but at other sites in this region.16,44, 76 
After the conflicting results yielded by Mariner et al.73 and Esser et al.74, a simple direct 
biochemical analysis was carried out by Dey et al.77 in an attempt to resolve the issue of 
what specific interactions were taking place. Specific binding of gp120 to CD4 on infected 
cells was followed and measured by Western blot assay techniques.77 This directly 
demonstrated that CV-N (15) was indeed blocking the interaction between gp120 and CD4 
ina dose-dependent fashion with no complications from possible co-receptor interaction, 
as the murine cells used did not possess them.77 They also noted that CV-N (15) had been 
postulated to interfere with post binding activities but no experimental evidence had yet 
been put forward to establish this theory. Using cells that only expressed CCRS but not 
CD4, it was shown that gp120 (preincubated with sCD4, necessary for binding) was 
strongly inhibited by CV-N (15).77 Because of the possibility that CV-N (15) may directly 
interact with the CCRS and CXCR4 receptors, an experiment was perfonned to detennine 
this. No direct interaction was observed for CV-N (15) with either receptor, showing that 
the blocking effects ofCV-N (15) are manifested only at the time of interaction with gp120 
and the co-receptors.77 To detenrune if the gp120-coreceptor binding inhibition was 
merely a consequence of CV-N (15) blocking sCD4 binding to gp120 (hence no activation 
or coreceptor interaction), an experiment was undertaken where CV-N (15) was added 
either before or after preincubation with sCD4.77 The results indicated that there was no 
difference between the two protocols with respect to fusion inhibition. The only other 
possible explanation apart from direct CV-N (15) interference of gp120 coreceptor 
interaction, is that the sCD4 binding is reversible and in dynamic equilibrium. This would 
mean even though CV-N (15) was added after sCD4, it may bind to gp120 as the sCD4 
dissociates, not allowing sCD4 to return, hence coreceptor blockage.77 However, granting 
this possibility, in combination these [mdings point to CV-N (15) having two distinct 
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inhibitory effects in the mV-I Env fusion process. The first is direct inhibition of gp120 
CD4 interaction post binding, and then further blocking of CD4 induced gp120 coreceptor 
interaction. Although previous studies had shown no other virus inhibition by CV-N (15) 
apart from mV-l, HIV-2 and the closely related SIV,71 it was thought with this new 
information about the dual blocking ability of CV -N (15), that further virus testing was 
warranted.77 The feline immunodeficiency virus (FIV) expresses only the CXCR4 receptor 
(no CD4) but even at lOnM concentrations, CV-N (15) was able to strongly block 
infection. 77 A two further non-immunodeficiency type viruses, MV and HHV -6, that 
express CD46 as the entry receptor were also both inhibited by addition of CV-N (15).77 
To add to this increasingly complex story O'Keefe et al.78 showed how CV-N (15) bound 
to both sgp120 and sgp4I in a highly specific, fully saturable, glycosylation dependent 
manner. The interaction with gp4I is 'similar to that of gpI20 in that the interactions are 
primarily electrostatic in nature and as both AG values are negative the binding appears 
spontaneous and favourable.78 The binding constant for CV-N (15) to gp41 also appears to 
be at least a factor of 20 less than for gpI20.78 A further distinction is the stoichiometric 
ratios of the two interactions. It appears through both optical biosensor studies and 
isothermal calorimetric (ITC) experiments that approximately five molecules of CV -N (15) 
bind to each gp120 while ITC showed the relationship with gp41 is one to one.78 No 
binding of CV-N (15) was detected when non-glycosylated gpI20 or gp4I was used.78 
However, in binding strongly to CV-N (15), there was no distinction noted between using 
two very different glycosylated forms of gpI20.78 The recombinant baculovirus-produced 
sgpI20 does not contain any O-linked oligo saccharides or any N-linked complex 
oligosaccharide chains found on the other H9 produced sgp12079, 80 but contains only high-
mannose type N-linked oligosaccharides,81 Other glycoproteins tested such as a-acid 
glycoprotein, horseradish peroxidase, human serum albumin, and human IgGs showed no 
binding whatsoever to CV-N (15).78 
The most recent paper by Mori and Boyd, published in 2001,82 manages to answer some of 
the questions surrounding interactions of CV-N (15), gp120, and CD4. Their experiments 
involved coimmunoprecipitation analyses and flow cytometry-based sgpl20-target cell-
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binding assays.82 The results conclusively indicated that CD4-dependent and CD4-
independent binding of soluble gpl20 (sgpI20) to target cells were both strongly inhibited 
by CV-N (15) in a concentration dependent manner.82 It was also found that more than one 
CV-N (15) molecule binding to sgpl20 is required to inhibit both fOlTI1S of sgp120 
binding. 82 The second series of experiments indicated that CV-N (15) could block the 
sCD4-induced sgpl20 binding to CXCR4-expressing cells.82 There was no distinction 
between the blocking ability if CV-N (15) was added after or before addition of sCD4 to 
activate sgp120.82 Therefore, it can be concluded that CV-N (15) leads to steric blocking 
and/or confonnational changes to sgp120 regardless of whether sCD4 has induced a 
confonnational change in sgp 120 itself. As important as these fIrst two series of 
experiments were, the third segment is undoubtedly the most intriguing result to come from 
this particular paper. CV-N (15) was found to induce sgpl20 disassociation from target 
cells, again, from both CD4-dependent and CD4-independent binding. 82 There is no 
known antibody as yet that has been able to dissociate sgp120 from cell bound CD4. As 
Mab 2G 12 is known neither to inhibit sgp 120 binding or dissociation of bound sgp 120 
from CD4-expressing target cells the modes of action and/or binding sites of CV-N (15) 
and 2G 12 must differ to some extent. This unique dissociative property of CV-N (15) was 
found to occur rapidly (less than 2.5 min) after sgpl20-bound cells were incubated with 
CV-N (15). This could explain why CV-N (15) still showed activity even after a 60 min 
delay of addition of CV-N after exposure of cells to the virus.71 The CV-N (15) could 
conceivably have been displacing the bound virion from CD4+ cells. Further work here 
would be vitally important in determining the implications and relevance of this novel 
propertyofCV-N (15). 
A thorough explanation for these complex inhibitory effects of CV-N (15) is difficult to 
achieve as yet. Combining the results from Dey et al.77 with those of Esser et al.74 it is 
tempting to suggest that the diverse interactions of CV -N (15) are as a result of its affinity 
for carbohydrate moieties. In particular, the experiments by Esser et az.74 in discovering 
how CV-N (15) blocks the 2G12 epitope on gp120 which is present in the immunologically 
'silent face' lends support to this theory. The evidence for a direct interaction between 
carbohydrate functionalities and CV -N (15) was further enhanced with 
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the experiments by O'Keefe et al.78 where CV-N (15) bound glycosylated, but not non-
glycosylated, gp120 and gp41. However, this 'carbohydrate model' of interaction fails to 
explain how some distinctly different carbohydrate moieties bind strongly to CV-N (15) 
(HlV-l, HIV-2, SlY, FlV, MV and HHV6) 7 1 , 77 while other glycosylated viruses and 
proteins have no affmity (herpesvirus type 1, cytomegalovirus, vaccina virus, human serum 
albumin, horseradish peroxidase, a-acid glycoprotein, human IgGs).71, 77, 78 Compounding 
these results is the different range of receptors used by the viruses that do bind CV-N (15), 
from CD4 to CCR5 and CD46. The most recent results from Mori and Boyd82 have shown 
that CV-N (15) binds to sgp120 in a way that alters or hides the 2G12 epitope, inhibits 
CD4-dependent and CD4-independent gp120 binding, and prevents sCD4-induced gp120 
binding to cell-associated CXCR4. They fmally showed how CV-N (15) has the 
remarkable ability to induce sgp120 dissociation from target cells which could explain 
several as yet unexplained results.82 It now appears that CV-N (15) acts in three distinct 
stages of the Env fusion process. The primary site of inhibition appears to be gp 120-CD4 
interaction, with additional inhibition of CD4 induced coreceptor binding and fmally a 
gp41 interaction that also presumably interferes with the conformational changes necessary 
for complete fusion. This three-pronged attack by CV -N (15) only serves to highlight 
again its remarkable properties of binding and anti-HIV activity that is unprecedented 
among other potential HlV therapies. More investigations into the specific binding 
positions and kinetics of these complex series of interactions are required before any 
conclusive theory can be formulated that explains all of the above data. 
1.2.3 Recombinant Production 
One of the advantages of isolating and determining the sequence of such a protein as CV -N 
(15) is that it is possible to 'grow' more of the compound through use of Escherichia coli 
(E. coli) expression techniques. 71 For CV -N (15), this firstly involved translating the 
amino acid sequence into a DNA sequence by selecting appropriate codons to represent 
each amino acid. Supplementary codons were included to facilitate incorporation of the 
gene into the expression vector, p-FLAG-l.71 Transformation of E. coli was carried out 
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incorporating the synthetic gene sequence ligated into the E. coli genome. Induction of the 
clones produced an anti-HIV active FLAG-fusion protein that was purified by affinity 
chromatography.71 Removal of the supplementary pieces of the coding by site directed 
mutagenesis left the final construct.71 This was used to transform E. coli and CV-N-Cys 
was expressed from the recombinant organism.71 Purification of the protein was by C4 
reverse phase chromatography, followed by reverse phase C18 HPLC and fmally C4 
reverse phase HPLC with an increasing concentration of CH3CN to H20.71 Initially it was 
the HPLC retention time, ESI mass spectrometry and amino acid analysis that confirmed 
the identity and accuracy of the synthetic CV-N (15) compared to the natural protein. To 
provide further evidence, N-terminal sequencing was employed on the first 25 amino acids 
of each of the proteins and their anti-HIV activities tested together.71 There was no 
difference observed between the two proteins throughout all the tests confirming the 
success of the transformation and expression process. 71 
In 1998 further work by Mori et al.83 was published on this expression process for CV-N 
(15) and a modified approach was used utilising a different expression vector (PET-
26b( +)). This was because of impure partial CV -N proteins present with the final product 
making purification difficult in the original process.71 The revised method produced tight 
transcriptional control with homogeneous CV-N (15) and no sign of any truncated 
species. 83 The yield was also significant with approximately 10 mg ofCV-N (15) per litre 
of cell culture. 83 The ability to produce large quantities of pure CV -N (15) is essential if it 
is to progress as an anti-HIV therapy of any kind. This is an advantage over other natural 
products that cannot be produced recombinantly and which are often difficult synthetic 
targets. 
1.2.4 Sequence Requirements 
To obtain further information about the binding characteristics of CV-N (15), a series of 
DNA constructs were produced and expressed in E. coli to create mutant forms of CV-N 
(15).84 These mutants represented changes in the terminal makeup and functional domains 
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of the protein. A sequence comparison of the 101 amino acids in CV-N (15) yields some 
very intriguing information. The first 50 amino acids fonn Domain 1 (D1), and when 
compared to the next 51 amino acids of Domain 2 (D2), there is a striking similarity with 
32% of the sequence identical, while a further 26% show merely conservative changes 
(Figure 1.5).84 This gives a very high 58% overall homology that suggests within the 
cyanobacteria a tandem gene duplication of coding for CV -N (15).84 
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Figure 1.5 CV -N sequence comparison 
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The first series of mutants were constructed to study the effect of altering either the N- or 
C-terminus by deletion of amino acids. There were three N-terminal mutants, namely CV-
N(-lN), CV-N(-2N) and CV-N(-3N) which removed 1,2, and 3 amino acids respectively.84 
Removal of the single amino acid showed comparable anti-HIV activity to that of native 
CV-N (15) while the omission of 2 amino acids resulted in a 9-fold decrease in potency 
and the removal of the tem1inal tripeptide gave a 156-fold decrease in anti-HIV activity.84 
This trend was mirrored in the gp 120 binding ELISA studies on the mutants which showed 
comparable gp120 binding of the CV-N(-lN) mutant with respect to native CV-N (15) 
while the (-2N) and (-3N) mutants showed only 73% and 50% gp120 binding affinity 
respectively.84 The C-terminal mutants were made with an octapeptide leader (FLAG) to 
facilitate purification.84 The control protein for this series was F-CV-N (F=FLAG), which 
although showing a modest decrease in potency compared to native CV -N (15), was 
sufficient to act as the standard. 84 Two mutants were constructed, F-CV-N(-3C) which 
lacked the C-terminal tripeptide and F-CV-N(-8C) in which the last 8 amino acids were 
deleted. 84 The F-CV-N(-3C) mutant showed a 42-fold decrease in anti-HIV activity and a 
22% gp120 binding affinity compared to F-CV-N for each experiment. 84 The F-CV-N(-
8C) construct however had no anti-HIV potency at all and essentially no gp120 binding 
affinity either. 84 These deletion mutants demonstrate how sensitive the respective 
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terminals ofCV-N (15) are to modification upon their anti-HIV activity and gpl20 binding 
affmities. 
The second series of mutants involved swapping the domains of CV-N (15) around. The 
first of these was the circularly permuted F-D2Dl mutant, which showed relatively weak 
anti-HIV and gpl20 binding activities.84 The tandem mutants however, F-DIDI and F-
D2D2 did not show any activity for either assay. 84 The fmal series of mutants involved 
replacing the two pairs of cysteines of each disulfide bond with serine residues in turn, 
leading to the F-C>S#8-22 and F-C>S#58-73 mutants thereby lacking each of the disulfide 
bridges respectively.84 Neither showed any anti-HIV activity but surprisingly the F-
C>S#58-73 construct did show a modest gpl20 affinity comparable to the F-D2Dl 
mutants.84 While all of the mutants that displayed anti-HIV activity showed gpl20 binding 
affinity, this fmal result would tend to suggest that while binding of gp 120 is desirable, it is 
not the only requirement for blocking of HIV. 
1.2.5 Solution and Crystal Structures 
In 1998 the solution structure of CV -N (15) was solved by using double and triple 
resonance multidimensional heteronuclear NMR spectroscopy, utilising the uniformly l~_ 
and 15N/l3C-Iabelled protein. 85 The final structural calculations were obtained by simulated 
annealing with 2,509 experimental NMR restraints including IH, l3C, 3J couplings and 
residual dipolar couplings.85 The dipolar couplings, unlike the other restraints which 
require a degree of spatial proximity of atoms «5 A), provide long-range structural 
information.86 The shape of CV -N (15) in solution is an elongated prolate ellipsoid with a 
length of -55 A and a maximum width of -25 A. The secondary structure is comprised of 
10 fJ-strands and four short 31O-helical turns. As already shown in Figure 1.5, CV-N (15) 
can be easily divided into two series of sequence repeats, however, these repeat units do 
not form individual domains in the three dimensional structure (Figure 1.6a»). In reality, 
the overall folding pattern of the protein relies on multiple contacts between the two 
sequence repeats with this interaction burying 3,085 A2 of accessible surface area.85 
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Figure 1.6 Internal 2-fold symmetry of CV-N 
a) Ribbon diagram with two sequential repeats coloured blue (residues 1-50) and 
red (residues 51-101) 
b) Ribbon diagram with structural domains A coloured purple, (residues 1-39 and 
90-101) and B coloured green (residues 39-90) 
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The structure can be divided into two symmetrically related domains, A and B (structure 
based domains), which are formed by a strand exchange between the two sequence repeats 
(Figure 1.6b».85 Both N- and (,-termini are contained within domain A which comprises 
residues 1-39 and 90-101, with domain B containing the residues 39-90. As viewed in 
Figure 1.6b), these represent the green and purple sections respectively which will be 
referred to as 'structural domains '. These domains can be overlaid to produce a Ca atomic 
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r.m.s. difference of only 1.3 A.85 One of the most striking features that is a product of the 
internal two fold pseudosymmetry is that the N- and C-termini are adjacent to each other 
with van der Waals interactions between the side chains of Leul and GlulO1. 85 The 
closeness of these residues in space would tend to support and explain the mutagenesis 
studies of Mori et al. 84 as deletion of amino acids from either terminus resulted in a loss of 
anti-HIVactivity. Presumably the removal of the terminal peptide regions would disrupt 
the secondary structure with loss of the electrostatic 'bridge' joining residues 1 to 101. 
When proteins interact with each other (as with CV-N (15) and gp120) the surface 
hydrophobicity of each protein plays a crucial role in determining this interaction.87-9o 
Therefore, Bewley et al. 85 mapped the most hydrophobic regions of CV-N (15) using the 
method of Covell and co_workers88-9o in order to predict regions which may interact with 
gp120. For example, the most hydrophobic cluster involves residues Leul, Gly2, Lys3, 
Gln6, Thr7, Thr25, Asn26, Asn93, Ile94 and Asp95, and is centered around the N-
terminus.85 This also helps explain how the gp120 binding and anti-HIV activity are 
reduced to nothing with loss of the N-terminal tripeptide.84 Other hydrophobic clusters can 
also be mapped and with further structural relationship studies, the interaction between 
CV-N (15) and gp120 can be more closely defined. 
A year later in 1999 the crystal structure of CV-N (15) was solved by Yang et al. 91 which 
allowed a direct comparison of the two structures and also a direct comparison of the 
accuracy of each method. Using the NMR structure as a model, a solution with the correct 
space group enantiomorph was quickly found and the structure well defined except for one 
region, residues 50 to 53.91 This region links the two sequence based domains and in the 
NMR structure showed no distortions. To attempt to overcome this disparity a model was 
built that incorporated two domains from two monomers connected by a new linker.91 This 
domain-swapped (dimeric) form reduced the uncertainty considerably giving an acceptable 
quality structure.91 In solution, CV -N (15) primarily exists as a monomer and so the 
discovery of this domain swapping was unexpected. New crystals were grown from a 
sample verified by gel filtration and NMR to be monomer but after identical refinement the 
domain-swapped structure was again resolved.91 Investigations into the conditions 
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necessary for formation of dimeric domain-swapped CV -N revealed that reverse-phase 
HPLC under acidic conditions (0.05% TF A) gave small amounts of dimeric product and 
obviously crystallisation conditions (low pH and 26% isopropanol) also allowed formation 
ofdimer.91 
The linker region from the Ca atoms of residues 49 to 54 is extended in the domain-
swapped structure to 13.8 A from 10.2 A in the solution structure.91 Apart from this linker 
region and a few flexible side chains, there was excellent compatibility between the two 
structures and a very high degree of similarity between the domains.91 It is important to 
keep in mind that without the NMR solution structure for comparison, the resolved crystal 
structure would have given the protein a form that is not the biologically significant one. 
There is no evidence as yet to suggest any properties of the dimer that may contribute to 
CV -N' s (15) anti-HTV activity but the possibility does exist and should be noted for further 
studies. 
An addition to this structural work was made by Bewley et al.92 with the pUblication of the 
dimeric form of CV-N in solution. Whereas the X-ray dimer can be considered as two CV-
N molecules side by side (albeit with units AB' and A'B), the solution structure was 
resolved to show the two halves of the dimer anti-parallel with each other.92 The reasons 
for these differing structures have been postulated by Bewley et al.92 The carboxylates of 
Glu41 and Glu41' hydrogen bond in the crystal structure but in solution at neutral pH they 
would be repelled away from each other. The X-ray structure also shows the stabilising 
effect ofa neighbouring subunit inserted between the two halves of the dimer. The absence 
of crystal packing in solution and the lack of hydrogen bonds between the glutamic acid 
residues is believed to lead to are-orientation of the two halves of the dimer.92 
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1.2.6 Applications of CV-N 
1.2.6.1 Microbicide 
From an early stage, due to its characteristic properties, CV -N (15) was investigated as a 
possible antiviral microbicide, which are products that can be used topically (ex vivo) to 
prevent the spread of the virus. There continues to be a enonnous need for a female 
controlled topical microbicide that can block HIV infection and the World Health 
Organisation, the National Institute of Allergy and Infectious Diseases, the U.S. 
Department of Health and Human Services and many others have aclmowledged this fonn 
of prevention as a critical global priority.93-96 CV -N (15) is a potential candidate for this 
type of application, particularly as any microbicide of this fonn would have to inhibit free 
viral particles and infected cells which are both transmitted sexually. There is also the 
added advantage that CV-N (15) is active against both M-tropic (macrophage-tropic) and 
T-tropic (CD4 T-cell-tropic) primary isolates of HIV-l with significant evidence that M-
tropic fonns of the virus are crucial for sexual transmission.41 , 97-99 
1.2.6.2 CV-N-PE38 Construct 
Because of CV-N (15)'s unique ability to selectively target and bind to gpl20 across 
various M- and T -tropic isolates, as well as the virion itself, there is the potential for using 
CV-N (15) as a targeting moiety with suitable compounds attached that will actively kill 
infected cells and free virus. Similar compounds have been made that use sCD4 as the 
targeting moiety but although early results were promising in vitro, the gp120 targeting 
ability in fresh clinical isolates and HIV+ patients was dramatically reduced. IOO-107 With 
the potent activity of CV -N (15) shown against a variety of clinical isolates in mind, a 
chimeric toxin molecule was constructed consisting of CV-N (15) and the potent, active 
section of Pseudomonas exotoxin (PE).108 This was done by constructing an E. coli 
expression plasmid that contained a gene coding for both FLAG-CV-N and amino acids 
253-364 and 381-613 of PE.108 This section of PE, labelled PE38, contains domains 
·bl.C: l' d ADP 'b l' 109 11 0 responSl e lor trans ocatlon an -n osy atlOn. ' Purification by affinity 
Chapter 1 - Introduction 31 
chromatography and gel filtration led to the single product of approximate molecular mass 
49.3 kDa.108 In subsequent, testing the toxin conjugate did show enhanced specificity for 
killing of chronically infected gp120 expressing H9/HIVrrib cells with a much lower ICso 
(0.004 nM) than for the control, healthy, non-gp120 expressing cells (ICso=0.3 nM).108 
Another experiment tested the competition between F-CV-N-PE38 and native CV-N (15) 
for H9lHIVIIIb cells where addition of the native protein reduced the toxicity of the 
conjugate to that of uninfected H9 cells. 1 08 An ELISA binding assay with gp 120 treated 
plates showed that the F-CV-N-PE38 had distinctly less binding affinity for gp120 than 
native CV-N (15).108 This reduced affinity can be somewhat expected with the "'38 kDa 
addition of a large protein mass to the 11 kDa CV-N (15) molecule sterically hindering the 
interaction between gp120 and CV-N (15). Although the binding was somewhat reduced, 
this compound does show the potential for such an application. 
1.2.6.3 Immobilised CV-N 
Another novel approach to the application of CV -N (15) is in solid phase immobilisation in 
order to screen out HIV in blood and plasma products. Gandhi et al. III achieved this by 
biotinylating CV-N (15) and coupling this to streptavidin-coated glass porous magnetic 
beads (SGPM-beads). Tests on biotinylated CV-N (bCV-N) against native recombinant 
CV -N (15) in an anti-HIV assay showed that the biotin did not interfere at all with the anti-
HIV activity of CV-N (15).111 More importantly the sessile CV-N (sCV-N) also showed 
potent inactivating ability for the two HIV strains tested. 1 11 However, R T -PCR tests on the 
virus attached to the sCV -N and on the supernatant left behind showed that only a fraction 
of the virus was removed by the sCV-N with the remainder of supernatant being non-
infectious virus (replication incompetent virions (RN) ).111 This RN is being investigated 
as a candidate vaccine due to its non-infectious, but still intact, whole virion status. Tests 
were also carried out under a variety of conditions to ensure that the CV-N that was bound 
to the beads did not leach out into the supernatant and all results indicated that this indeed 
did not occur.1ll 
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1.2.6.4 CV -N Based Assay 
A recent application of CV-N (15) takes advantage of its specific, tight binding to unique 
regions of gpl20 in order to screen thousands of natural product extracts for binding at, or 
near, the site(s) for CV-N (15).1l2 Previous assays based on soluble forms of gpl20 and 
CD4 have been used in a similar way in order to screen large collections for inhibition of 
their particular interactions.ll3 The assay system used for CV-N (15) was dissociation-
enhanced lanthanide fluoroimmunoassay (DEFIA®, PerkinElmer Wallac mc., 
Gaithersburg, MD, U.S.A.) which is well suited to screening crude natural products. The 
process involved pre-incubating the extracts in wells with gp120, adding europium labelled 
CV-N, incubating, washing, and detection by release of the Eu3+ in a fluorescent form with 
an enhancer solution.112 An assay 'hit' was defmed as an extract that inhibited the binding 
of Eu3+-CV-N to gpl20 by 60% or more. 112 Of the 50,865 extracts tested, covering a range 
of terrestrial plants, marine algae, microbes, marine invertebrates and dinoflagellates, there 
were a total of 120 'hits' (64 organic and 56 aqueous).1l2 This corresponded to a very low 
average hit rate of 0.2%, which is possibly due to CV-N's (15) very high affinity for gpl20 
and/or the unique binding site utilised by CV -N (15).112 None of the organic 'hits' were 
able to be reproduced in subsequent assays but 51 of the 56 aqueous extracts were 
confirmed to be positive.lI2 These 51 samples were then further tested for their ability to 
bind to C4 in a chromatographic column as previous work by the NCI had shown that 
aqueous extracts often contained high molecular weight polysaccharides and polyanionic 
compounds that non-specifically inhibited mv infection114 and did not bind well to C4. 
Of the 51 C4 retentates, 29 continued to inhibit Eu3+ -CV -N binding to gp 120, of which 7 
had significant in vitro anti-HIV activity.112 However, in each case the activity was 
subsequently determined to be due to polyphenolic tannins, which are not considered 
suitable for drug development.112 
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1 .. 3 Natural Products 
1.3.1 Marine Natural Products 
Natural products, the secondary metabolites produced by living organisms, have been 
extracted by Man and exploited throughout the ages for an extensive range of applications, 
from food to fragrances, pigments to poisons, and microbicides to medicines. 
Investigations into organisms of terrestrial origin has obviously been much more extensive 
as access and familiarity with the land have provided the 'path of least resistance'. 
However, as two third's of the surface of Earth is covered in oceans, this makes for a vast 
array of biodiversity in an estimated I.S-4.5 million species that has only relatively recently 
begun to be extensively studied. The last three decades have been marked by intense 
interest in the chemicals in marine organisms and their biological activity. This rise in 
interest can be significantly traced to the availability of Self Contained Underwater 
Breathing Apparatus (SCUBA), which has allowed a much further exploration of the 
oceans to depths of up to 40 m while mini-submersibles allow collection down to depths of 
1,000 m or greater. 
The saline environment seems to encourage the production of novel structures due to the 
high levels of halogens and nitrogen, as well as the need for soft sessile organisms to 
chemically defend themselves from predation. Indeed, it has been shown that many marine 
organisms produce natural products while under stress1l5 and furthermore that natural 
products are common in organisms without an immune system.1l6 Both these studies 
highlight the role of natural products as a chemical defence system. An interesting feature 
of marine natural products research is the variability in the chemicals found in an organism 
depending on the location and season. There is mounting evidence that this is perhaps tied 
to the role of symbiotic microorganisms in the production of the chemicals. 
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1.3.2 The Marine Chemistry Group 
The Marine Chemistry Group at the University of Canterbury began an intensive collection 
program in 1983 to exploit the high levels of bioactivity found throughout marine 
invertebrates. Over the next few years, collections were made from such diverse places as 
McMurdo Sound in the Antarctic, to the sub-tropical waters off the coast of northern New 
Zealand and throughout waters of both North and South Islands. Small-scale extractions 
were carried out on each sample to determine their biological activity and subsequent 
dereplication of larger extractions undertaken in order to elucidate the active component(s) 
to assess their pharmaceutical potential. 
Several species in particular, have demonstrated potent activity in the in-house assay 
system and have therefore been extensively studied. The ftrst of these is sponges of the 
genus Latrunculia (Order Hadromerida) found in waters ranging from Antarctica to NE 
New Zealand. They have produced an entire family of biologically active compounds 
discorhabdin C (16) 
called the discorhabdins. The compounds are readily 
identifted by their red or green colour due to the 1,3,4,5-
tetrahydropyrrolo[ 4,3,2-de ] quinoline rmg system. 
Discorhabdin C (16) is the simplest of the family but all are 
strongly cytotoxic against the P388 and BSC cell lines. 
Structural Activity Relationships (SAR's) have been 
carried out, particularly with discorhabdin C (16) in order 
to determine the functional source of the biological 
activity. 117 
Sponges of the genus Mycale (Order Poecilosc1erida) have produced one of the most potent 
antitumour and antiviral compounds to be isolated from a New Zealand programme. 
Purification of the active crude extract using bioassay guided fractionation led to the 
isolation of not one but two compounds, mycalamides A (17) and B (18).118 These 
compounds showed antiviral activity but proved to be too cytotoxic to be antiviral agents. 
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Similarly they were also rejected as 
antitumour agents after in vivo trials 
highlighted 
cytotoxicity. 
problems with 
The Marine Chemistry Group at the 
University of Canterbury continues to 
search and isolate novel bioactive 
compounds for their pharmaceutical 
potential. However, the dramatic 
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R=H mycalamide A (17) 
R=CH3 mycalamide B (18) 
increase and interest shown around the world in the last decades for isolating natural 
products has meant that the probability of fmding such novel compounds has decreased 
significantly. Recently, the Group has branched out to investigate marine fungi for 
bioactive compounds, which may hold as yet untapped sources of novel natural products. 
Although worldwide the number of new compounds isolated each year has stagnated 
recently, there remains a vast undersea resource to be explored with more advanced 
collection techniques utilising new technologies. The analogy of a treasure hunt is an apt 
one albeit with the caveat that participants must draw the treasure map as they go. 
1.3.3 The Halichondrins 
The series of compounds known as the halichondrins were fITst isolated from the Japanese 
sponge Halichondria okadai Kadota in the mid 1980'S.119, 120 These compounds, 
norhalichondrin A (19), B and C, halichondrin B (20) and C, and homohalichondrin A, B 
(21) and C represent tlrree classes of the halichondrin family. These A, B, and C families 
are distinguished by the degree of oxidation at Cl2 and Cl3 (Figure 1.7). Within the 
families the differences lie beyond the C45 position. The structures are characterised by a 
novel 2,6,9-trioxatricyclo[3.3.2.0Jdecane system (rings C-E), a 22-membered lactone ring 
(CI-C30), two exocyclic olefmic groups and several pyranose and furanose rings. 
Chapter 1 - Introduction 36 
H 
norhalichondrin A (19) 
:27 
"",t:(H3 C! 221 
111!f' 
11 
54 
H 
halichondrin B (20) 
HO 
homohalichondrin B (21) 
Chapter 1 -Introduction 37 
A family B family C family 
Figure 1.7 Halichondrin A, B, and C families 
In 1991 halichondrin B (20) and homohalichondrin B (21) were isolated from an unrelated 
sponge Axinella sp., collected ih Palau. 121 Two years later Pettit et ai. isolated two new 
halichondrin compounds, halistatin 1122 (22) and halistatin 2123 (23). The sponge that 
halistatin 1 (22) was isolated from, Phakellia carteri, was also found to contain 
halichondrin B (20) and homohalichondrin B (21). To add to this complex series of 
interconnections, all three of these compounds were also isolated from a Western Indian 
Ocean sponge Axinella cf. carten Dendy together with halistatin 2 (23). 
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The Marine Chemistry Group at the University of Canterbury joined this story in 1987 
when Rob Lake identified halichondrln-like compounds from two unrelated species of 
sponge. These sponges were Raspalia agiminata (order Axinellida, family Raspailiidae) 
from the Leigh area of the North Islandl24, and the second, a slimy yellow sponge off the 
Kaikoura coast identified as one or more new species of the genus Lissodendoryx Topsent 
(class Demospongiae, order Poecilosclerida, family Myxillidae). 125 An interesting aspect 
of the Kaikoura sponge extraction was that it was the highest yielding (-1 mg total 
halichondrinslkg wet weight of sponge) of any of the other halichondrin producing 
sponges. 119, 121, 122 A subsequent, larger extraction carried out by Mark Litaudon of the 
Lissodendoryx sp. yielded 4.5 mg of an unidentified halichondrin. Characterisation 
utilising 2D-NMR and MS techniques yielded the compound isohomohalichondrin B (24) 
isohomohalichondrin B (24) 
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which was named because it is isobaric to homohalichondrin B (21). The difference 
between them exists beyond C48, where isohomohalichondrin B (24) has the ring opened 
form of the terminal furanose unit. The activities of some of the halichondrin compounds 
are shown in Table 1.1. The three assays are cytotoxicity against B16 Melanoma cells, the 
Marine Chemistry Group's in-house P388 in vitro murine leukemia assay, and against the 
NCI's 60 cell-line in vitro primary screen. 
Table 1.1 In Vitro Cytotoxicities of selected Halichondrins 
Compound B-161Cso P3881Cso NCI Giso {ng/mq {ng/mq {x10-1OMl 
halichondrin B (20) 0.093 0.78 1.38 
homohalichondrin B (21) 0.1 0.22 3.16 
isohomohalichondrin B (24) not recorded 0.18 1.15 
Evaluation of the pattern of differential activity (mean-graph profile) of halichondrin B 
(20) against the NCI 60 human tumour cell line panel using the COMPARE126 algorithm 
found that it most closely resembled those of tubulin binders such as vincristine and taxol. 
This strongly suggested halichondrin B (20) was an antimitotic agent. A significant feature 
of cancer cells is that they divide more rapidly than healthy cells. As microtubules are 
involved in cell proliferation (mitosis), microtubule inhibitors such as halichondrins are 
useful tools to treat cancer. Studies by Bai et al. 127 indicated that halichondrin B (20) was 
binding in the vinca domain of the microtubules. These vinca domain drugs inhibit 
tubulin-dependent GTP hydrolysis and also inhibit GTP/GDP exchange at the 
exchangeable nucleotide site of tubulin. 
The most potent member ofthe family, halichondrin B, has undergone further testing at the 
NCt The sixty cell line in vitro cancer screen run by the Developmental Therapeutics 
Program at the NCI demonstrated the potency and differential activity of halichondrin B 
(20) against several human tumour xenograft models. The compound has reached Decision 
Network IIA status but is unlikely to progress further until a sufficient supply is made 
available. The three alternative supply routes appear to be sponge collection, 
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aquaculture or synthetic manufacture. There are several problems with each of the above 
methods which make supplying the necessary amounts required an onerous task. 
The natural supply of the highest yielding of the halichondrin containing sponges 
Lissodendoryx sp., found exclusively off the Kaikoura peninSUla, is limited. The supply 
has been estimated using an ROV and benthic camera to be 289 ± 90 tonnes which is 
insufficient for an estimated worldwide demand of 5,000 tonnes to yield 5 kg a year of 
halichondrin B (20). 
The second option of aquaculture has shown some initial encouraging results.128-130 
However, the levels of halichondrin-like compounds in the aquacultured samples were 
lower when compared to the native sponges, but there is potential for optimisation of 
conditions. 130 It was observed that the highest rate of halichondrin production was in 
sponges suffering from stress which correlates to the theory of sponges using the toxins as 
a defence mechanism. 130 
Because of the unique nature and challenging structure of the halichondrins, much effort 
h b . h . h' h 131 as een put In to t elr synt eSlS over t e years. Halichondrin B (20) and 
norhalichondrin B were completely synthesised by Kishi and coworkers in 1991. 132 
However, the usefulness of this impressive accomplishment is tempered by the fact that it 
took approximately 120 steps to achieve. Since then several improvements have been 
made to this synthesis. 133 This has included the complete synthesis of the right-half diol 
(25) which has shown the same activity 
pattern as the parent halichondrin B (20) HO 
with a cytotoxicity within an order of 
magnitude of the parent,134 This offers 
the potential for a commercially viable 
G ~ 
synthesis of a halichondrin based 
compound at much reduced effort 
compared to the full structure. 
0X:27 Q \\,., "IICH 
22 r 3 
1/, 
" 
right-half diol (25) 
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Future production of halichondrin compounds may also be possible if the organism 
producing it could be identified and the genetic component corresponding to halichondrin 
production spliced into an organism capable of fermentation. However, it is still unclear as 
to whether it is the sponge cells or a symbiotic organism that produces the toxin. Several 
groups are working on this problem while others are attempting to propagate sponge cells 
in culture which may provide a further alternative source but these studies are only at 
preliminary stages. 
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1.4 Project Aims 
The overall aini of this project was to develop and act upon a strategy to produce CV-N-
toxin conjugates capable of eradicating HIV-infected cells. This work primarily carries on 
from the experiments of Mori et al. 108 outlined in section 1.2.6.2 where CV-N was 
produced in tandem with a fragment of Pseudomonas exotoxin A attached. The 
conclusions reached indicated that although cytotoxicity was enhanced against gp120 
expressing cells, the size of the PE38 fragment prevented effective gp120 binding therefore 
limiting the usefulness of the construct. 108 What this thesis sets out is a synthetic strategy 
to make CV-N constructs containing much smaller toxins making them capable of binding 
efficiently to gp120. These compounds therefore optimise selectivity of killing of HIV-
infected, versus uninfected cells. 
One of the crucial aspects of this strategy will be the intemalisation of the constructs once 
formed. The gp 120 is expressed on the outside of infected cells and most virologists 
consider that the envelope proteins are in the process of leaving the cell via viral budding. 
However, the efficacy of toxin conjugates that target the envelope proteins is such, that at 
least a portion of the gp120/gp41 complex is reintemalised. 135 Studies by Pincus135 have 
demonstrated that not only is there a recirculating pool of envelope protein, but that the 
rates of intemalisation are subject to regulatory influences. 
As noted (section 1.2.6.2) there have been several HIV-targeted toxin conjugates made in 
different labs utilising a range of toxins and carriers.136-138 These include using free CD4 
and IL-2 (IL-2 receptors are found on activated T-cells) as targeting moieties and toxins 
that include ricin A chain and truncated forms of diptheria toxin and Pseudomonas 
exotoxin A. The CD4-Pseudomonas exotoxin performed wonderfully in in vitro studies, 
but in vivo clinical trials raised serious issues of hepatotoxicity. 106, 107 However, Berger et 
al. 139 published a discussion of the reasons for this disappointing result in 1998 which 
offered renewed hope for this approach with insights that may be applicable to the results 
of this study. At present an IL-2-diptheria toxin fusion is also undergoing clinical trials. 
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Although the disappointing results of the CD4-pseudomonas exotoxin conjugate markedly 
diminished the enthusiasm for the development and clinical testing of similar constructs, 
the concept is valid and only awaits a more suitable candidate. 
Another issue that would need to be addressed is the pool of latently infected cells (section 
1.1.7) that have the potential to 're-initiate' active virus production after levels had been 
reduced by anti-retroviral therapies. To be truly effective at eliminating all HIV from the 
body whether latently or actively infected cells, the type of CV-N-toxin conjugates under 
investigation would need to be introduced with compounds that 'turn on' the latent 
reservorr. There are several compounds that have this remarkable property, one of which, 
prostratin (26), has been proposed for this purpose.140 
OAc The idea would be to initiate virus production in the 
OH 
prostratin (26) 
H3 latently infected cells with prostratin (26), therefore 
'identifying' the cells to the CV-N-toxin conjugates 
which would then target and destroy them. The aim 
would ultimately be complete eradication of the virus 
from HIV infected individuals, something that has not yet 
been clinically achieved. 
The limitations imposed on the synthesis of the toxin conjugates in this proj ect were as 
follows. 
• The alterations made to the native CV -N (15) must not interfere 
significantly with the biological binding profile of the CV-N (15) to gp120. 
• Any synthetic modifications to the toxins must not inhibit their toxicity. 
" Ideally the toxin should not become 'active' until internalised within the 
infected cells. 
• Synthetic steps must ideally be high yielding partiCUlarly when dealing with 
toxins. 
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Overall this work was undertaken to combine the remarkable binding and stability of CV-N 
(15) with the potent toxicity of marine natural products such as the halichondrins. The 
fusion of these two distinct biological profiles was aimed at providing a specific yet 
powerful cell killing strategy. 
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Chapter 
EARLY APPROACHES AND 
STRATEGY DEVELOPMENT 
2.1 Introduction 
Early work for this project focused on the best strategies to couple together CV-N (15) with 
the toxins available. The starting point was the production of CV -N(-3N) by Mori et al. 84 
mentioned in section 1.2.4. This suggested a method to synthetically produce the 'missing' 
terminal tripeptide with toxin attached, then couple to the truncated CV-N(-3N) and hence 
produce an intact CV-N-toxin conjugate. 
As more aspects of protein modification strategies were investigated, more useful and 
productive routes were developed incorporating cleavable biolinkers. These biolinkers 
would be the basis by which the toxin would be released in vitro and in vivo once inside an 
HIV-infected celL 
Other methods involved activation strategies in order to promote the coupling of CV-N 
(15) functionalities with modified toxin constructs. Two activation methods stood out as 
suitable with one relying on reaction of CV-N's (15) lysine side chain arnines with 
succinirnidyl esters and the other utilising thiols added to CV -N (15) in order to react with 
maleirnide functionalities. 
The development of suitable toxin derivatives capable of surviving various chemical 
reaction conditions and synthetic steps was crucial as the toxins represent the killing power 
of the final constructs. A careful selection was made from the group of toxins isolated by 
Chapter 2 Early approaches and strategy development 46 
the Marine Chemistry Group over the past decades. The halichondrin derivatives were 
chosen for their potent activity, the extensive in-house knowledge of their chemical 
behaviour and ease of modification. 
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2.2 Terminal Tripeptide 
The initial strategy developed to synthesise CV~N~toxin conjugates was based on the work 
by Mori et al. at the LDDRD in recombinantly producing CV-N(-3N).84 As the 'missing' 
terminal tripeptide represents the residues Leu-Gly-Lys, there was potential to attach the 
toxin molecule through the side chain of the lysine residue. This method had the advantage 
of minimal modification to CV-N (15) as once the tripeptide was 'reunited' with the CV-
N (-3N) the resulting product should be intact CV -N with a toxin attached in one position 
only (Figure 2.1). 
R1 = protecting group 
Rz = activating group 
HN 
S 
pH 7 
Figure 2.1 N-terminal strategy 
However, the major obstacle to the success of this method is that it relied heavily on the 
fact that the tripeptide with toxin attached would have to be selectively coupled to the N-
terminal ofthe CV-N(-3N). This is not a completely unfeasible requirement as N-terminal 
selectivity over lysine side chain amines is possible at a pH of 7 due to the difference in 
pKa's of lysine side chain amines and an N-terminal amine. Although initial peptide 
couplings were carried out to synthesise the terminal tripeptide, other strategies were 
developed that were deemed more achievable and so this strategy was discontinued. 
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2 .. 3 Biolinker Development 
A crucial aspect of attaching toxins to CV-N (15) is that once transported into infected 
cells through gp120 binding and recycling of the receptors there is a requirement for the 
toxin to be released in order to effectively kill the cell. Cell death may be possible with a 
non-biodegradable linker as the toxin may still be active even while attached to CV-N. 
Ideally though, the toxin should be released from the CV-N molecule once inside the 
infected cell. 
Study in the field of polymer therapeutics has led to the discovery of several peptidyl 
linkers that are cleavable under low pf{ enzymatic conditions. 141 One such linker is the 
tetrapeptide Gly-Phe-Leu-Gly. Originally designed with treating cancerous tumours in 
mind, the linker will cleave inside the lysosomes of cells, which is at the low pH of 5.5, in 
the presence of pH-tolerant lysosomal peptidases such as cathepsin B.141 The concept has 
been applied to this project, where once the CV-N-toxin conjugate is taken into the 
infected cell, cleavage of the biolinker will follow (Figure 2.2) releasing the toxin. This 
enzymatic cleavage 
y 
Figure 2.2 Biolinker 
linker also acts as a spacer to separate the toxin from the surface of the CV-N molecule 
which is also crucial in allowing CV-N to bind gp120 effectively. 
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2 .. 4 Succinimidyl Ester Strategy 
Literature research suggested the most commonly utilised site of attachment of compounds 
to proteins was via the side chain of lysine residues present. The side chain amines of 
lysines are convenient nucleophilic functional groups that can be reacted with a variety of 
activated structures. Lysine is the preferred site of attachment as modification of other 
functional groups often leads to inactivation of the protein.142 
The N-hydroxysuccinimidyl moieties were found to be such groups that are selectively 
targeted by primary amines with no interference with other functional groupS.143-J47 
Therefore, if these succinimidyl deriyatives were to be incorporated into the overall 
structural design of the biolinker-toxin compounds, they would react with the N-tenninal 
and/or the lysine side chains present in the CV-N (15) protein (Figure 2.3). This strategy 
means that multiple sites on CV-N (15) could be conjugated to toxin molecules. This has 
the advantage of ensuring more toxin is released into the cell, hence the opportunity for a 
quicker cell death. However, it also means that the products formed will not represent a 
homogeneous compound, but rather, a collection of CV -N molecules with varying numbers 
of toxin molecules attached. 
-NH2 represents lysine side 
chain and N-terminal amines 
o 
H2 + y~ Biolinker H Toxin J 
Biolinker Toxin 
coupling may occur at more than one amine site 
Figure 2.3 model for succinimidyl activation and reaction 
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Maleimides 
2.5.1 CV-N-Cys Strategy 
With the recombinant production of yet another CV -N variant at the LDDRD, this time 
with an extra cysteine residue present on the C-tenninus, there arose the possibility of 
utilising the thiol side chain for attachment of conjugates. The native CV-N (15) already 
contains four cysteine residues but these are involved in internal disulfide bonds and 
unavailable for reaction. The presence of an additional cysteine residue provides the only 
free thiol present in the CV-N molecule. If conjugates could be linked through this thiol, 
the products would be homogeneous with the toxin attached at a defined position. 
While looking at the feasibility of utilising succinimidyl esters, references to the use of 
maleimides through exclusive reactions with thiols was noted. However, without the 
presence of a free thiol group on the native CV -N (15) this method of attachment was not 
considered. Therefore, after the successful production of the CV-N-Cys construct it was 
extra cysteine provides 
the only free thiol 
o 
+ y'1CH2)~ Biolinker H Toxin J 
J 
Biolinker Toxin 
coupling will occur at only one site 
Figure 2.4 model for maleimide reaction with thiol 
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decided to develop methods to exploit the unique reactivity of the thiol towards 
maleimides. 148, 149 The reaction involves addition of the thiol across the double bond of the 
maleimide to yield a thioether (Figure 2.4). Maleimides do react with amines but usually 
require a higher pH than that for reaction with thiols. 
2.5.2 Amine Conversion to Thiol Strategy 
Recombinantly producing CV-N-Cys is not the only way to make available a free thiol on 
CV-N (15). There exist several reagents that selectively react with amines and convert 
them to thiols. With respect to CV-N (15) this converts the N-terminal and/or 5 lysine 
amines into sulfhydryl groups which become available to react with maleimides in the 
same way as CV-N-Cys above. A compound capable of this functionality conversion is 2-
-NH2 represents lysine side 
chain and N-terminal amines 2-iminothiolane (27) 
H2 + (\ ~s~NH2+cr 
J 
J 
o Y'(CH')~ Biolinker H Toxin J 
Biolinker Toxin 
Figure 2.5 amine to thiol conversion strategy 
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iminothiolane (27).150 This reaction opens the ring to form an ami dine derivative with a 
pendant thiol ready for reaction with maleimides. The relative stability of 2-iminothiolane 
(27) in aqueous solution contrasts with the more rapid hydrolysis of other imido esters. 
This slow rate of hydrolysis makes it ideal for modification of proteins at low 
concentrations of reagent. Figure 2.5 outlines the strategy developed to utilise this 
particular reagent in forming thiolated-CV-N and subsequent maleimide reaction. There 
are similarities with the CV-N-Cys approach with respect to the thiol-maleimide reaction, 
but in addition there is a distinct resemblance to the succinimidyl ester strategy in that there 
will be multiple sites of attachment for the biolinker-toxin conjugates. 
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2.6 Toxin Development 
2.6.1 Mycalamides 
Of the several toxin molecules available in the Marine Chemistry Group, two stood out as 
most suitable for use in this application. The fIrst of these was the compound mycalamide 
A (17). The functionality available for conversion in this structure is the primary alcohol. 
QH 
18 ~OH 
. 17 
HO"'" = 
<"'I'CH3 
"OJIIOCH3 
mycalamide A (17) 
N3 
17 ~ 
.... 
,ICH3 40lIl( 
"'I/IOCH3 
reduction 
Lindlar's catalyst 
ethanol 
OH 
NaN3 
NHZ 
17l; 
OTs 
17~ 
""I'CH3 
""I'OCH3 
k H = 
~ 
"" liCH3 
""'IOCH3 
17-formyl-nor mycalamide A 
oil( 
''''IICH3 
""I'OCH3 
1 
~:~~~on 
IPA 
OH 
T osylation 17 ~ 
TsCI ~ 
pyridine . 
""I'CH3 
""" OCH3 
17-amino-nor-mycalamide A 
Figure 2.6 attempted mycalamide A (17) to amine conversion 
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Previous work done by Marie Squire in the Marine Group as part of an Honours project 
attempted to convert the alcohol to an amine in order to allow attachment to biolinkers.151 
The synthetic strategy is shown in Figure 2.6. The scheme shows initial oxidation of the 
diol (17) to an aldehyde and subsequent reduction to the single alcohol. Tosyl chloride 
converts the alcohol to the tosylate which allows transformation to the azide. Finally, 
reduction produces the amine. However, while this strategy worked up to the azide step, 
the fInal reduction yielded a product with a molecular mass two units higher than what was 
calculated for the amine. This result could not be rationalised at the time and so did not 
provide a suitable strategy to pursue. 
An alternative, much simpler scheme was attempted by Sean Devenish as part of his Ph.D. 
research using reductive amination of the 17-formyl-nor-mycalamide A to give the desired 
amine.152 While mass spectrometric analysis did show formation of the amine there was 
also a substantial amount of dimer present from the reductive amination of a 17-formyl-
o 
Jz H :: 
~ CH3 
QH HR""I'CH3 
N " 
"I'OCH 3 
'-.../0 
17-formyl-nor mycalamide A 
H2 
reductive ami nation 
NaCNBH3 
NH4 +CH3C02-
QH 
NH2 '17~ 
~ CH3 
HR'''"
ICH3 
N '" 
"'OCH3 
'-.../0 
17-amino-nor-mycalamide A 
mycalamide dimer 
Figure 2.7 reductive amination of 17-formyl-nor-mycalamide A 
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nor-mycalamide A molecule with an already fonned amine (Figure 2.7). This dimer did 
not possess a primary amine and as a dimer may not be as cytotoxic as the monomer. 
Various different reaction conditions and reagents were tested in order to prevent dimer 
fonnation, but with little success. 152 Work is continuing on alternatives to this reaction in 
order to be able to utilise the mycalamide class of toxins. 
2.6.2 Halichondrins 
A very similar set of reactions to those done on the mycalamide A toxin was perfonned on 
the halichondrin B molecule with more success. Dr Rachel Lill, as part of her Ph.D. thesis 
work, completed the series of reactions outlined in Figure 2.8 leading to the synthesis of 
norhomohalichondrin B amine (28) from homohalichondrin B (21).130 Although ultimately 
successful, this series of reactions was time consuming and difficulties in purification at 
each stage proved troublesome. 
Chapter 2 - Early approaches and strategy development 
55 
HO 
H 
H 
homohalichondrin B (21) 
diol cleavage 
Nal04 
Tosylation 
.. 
TsCI 
DMAP 
DIPEA 
norhomohalichondrin B 
aldehyde (29) 
norhomohalichondrin B amine (28) 
H 
56 
__ N_aN_3--t11._ ,Y' 
DMF M'f 
N3 H 
reduction 
Lindlar's catalyst 
ethanol 
Figure 2.8 conversion of hom ohali chondrin B (21) to norhomohalichondrin B amine (28) 
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2.6.2.1 Reductive Amination of Norhomohalichondrin B Aldehyde 
After the partial success of Sean Devenish's attempt at reducing the number of steps for 
this synthesis with respect to the mycalamide structure it was decided to attempt the same 
reductive amination on norhomohalichondrin B aldehyde (29) (Figure 2.9). It was hoped 
that the increased size of the halichondrin skeleton would prevent dimer fonnation. For 
HO 
H 
homohalichondrin B (21) 
reductive ami nation 
I\IH4 +CH3C02-
NaCNBH3 
norhomohalichondrin B 
aldehyde (29) 
H 
norhomohalichondrin B amine (28) 
Figure 2.9 simple two step procedure to norhomohalichondrin B amine (28) 
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this to occur, two large halichondrin structures would have to meet in the correct 
orientation in order to react. This would be in competition with the reductive amination by 
the reagents sodium cyanoborohydride and ammonium acetate. 
Norhomohalichondrin B aldehyde (29, 1.0 mg), ammomum acetate (100 equiv.) and 
NaCNBH3 (0.7 equiv.) in MeOH were stirred together under argon at room temperature for 
18 hours. Repeated TLC experiments demonstrated the formation of a much more polar 
product that was ninhydrin active. After complete disappearance of the aldehyde (TLC) the 
reaction mixture was purified using C18 column chromatography. A IH NMR spectrum 
was a very good match to that of Dr Lill' s previous norhomohalichondrin B amine (28). 
Additionally there was no sign of the distinctive aldehyde resonance at B 9.70 ppm. The 
most visible proton shifts of the '0' ring of the aldehyde were the H53 and H50 proton 
resonances (shown in Figure 2.10) which had shifted from their initial values. Severe 
overlap in the 2D NMR spectra of the amine prevented the complete assigmnent of the '0' 
ring by Dr LilI. More compelling evidence was obtained by ESIMS analysis with no sign 
of the MH+ for the aldehyde (mlz 1091) nor the dimer (mlz 2199) as had been the case with 
mycalamide A (17). 
This experiment was important as it circumvented the need for a five step synthetic scheme 
and allowed formation of norhomohalichondrin B amine (28) in two simple quantitative 
reactions with simple purification. As this reaction worked well and provided the amine 
efficiently, this toxin amine was chosen for subsequent attachment to biolinkers. 
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Figure 2.10 IH NMR comparison ofnorhomohalichondrin B aldehyde (29) and amine (28) 
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Chapter 3 
PU FICATION OF CV-N AND 
CV-N DERIVATIVES 
3 .. 1 Introduction 
The delivery agent that provides targeting to HIV infected cells and virions is the CV-N 
(15) molecule. This whole project was based upon its efficacy in targeting gp120 
expressed on the outer surface of infected cells. Therefore a supply of the native CV-N 
(15) and derivatives was essential in order to carry out the experimental aims of this thesis. 
There were ultimately three different CV-N type molecules utilised throughout this project. 
The first of these was the native CV-N (15) itself, then CV-N with an extra C-terminal 
cysteine residue (CV-N-Cys), and finally CV-N with lysine amines converted to thiols by 
iminothiolane (27) (thiolated-CV-N). 
A crude batch of CV-N was kindly supplied by the LDDRD which represented side cuts 
from a previous large-scale purification of CV -N. A method of cleaning up the sample was 
needed to remove smaller proteins and other molecules from the mixture. Preparative 
HPLC was chosen as the best method to purify this crude CV -N. 
The CV-N-Cys was produced recombinantly at the LDDRD while a guest in their 
laboratory. Utilising standard E. coli molecular biology techniques the CV-N-Cys protein 
was produced and purified. Mass spectrometry indicated the presence of a glutathione 
molecule attached to the free thiol rendering the product incapable of reacting with 
maleirnides. Several methods of glutathione removal were carried out producing mixed 
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results. Subsequent experiments at the LDDRD using CV-N-Cys-glutathione did 
eventually successfully provide some CV-N-Cys. 
The alternative method to produce thiols via amine conversion was at first carried out on a 
model protein, lysozyme. The concepts underlying these conversions were developed in 
co-operation with another Ph.D. student, Marie Squire. Analysis of this reaction of 
iminothlolane (27) with lysozyme allowed optimisation of the reaction conditions as well 
as optimisation of the mass spectrometry. Once satisfactory results were obtained with 
lysozyme, CV -N (15) was substituted in its place. Following size exclusion 
chromatography the products were analysed by mass spectrometry allowing an estimation 
of the degree of amine to thiol conversion. This thiolated-CV-N product was then ready 
for maleimide reaction. 
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3.2 Native CV-N Purification 
A batch of CV-N side cuts was obtained from the LDDRD containing 1.712 g of semi-
purified CV -N along with other smaller proteins and molecules. This mixture needed to be 
chromatographed in some way in order to separate out the pure CV -N (IS) protein. The 
most obvious method of purification was by preparative HPLC. Successive analytical 
injections utilising various different gradient profiles demonstrated that a 20% to 50% 
CH3CN/H20 (0.05% TF A) mixture on a reverse phase C 18 column gave the best 
separation and resolution of the CV-N (IS) peak. Larger scale preparative HPLC runs were 
undertaken on a C4 column with the same solvent gradient protile as used analytically. 
Collections were made and the putative CV -N peak was reinjected analytically to confinn 
the success of the purification. The chromophore of CV -N (IS) is shown in Figure 3.1 and 
is typical of proteins in general as all 
140 
residues contribute and produce an 
120 
average UV spectrum. The slight 100 
maxima around 280 nm is due to the 80 1 
rnA&!! 
aromatic residues such as 40 
phenylalanine, and 20 
tryptophan. A companson of the 
crude. purified CV -N, and pure CV-N 
(supplied by the LDDRD) samples is 
190 200 210 220 230 240 250 260 270 280 290 300 310 
Figure 3.1 UV spectrum of CV-N 
nm 
shown in Figure 3.2. These HPLC traces demonstrate the effectiveness of this method for 
selec6vdy collecting the compound of interest. This peak was also submitted for mass 
spectral analysis by LCMS which showed it represented a mass of 11,009 Da as expected 
for CV -N (IS). A small shoulder peak of mass 6,584 Da was also noted but was estimated 
to represent <5% of the mass of the sample. Indications from the LDDRD had been that 
the crude CV -N was ~50% pure by mass, but after successive preparative HPLC 
collections the percentage purity was found to be only 12% by mass. A large proportion of 
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material was found to come off very early in the HPLC runs and therefore must have come 
from more polar compounds than CV -N (15). 
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3.3 CV-N-Cys 
In comparing the strategies developed for this project, and discussed in chapter 2, the 
method employing the use of CV-N-Cys is probably the most desirable. This is because 
the product formed will be homogeneous, having only one toxin molecule per CV-N 
molecule. Therefore, production of CV-N-Cys was important in order for this strategy to 
be viable. Recombinant production of proteins from a DNA sequence is now standard 
practice around the world. The production of CV -N-Cys followed very similar protocols to 
those of native CV-N (15) reported by Boyd et al.71 and Mori et al. s3 and described in 
section 1.2.3. The basic idea, as outlined in Figure 3.3, is to introduce a plasmid (vector) 
containing the coding sequence for CV-N-Cys into E. coli cells through transformation. 
After incubation of the cells, the CV-N-Cys protein will be expressed through induction 
and then move into the periplasmic space. While cells exposed to slowly varying 
extracellular osmotic pressure are usually able to adapt to such changes, cells exposed to 
rapid changes in external osmolarity, can be mechanically injured. The procedure in this 
case was conducted by fIrst allowing the cells to equilibrate internal and external osmotic 
pressure in a high sucrose medium, and then rapidly diluting away the sucrose. The 
resulting immediate overpressure of the cytosol is assumed to damage the cell membrane. 
Proteins released by this method are believed to be periplasmic, or at least located near the 
surface of the celL In this way the CV -N -Cys is released into solution and 
chromatographic purifIcation can take place. 
3.3.1 Recombinant Production of CV-N-Cys 
Whole E. coli cells containing the plasmid pET26b with coding for CV -N-Cys were added 
to a "Super Broth" solution made up of kanamycin (30 Jlg/mL), glucose (0.5%) and MgS04 
(1.6 mM). This broth was incubated overnight at 37°C. A sample of this inoculation broth 
was added to each of eight conical flasks (with fms for aeration) containing "Super Broth" 
(500 mL). These solutions were in turn incubated at 37°C for four hours. An OD6oo 
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Figure 3.3 transformation and expression of CY -N-Cys protein in E. coli cells 
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(optical density) test indicated that the cells had grown sufficiently and were ready for 
induction. IPTG was added to each broth mixture (5 mL, 100 roM) in order to start the 
process of protein production. After another 2 hours incubation at 37°C, the protein had 
been produced and needed purification. The combined broth solutions were centrifuged at 
4°C and the supernatants discarded. The remaining pellet containing the whole E. coli cells 
with CV-N-Cys incorporated in the periplasmic space was suspended in a high sucrose 
content solution and stirred for 15 min. Following centrifugation at 4°C the supernatant 
was again discarded. The pellet was now suspended in ice cold MgS04 (5 roM) and again 
stirred for 15 min. This process burst open the outer membrane and released the CV-N-
Cys into the surrounding solution. After centrifugation at 4°C, the supernatant was retained 
this time as it contained the protein of interest. The solution was then frozen and freeze 
dried. 
3.3.2 Purification and Analysis of CV -N-Cys 
The freeze dried solid was resuspended in water and washed onto a reverse phase C4 pad. 
Washing with water removed salts such as MgS04 and other polar contaminants. An 
increasing gradient of methanol eluted the CV-N-Cys protein. Solvent was removed under 
vacuum. A Bradford Protein Assay (described in section 8.1) estimated the mass of protein 
content to be approximately 75 mg at this stage. This value represented all proteins 
present, not specifically CV-N-Cys, and so would be reduced after further purification. At 
this stage, an SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis) 
(described in section 8.1) was also run in order to ascertain the relative molecular weights 
of all proteins present. SDS-P AGE utilises a voltage difference applied across a gel on 
which proteins migrate according to their size. Pre-determined size markers give an 
indication of the size of protein(s) present. In this case, the gel indicated the major 
component was a protein of approximately 11 lilla, but with many contaminants from 
proteins of various molecular masses with most being greater. This was expected at this 
stage of purification as the many proteins present in the periplasmic space would also be 
retained on the C4 pad and elute with the methanol-containing fractions. 
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The next stage was reverse phase C18 preparative HPLC with PDA detection at 2lO nm. 
An increasing gradient from 20% to 50% CH3CNIH20 (0.05% TF A) eluted the major 
protein at approximately 35% CH3CN. Collection of the peak over multiple injections 
yielded 43 mg of purified sample. A further SDS-PAGE experiment established that the 
sample had been purified with a single spot at approximate molecular weight 11 kDa. The 
correct mass for CV-N-Cys is 11,112 Da but an LCMS of the sample revealed a mass of 
11,417 Da. This particular mass had been seen as a minor component with previous CV-
N-Cys cultures at the LDDRD and determined to be CV-N-Cys-glutathione (30). 
Glutathione is a common cellular component containing a free thiol and during the 
expression or purification procedures, coupled to the free thiol presented by the extra 
cysteine residue to form a disulfide. However, in this case, all of the CV-N-Cys appeared 
to be coupled to glutathione. This was- obviously unsuitable as the thiol side chain of the 
cysteine was to be utilised to react with maleimides. 
3.3.3 Removal of Glutathione from CV-N-Cys-Glutathione 
In order for the CV-N-Cys-glutathione (30) to be useful as a protein carrier the glutathione 
had to be removed. As the bond between the cysteine and the glutathione was a disulfide, 
the obvious method for breaking this bond would be reducing conditions. This would, 
however, also break the existing two disulfides present in the native CV-N structure. The 
early studies on CV-N (15) showed that a breakage of the internal disulfides led to a loss of 
anti-HIVactivity.71 This points to the disulfides having a crucial role in determining the 
active tertiary structure of CV-N (15). Therefore, under reducing conditions the anti-HIV 
activity would be lost. Ideally, a reagent that selectively cleaved a glutathione disulfide 
over a 'normal' cystine bond would be most useful, but such a reagent could not be found. 
Many reagents exist that do cleave all types of disulfide bonds such as dithiothreitol (DTT) 
and 2-mercaptoethanol. If these reagents were employed the protein would have to be 
allowed to refold back in the correct tertiary structure, forming the correct disulfides. 
Therefore, a strategy was developed to overcome the problem of glutathione addition by 
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cleaving all disulfides, removing the small molecules present, and fmally allowing the CV-
N-Cys to refold gently while reforming the native disulfide bridges. 
3.3.3.1 Dialysis Treatment of CV -N-Cys-Glutathione 
The first attempt undertaken for removal of the glutathione from CV-N-Cys utilised 
dialysis as the method for separation. The process was carried out using a 'Protein 
Refolding Kit' (Novagen) containing a dialysis cartridge, dialysis buffer and DTT (1 M). 
The cartridge contained a semi-permeable membrane with a MW cut-off of 2,000. 
Therefore, smaller molecules could transverse the membrane while larger molecules (such 
as CV-N-Cys) would be retained inside the cartridge. The driving force of this reaction 
was the change in. concentration of the outer and inner solutions. The buffer in both inner 
(2.5 mL) and outer (1,000 mL) solutions was initially made up to 0.1 mM DTT therefore 
equilibrating both solutions. The DTT cleaved off the glutathione which then moved 
through the membrane to the larger volume. This would be due to the high concentration 
of cleaved glutathione inside the membrane which must equilibrate with the much larger 
outer solution, hence, effectively diluting it from the inner solution. This solution was left 
gently stirring at 4°C for six hours and then the outer solution was changed to fresh dialysis 
buffer (0.1 mM DTT). After another 12 hours of stirring the outer solution was changed 
again, this time to just dialysis buffer. This would therefore permit any DTT remaining in 
the inner solution to permeate through the membrane and allow the CV -N-Cys, now free of 
glutathione, to refold. After another 6 hours the outer solution was refreshed with buffer 
and left stirring overnight. The inner solution was then removed from the cartridge and 
chromatographed on a small C4 column and washed with water to remove all salts and 
buffers present. Elution with methanol yielded the putative CV -N-Cys. 
An SDS-PAGE revealed that when the sample was boiled prior to addition to the gel (as is 
standard for SDS-P AGE), the protein was a monomer of approximate molecular weight 11 
kDa. If the sample was run without boiling, a dimer of weight 22 kDa was observed. An 
LCMS analysis also showed a molecular weight corresponding to dimeric CV-N-Cys. 
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Therefore the dialysis process had successfully removed the glutathione adduct but in the 
refolding process two monomers had come together to form a non-covalently bound dimer. 
Dimers of CV-N are not unusual as discussed in section 1.2.5 with respect to the solution 
and crystal structures of CV-N. The refolding conditions of the dialysis process must have 
been sufficient for the inducement of dimer formation. The dimeric CV -N -Cys was 
submitted for an XTT (anti-HIV) assay and showed an ECso 12 times less than native CV-
N (15) (submitted in tandem). However, at the level tested, a variation of only 12 times 
was not a significant difference. An ECso is a measure of how well a drug will protect cells 
from infection by HIV virus. A thorough explanation of the XTT assay and the meaning of 
the ECso result is discussed in section 6.2.2. Together the analytical results show that the 
CV-N-Cys had more than likely refolded correctly (as the activity was still good) but in the 
process had formed a dimer. 
3.3.3.2 Repeat of Dialysis of CV -N-Cys-Glutathione 
The encouraging results above led to a second attempt to produce CV-N-Cys using dialysis 
to remove the glutathione. Several experimental changes were made, hopefully to improve 
the refolding section of the procedure and prevent formation of dimer. The initial dialysis 
treatment was the same as that above with the CV-N-Cys-glutathione placed in the dialysis 
cartridge with the inner and outer solutions set to 0.1 mM DTT. This was left stirring 
overnight. The inner solution was then transferred to 500 mL of water in order to dilute 
out the CV -N-Cys, allowing it to refold slowly. The solution was then progressively 
loaded into two (for balance) 3,000 MW cut-off Centriprep filters. These filters have a 
membrane which only allows molecules below a certain molecular weight cut-off to pass 
through the membrane, under centrifugal forces. As the initial solution passes through the 
membrane, more solution is added fmally leaving a concentrated sample containing only 
compounds over MW 3,000, in this case CV-N-Cys. After this process the two samples 
were combined and freeze dried. The SDS-P AGE for this sample was similar to the first 
dialysis in that with pre-boiling of the sample it appeared as a monomer but without boiling 
the compound appeared as a dimer. The mass spectral analysis (LCMS) also revealed the 
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presence of dimer. The XTT assay result showed an ECso 60 times greater than CV-N 
(15). Therefore, this experiment also successfully removed the glutathione molecule, but 
the protein also failed to refold as monomeric CV-N-Cys. 
3.3.3.3 Chemical Removal of Glutathione 
In an alternative approach to glutathione removal and protein refolding, CV-N-Cys-
glutathione (10 mg) was dissolved in guanidine HCI (8 M) and vortexed gently before Tris 
HCI (33 ilL of 3 M) and DTT (20 J.1L of 500 mM) were added to firstly denature the protein 
and secondly to cleave all disulfides present. Finally, the sample was flushed with N2 gas, 
sealed with foil and left in the dark for 2 hours. A G100 column (40 x 2.5 cm) was 
prepared eluting with PBS (Phosphate Buffered Saline). The sample was chromatographed 
and fractions collected every 2 min with a flow rate of 2.1 mLimin. Monitoring at 280 run 
allowed collection of a single peak over 10 fractions from 32-52 min. The combined 
fractions were filtered through a 3,000 MW Centriprep as for the previous sample above 
and concentrated to a small volume (--10 mL) and then freeze dried. SDS-PAGE showed 
monomer with boiling of the sample, and approximately a ratio of 1:2 monomer to dimer 
without boiling. In contrast to the dialysis experiments the LCMS of this sample showed 
distinctly monomer with a mass of 11,112 Da. However, the XTT assay showed an ECso 
668 times greater than CV-N (15) which means that this sample is significantly less active. 
Therefore, this method also removed the glutathione successfully and importantly produced 
CV-N-Cys monomer (LCMS), but on refolding had obviously failed to form the correct 
tertiary structure. 
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3.4 CV-N Amines Converted to Thiols 
3.4.1 Lysozyme Model with Iminothiolane 
ill order to test the efficiency of converting a protein's lysine side chain amines to thiols 
with iminothiolane (27), a model protein (lysozyme) was first tested. This model system 
would form the basis of subsequent reactions with CV-N (15) to perform the same 
functional group transformation as outlined in section 2.5.2. Lysozyme has a molecular 
weight of approximately 14,300 Da and so was similar in size to CV-N (15) therefore 
making it a suitable model. More importantly lysozyme has eight lysines and an N-
terminus therefore giving nine potential sites for conversion as compared to CV-N's (15) 
six amines. 
Lysozyme (1 mg) was dissolved in reaction buffer (1 mL, 0.1 M sodium borate, 0.001 M 
EDTA, 0.15 M NaCI) and 10 equivalents of iminothiolane (27) added (96 J.!L of 1 mglmL 
solution). The reaction was followed by ESIMS analysis with 5 J.!L aliquots diluted 30-fold 
and inj ected directly into the mass spectrometer with 5 J.!L of a 10% formic acid solution to 
protonate the protein. The spectrum from the first injection, 5 min after the iminothiolane 
(27) was added, is shown in Figure 3.4a) and is typical of proteins. 
ill order to show a signal in an electrospray mass spectrometer the compound of interest 
must have the ability to be protonated for positive mode electro spray, or lose a proton for 
negative mode work. Proteins have many functional groups that can be protonated and 
therefore can be readily multiply charged. The signal from the mass spectrometer is plotted 
as an intensity versus mass/charge (mlz) ratio. So, for example, if a compound had a 
molecular mass of 10,000 Da and was capable of holding 10 charges (10 Hl a signal 
would be detected at 1,001 mass units. Therefore, in this case the 'A' series ions (blue) in 
Figure 3.4a), representing native lysozyme, are shown with charges ranging from 9 (mlz = 
1590.3) to 17 (mlz 842.4). The 'B' series (red) showed the beginnings of formation of 
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lysozyme protein with one single iminothiolane molecule attached. The numbers in the top 
right hand comer of Figure 3.4a) represent an estimate of the total molecular mass of the 
protein [calculated by multiplying the particular ions by their charges and then taking away 
the number of charges (as a charge is due to a proton of mass ~1)]. The numbers are 
averaged and the error is shown to the right of the mass. As the peaks become smaller or 
more concentrated they are less easily resolved and the error in the calculation increases to 
reflect this. 
The addition of a single iminothiolane molecule to form the amidine derivative of 
lysozyme increases the mass of the protein by 101 mass units and therefore raises the 
overall mass from ~14,305 to ~14,406 Da. The next injection, 25 min after addition of 
iminothiolane (27) is shown in Figure 3.4 b). Now the'S' series of ions has surpassed the 
'A' series in intensity confirming that lysozyme has had a single iminothiolane molecule 
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added. There was also the beginnings of a series of ions CC', green) that represented 
addition of two iminothiolane molecules to lysozyme. After 45 min, (Figure 3.4c») the 
dominant species was lysozyme plus one iminothiolane CB' series) while the plus two ('C' 
series) had almost reached the level for that of the native lysozyme CA' series). The next 
spectra at 65 min (Figure 3.4d») continued the same trend with the 'B' series dominant, 
then 'c' and 'A'. The final spectrum at 90 min (Figure 3.4e») showed the lysozyme plus 2 
iminothiolane molecule(s) as the most abundant species while the remaining native 
lysozyme had dropped below the observed level of the +2, +3, and +4 additions. 
This experiment confirmed that the reaction of iminothiolane (27) with a protein converted 
the lysine side chain amines to thiols in a time-dependent manner. It also demonstrated 
how readily the reaction can be followed by mass spectrometry. Importantly, there is 
minimal sample wasted by analysis. 
The reaction mixture was then further reacted with maleimide derivatives to test the next 
stage of the reaction scheme. This is detailed in section 5.2.1. 
3.4.2 CV .. N Plus Iminothiolane 
3.4.2.1 Preliminary Reaction to Test Effectiveness of Thiolation 
The positive result with the model protein lysozyme led to the same reaction being 
performed on CV-N (15). The first attempt at this reaction used 200 Ilg of CV-N (15) with 
10 equiv. of iminothiolane (27) but yielded different results from that observed for 
lysozyme. The reaction mixture was analysed by taking 10 JlL aliquots, diluting them 
followed by ESIMS analysis. This was carried out after 5 min and 25 min. The 5 min 
sample merely showed native CV-N (15) with no modified protein visible in the mass 
spectrum. The 25 min sample showed only a very small conversion of CV-N to the plus I 
iminothiolane product. A further 20 equiv. of iminothiolane (27) was added to force the 
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reaction to proceed. After another 5 mm reaction period, ESIMS analysis showed 
formation of the single iminothiolanc addition product. At a total reaction time of 45 min 
the analysis indicated plus 1 and plu 2 iminothiolane adducts present. Addition of a third 
iminothiolane was apparent after 60 min although the reaction rate was much slower than 
f()[ lysozyme. There was still a large proportion of native CV -N (15) present, therefore 
another 20 equiv. of iminothiolane (27) was added to the reaction mixture. The 80 min 
spectrum (Figure 3.5) showed approximately equal proportions of native CV -N (15) to the 
plus I iminothiolane adduct with smaller proportions of the plus 2 and plus 3. At this stage 
the mixture was reacted with a maleimide group (see section 5.2.2). 
In comparison to lysozyme there were distinct differences to this situation. All reaction 
conditions remained identical, but the CV -N (15) protein was much slower to react with 
the iminothiolane (27). However, the main objective was achieved as reaction did take 
place, with CV -N (15) requiring a greater number of equivalents of iminothiolane (27) 
and/or a longer reaction time compared to lysozyme. 
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3.4.2.2 Second Reaction with Modified Conditions 
The reaction between CV -N (15) and iminothiolane (27) was re-examined over a longer 
time frame and using a higher ratio of iminothiolane (27) to CV-N (15). CV-N (15, 200 
f.lg) was taken up in reaction buffer and 50 equiv. ofiminothiolane (27) added. Monitoring 
by ESIMS analysis at intervals did indeed show formation of the desired iminothiolane 
adducts. The reaction was still somewhat slower than that for lysozyme, but the formation 
of significant amounts of thiolated-CV -N was observed by ESIMS analysis. 
With the large excess of iminothiolane (27) present it became necessary to purify the CV -N 
adducts prior to reaction with maleimides. Although iminothiolane (27) reacts 
preferentially with amines it is also slowly hydrolysed to a free thiol. With a, slow reaction 
and a high ratio of iminothiolane (27) to protein there is a significant concentration of free 
thiol originating from the iminothiolane. This would interfere with reaction of any 
maleimide derivative with the protein thiols necessitating a purification step. The 
thiolated-CV-N adducts were chromatographed on a G25 size exclusion column eluting 
with water with monitoring at 276 nm. The protein adducts eluted first followed by the 
lower molecular weight components present including excess iminothiolane (27) and its 
hydrolysed form. After concentration of the protein fraction, the thiolated-CV-N was ready 
for derivatisation with maleimide containing constructs (section 5.3.2). 
3.4.2.3 Optimised Reaction of CV-N Plus Iminothiolane 
This final reaction between CV-N (15) and iminothiolane (27) took into account the 
previous reactions in order to optimise the attachment of the thiol group to the protein. To 
CV-N (15, 200 f.lg) in reaction buffer (O.IM sodium borate, O.OOIM EDTA, 0.15M NaCI) 
was added 100 equiv. ofiminothiolane (27). The start of formation of the thiolated-CV-N 
was noted after ESIMS injections at 5 min and 25 min respectively. The signal to noise 
ratio was quite poor mainly due to the presence of the buffer suppressing the ionisation of 
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the protein. However, the product fOimed was primarily of the H with a little +2 adduct 
and therefore the reaction was stopped. This was achieved by adding the reaction solution 
to a G25 chromatographic column eluting with water 30 min after the reaction had begun. 
The column separated the protein material from the small molecule buffering ions and 
excess iminothiolane (27) present. The protein fraction was collected and with the removal 
of the small molecules, easily analysed by ESIMS (Figure 3.6). The reason the reaction 
was stopped and purified at this stage was to provide primarily one site on the CY-N 
protein for modification with maleimides. The 100 equiv. of iminothiolane (27) (as 
opposed to the previous 50 equiv.) allowed the reaction to proceed faster with the G25 
chromatography removing the excess reagents effectively. If a larger degree of 
modification was required then the reaction would merely need to be left for longer with 
monitoring by ESIMS injections at various time intervals. The thiols formed were 
relativdy stable in that they survived the column chromatography and it was noted that 
they can be kept in solution for at least 24 hours although ideally they should be formed 
and reacted as needed. This particular thiolated-CY -N was reacted with a maleimido toxin 
derivative in section 5.5.2. 
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3.5 Conclusions from CV-N Development 
There were three CV-N derivatives developed as part of this project. The first was the 
native CV-N (15) itself. Although a lengthy and time consuming process, preparative 
HPLC did purify the CV-N (15) protein to an acceptable level. The second derivative, CV-
N-Cys, proved much more difficult to obtain as, although the recombinant production 
proceeded smoothly, the fmal product had glutathione attached. Removal of this impurity 
was achieved although refolding of the protein caused either dimer formation or loss of 
bioactivity. The last derivative utilised in this project was thiolated-CV -N obtained 
through reaction of CV-N (15) with iminothiolane (27). After initial testing with 
lysozyme, the transformation was carried out on CV-N (15) to produce the protein with the 
presence of free thiols. 
If the CV -N -Cys could be produced free of impurities then its manufacture and purification 
would be identical to that of the native CV-N (15) originally produced. The thiolation was 
a single quick step from the native protein and so overall there would be very little 
difference in long term supply or production of these three CV-N derivatives. The 
differences lie in the fact that the native protein can have conjugation in up to six sites, the 
CV-N-Cys at a single position while the thiolation can produce whatever degree of 
conjugation is required between these numbers. Therefore, although very similar in 
structure, these three CV-N derivatives have distinct profiles that can be exploited to 
produce specific target conjugates. 
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Chapter 4 
SUCCINIMIDYL METHODOLOGY 
4 .. 1 Introduction 
The succinimidyl entity is the most commonly utilised grouping for attaching small 
molecules to proteins. The rationale for this usage is the relative stability of the 
succinimidyl group in solution and selective reactivity towards primary amines. The 
introduction of the succinimidyl group can be through either a carboxyl, amine or alcohol 
functionality on the compound to be activated, which is again a demonstration of the utility 
of this activation method. This chapter describes three areas where succinimidyl ester 
methodology was utilised. 
Many of the derivatising reagents available for protein modification exploit the reactivity 
of the succinimidyl ester. Two such compounds are the fluorescent reagents 5-SFX (31), 
and BODIPY FLX-SE (32), both of which were chosen to react with CV-N (15) to test a 
variety of reaction parameters before commitment of toxin derivatives. These activated 
dye molecules did not contain a cleavable biolinker and as such did not specifically test 
that phase of the reaction scheme. However, their reaction profiles and subsequent analysis 
allowed formulation of a strategy when dealing with the subsequent biolinker derived 
conjugates. 
Before reaction of CV-N (15) with toxin containing conjugates, the synthetic scheme 
leading to these final products needed to be tested to optimise each reaction step. The 
choice was made to substitute the toxin for a fluorescent derivative. This derivative would 
have the advantage of being chromatographically distinct by UV profile and ultimately lead 
to fluorescent conjugates of CV-N (15) that could be more easily detected and tested. The 
coumarin molecule is a well-characterised fluorescent compound and was readily available 
with a free primary amine as is the case with toxins such as norhomohalichondrin B amine 
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(28). A final strategy was developed that would be suitable for replacement of the 
coumarin with the halichondrin moiety. 
The last section of this chapter deals with the synthesis of succinimidyl ester biolinker-
toxin conjugates in order to activate them for reaction with CV-N (15). The synthetic 
strategy was again developed from the reactions involving the coumarin conjugate in 
overcoming various problems. The final synthesis was successful and yielded a CV-N 
conjugate with a biolinker and toxin attached. 
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4 .. 2 Fluorescein 5-SFX and BODIPY FLX-SE 
4.2.1 Dye Reactivity 
The structures of the two dye molecules (Molecular Probes Inc.) are shown below. Both 
dyes have a (CH2)s linker separating the 'fluorescent' section of the molecule from the 
succinimidyl ester. These were specifically chosen to mimic the relative size of the peptide 
biolinker that would ultimately be present in the toxin conjugates. This pendant chain also 
separates the fluorophore from its point of attachment, potentially reducing the interaction 
of the dye molecule with the protein after conjugation and minimising interference of the 
binding of the CV-N derivative to gp120. The molecular weights of the two dyes are 587 
Da for 5-SFX (31) and 502 Da for the BODIPY conjugate (32). Once attached to the side 
chain amines ofCV-N (15), the increase in mass per addition would be 471 Da and 387 Da 
respectively, allowing easy identification of the CV-N-dye co~ugates. 
HO 
Fluorescein 5-SFX(31) 
BODIPY FLX-SE (32) 
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4.2.2 5-SFX Reactions with CV-N 
4.2.2.1 Reactions at pH 8.2 
The reactions of 5-SFX with CV-N (15,200 Ilg) was carried out on in NaHC03 buffer (200 
ilL, 0.1 M) at room temperature. The pH of the buffer was 8.2 which is ideal for the 
reaction of primary amines with succinimidyl esters. To test the efficiency of the reaction 
and to judge the reactivity profile of the succinimidyl esters, three different ratios of dye to 
protein were used (2 (33), 6 (34), and 25 equiv. (35)). The reaction time in each of these 
three experiments was 15 min (as recommended by Molecular Probes Inc.) The 25 
equivalent reaction was also repeated :vith a reaction time of 1 hour (36) to ascertain if 
reaction time was a factor in product formation. 
For each experiment the 5-SFX dye (31) was dissolved in DMF and the appropriate volume 
added to the CV -N buffer solution and left at room temperature for the required time. 
After each reaction was complete the sample was chromatographed on a G25 size 
exclusion column (140 x 10 mm) eluting with phosphate buffered saline (PBS). On the 
column the sample separated into two coloured bands, the first eluting being light orange 
("" 5 mL) and the second bright yellow. This was noted for all four reactions with the light 
orange band becoming more intense as the equivalents of dye and the reaction time were 
increased respectively. This was a positive sign that the reaction had taken place as the 
first band eluted would represent the fluorescent protein derivatives followed by the 
smaller unreacted and/or hydrolysed dyes. Each sample was submitted for LCMS analysis. 
The results are shown in Table 4.1. 
Table 4.1 CV-N (15) reactions with 5-SFX (31) at pH 8.2 
Number of dye molecules attached (%) 
Conditions 0 1 2 3 4 
5-SFX, 2eq, 15min (33) 42 48 10 a a 
5-SFX, 6eq, 15min (34) 7 46 37 10 a 
5-SFX, 25eq. 15min (35) a 15 47 30 8 
5-SFX, 25e9, 60min (36) a a 9 47 44 
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The percentages expressed in Table 4.1 are derived from the abundance of the relevant mlz 
ions in the mass spectra. This table is also displayed graphically below (Figure 4.1). 
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o 5-SFX, 25eq, 15min 
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Figure 4.1 CV-N reactions with 5-SFX (31) at pH 8.2 
The results show a clear trend with respect to the reactivity of the succinimidyl ester of 5-
SFX. As the number of equivalents was increased from 2 to 6 to 25, the number of dye 
molecules attached increased significantly. The final data series (light blue) representing 
the extended reaction time of 1 hour also increased the average number of dye molecules 
with most CV -N molecules having 3 or 4 fluorescent tags. Interestingly, there was no sign 
of any conjugates beyond the attachment of four dye molecules. This could mean that there 
ar one or two arnines pr sent in CV -N (IS) that are not as accessible in terms of reactivity. 
CV-N (15) has 5 amines and an N-terminal, potentially allowing attachment of six dye 
molecules. Figure 4.2 shows in three dimensions the positions of the lysine residues and 
the N-terminal derived from the published solution stmcture ofCV-N.85 As can be noted, 
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the side chains of the lysine residues seem to be free of any obstruction (not buried 
internally), although the visualisation does not highlight the rest of the amino acids' side 
chains (for clarity). However, even taking this factor into account, all amines appear to be 
pointed outwards, towards the surrounding solution and are therefore presumably available 
for reaction. Another, more appealing hypothesis is that once a dye molecule is attached to 
a lysine side chain, it may, due to steric interference, prevent a further succinimidyl group 
from reaching a neighbouring lysine amine. The N-terminal and adjacent lysine side chain 
amines are a mere 5.1 A apart while the two lysine side chains to their len in Figure 4.2 
" 
are relatively close at J 3.7 A. It will ultimately take an enzyme digest analysis to 
determine where exactly the dye molecules are attached and even then, it may still prove 
diffi cult to distinguish a clear relative reactivity of the amines. 
c-5.1 A 
N-Terminal ! Ir ' 
13.7A~ 
Ir------'~-__, 
This view is rotated 900 to the right 
Figure 4.2 CV -N with lysine amines and N-terminal highlighted 
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In summary, this fIrst series of reactions indicated that CV-N (15) was capable of reacting 
with succinimidyl esters in a concentration and time dependent manner with up to four dye 
molecules able to be attached. 
4.2.2.2 Reactions at pH 7.2 
The optimum pH for the reaction of succinimidyl esters was suggested as -pH 8.0 to 9.5, 
however, literature149 had suggested the possibility of N-terminus amine selectivity if the 
pH of reaction was lowered to around 7. This is due to the differential pKa of an N-
tenninus (~7) amine versus a lysine side chain amine (-10.5). To determine if this maybe 
the case, and to also test the reactivity of the succinimidyl esters at near neutral pH, a series 
of reactions was also carried out at pH 7.2. 
The reaction conditions were exactly the same as those in section 4.2.2.1 with 2 (37), 6 
(38), and 25 equiv. (39) of dye reacted for 15 min and 25 equiv. reacted for 60 min (40). 
The only difference was the change of buffer, from NaHC03 to PBS. After the reactions 
were completed, the samples were again chromatographed on a small G25 colunm, but this 
time it was much more difficult to determine coloured bands representing the protein-dye 
conjugates. As elution times were consistent for all reactions of this type, fractions were 
still collected at the appropriate times for separation of 'protein' material and 'small 
molecule' material even if they could not be determined visually. The results are shown in 
Table 4.2 and Figure 4.3 below and indicate a signifIcant difference from the series of 
reactions at pH 8.2. Only 3% of the CV -N (15) was converted to the single dye fonn at 2 
equiv. with still only 21 % even at 25 equiv. The fInal reaction with 25 equiv. over a 1 hour 
reaction period showed 47% of single dye and 8% of two dye conjugates. A comparison 
between Figure 4.1 and Figure 4.3 shows this decrease in reactivity from pH 8.2 to 7.2. 
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Table 4.2 CV-N (IS) reactions with 5-SFX (31) at pH 7.2 
Number of dye molecules attached (%) 
Conditions 0 1 2 3 4 
5-SFX, 2eq, 15min (37) 97 3 0 0 0 
5-SFX, 6eq, 15min (38) 89 11 0 0 0 
5-SFX. 25eq, 15min (39) 79 21 0 0 0 
5-SFX, 25eq, 60min (40) 45 47 8 0 0 
It was difficult to tell from this series of reactions whether the data point towards an 
attachment of dye at primarily a single position (the N-terminal), or whether the 
preponderance of only a single attachment meant the reaction had slowed due to the non-
optimal pH. One of the reasons for this series of experiments was to determine if N-
terminal selectivity did occur in order to justify the oliginal strategy of attaching the 
terminal tripeptide with toxin attached to the CV-N(-3N) as discussed in section 2.2. 
100 
90 
80 
70 
% 60 
50 
40 
30 
20 
10 
0 
0 
3 
No. of dye molecules attached 4 
o 5-SFX, 2eq, 15min 1 
• 5-SFX, 6eq, 15min 
o 5-SFX, 25eq, 15min 
D5-SFX, 25eq, 60min 
Figure 4.3 CV-N reactions with 5-SFX (31) at pH 7.2 
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These results, and those to come with the BODIPY dye, were not as conclusive as would 
be needed to validate that particular strategy which is one of the reasons it was 
discontinued. The lack of general reaction for these four experiments demonstrated how 
crucial the pH was in the reactivity of lysine primary amines towards succinimidyl esters. 
4.2.3 BODIPY FLX-SE Reactions with CV-N 
4.2.3.1 Reactions at pH 8.2 
In order to contrast the reactivity profile of the succinimidyl esters present in the 5-SFX 
(31) compound, a separate dye, BODIPY FLX-SE (32), was also reacted in the same way. 
The experimental protocols were identical to those explained in section 4.2.2.1 with only 
the identity of the dye changing. After reaction, the colours of the eluted bands from the 
G25 column were orange for the protein-dye conjugates and a light green colour for 
unreacted dye. For the two reactions with 25 equiv. of the BODIPY dye (32) for a 15 (41) 
and 60 min (42) reaction time, reaction appeared to take place with coloured bands eluting 
as usual. However, mass spectral analysis by LCMS failed to show any sign of CV-N-dye 
conjugates or indeed, native CV-N (15). The coloured band eluting at the correct time for 
these reactions suggested that the conjugation had taken place with CV-N, so it was 
therefore puzzling to be unable to see the results by LCMS. A sample of these two 
fractions was further purified by loading onto a small C4 cartridge, washing with water to 
remove salts and buffers and then eluting with MeOH. These were then dried under a 
stream of N2 and resubmitted for LCMS analysis. Again, no sign of CV-N (15) or a 
conjugated derivative was observed. A possible explanation is that these reactions 
sufficiently 410aded' the CV -N with multiple dye attachments and this prevented 
protonation and ionisation in the mass spectrometer, although this did not take place for the 
5-SFX reactions with high loading. As the remaining reactions worked well it was not, 
however, considered to be a major obstacle. The results for the first two reactions with 
BODIPYusing 2 equiv.(43) and 6 equiv. (44) are shown in Table 4.3 and Figure 4.4. 
% 
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Table 4.3 CV -N (15) reactions with BODIPY FLX-SE (32) at pH 8.2 
Number of dye molecules attached (%) 
Conditions 
BODIPY FLX, 2eq, 15min (43) 
BODIPY FLX, 6eq, 15min (44) 
0 
2 
No. of dye molecules attached 
o 1 234 
75 25 0 0 0 
40 60 0 0 0 
3 
4 
o BODIPY FLX-SE, 
2eq, 15min 
• BODIPY FLX-SE, 
6eq, 15min 
Figure 4.4 CV -N reactions with BODIPY FLX-SE (32) at pH 8.2 
It is difficult to precisely define a trend with only two representative points but it was clear 
that as the number of equivalents increased from 2 to 6, the percentage of conjugates with 
one dye molecule attached increased. Compared to the results from the 5-SFX dye (31) 
(Table 4.1) the BODIPY dye (32) does not seem to be as reactive at this pH. 
% 
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4.2.3.2 Reactions at pH 7.2 
This series followed the protocol for the above reactions except at the lower pH of 7.2. 
There were no problems with the 25 equiv. reactions this time. The resulls are shown in 
Table 4.4 and in Figure 4.5. Both the 2 (45) and 6 equiv. (46) experi ments showed no 
modification to CV -N (15) whatsoever with moderate rates of attachment for the dual 25 
equiv. (47, 48) reactions. A c mparison of the two dyes shows, that like the reactions at 
pH 8.2 the BODIPY dye (32) appears to react more slowly than the 5-SFX (31). The 
results are again inconclusive as to N-tenninal selectivity of the succinimidyl est at the 
lower pH. 
Table 4.4 CV-N (15) reactions with BODrPY FLX-SE (32) at pH 7.2 
Number of dye molecules attached (%) 
Conditions 0 1 2 
BODIPY FLX, 2eq, 15min (45) 100 0 0 
BODIPY FLX, 6eq, 15min (46) 100 0 0 
BODIPY FLX, 25eq, 15min (47) 82 17 0 
BODIPY FLX, 25eq, 60min (48) 63 37 0 
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Figure 4.5 CV -N reactions with BODIPY FLX-SE (32)at pH 7.2 
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4.2.4 Conclusions Reached from the Dye Reactions 
The fIrst premise from this series of reactions was to confirm that the succinimidyl esters 
do in fact react with CV-N (15) forming stable amide bonds through the lysine side chain 
andlor N-terminal amines. These reactions clearly showed extensive reaction taking place 
in a concentration and time-dependent manner. The 5-SFX dye (31) appeared more 
reactive than its BODIPY counterpart (32) and both reacted more slowly at pH 7.2 than at 
8.2. Whether the lower rate of reaction at the lower pH was due to N-terminal selectivity 
or merely a consequence of the non-optimum pH was difficult to tell, and may be a 
combination of both factors. Further analysis of these samples to determine their binding 
affinities to gp120 and anti-HIV properties was also undertaken (section 6.3). In short, the 
results from the testing of these conjugates using the ELISA and XTT assays showed that 
the dye molecules did not interfere with binding of CV -N to gp 120. Therefore, the strategy 
to attach conjugates to CV-N (15) in this way could be continued (as follows). 
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4 .. 3 Biolinker-Coumarin Constructs 
While the reactions involving the fluorescent dye conjugates in section 4.2 showed that 
succinimidyl esters would react with amine groups in CV-N (15), there remained the 
question of whether or not the rest of the synthetic strategy outlined in section 2.4 and 
Figure 2.3 would work. There needed to be a systematic approach to joining the 
succinimidyl ester, biolinker, and toxin together in a way to maximise the yields of reaction 
while preserving the bioactivity of the toxin. A fluorescent coumarin derivative was 
chosen as a substitute for the toxin as it was commercially available, had a primary amine, 
and had the advantage of fluorescence for ease of purification and identification in further 
testing. 
4.3.1 Peptide Biolinker 
4.3.1.1 Peptide Bond Formation and Solid Phase Peptide Synthesis 
F ormation of a peptide bond requires that the carboxyl group of an amino acid be activated 
(X) while the amino group (Y) and non-participating carboxyl of the other amino acid (Y') 
be protected153 as shown in Figure 4.6. It is also necessary for some side chains of 
particular amino acids (e.g. lysine) to be protected so that they do not interfere with the 
coupling process. During this coupling the chiral integrity of the amino acids must also be 
preserved. In an ideal situation the protecting groups must be orthogonal to one another 
which means that they must be easily removable without simultaneous loss of the others, 
and vice versa. There is a wide selection of protecting groups available from which a 
o 
H II 
/N~C, + Y : X 
+HX 
R 
Figure 4.6 Model peptide coupling 
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strategy needs to be formulated to accomplish the specific peptide goal. 
The most efficient method for synthesising peptides is by using 'Solid Phase Peptide 
Synthesis' (SPPS) techniques. The synthesis is carried out from the C to N-terminal of the 
peptide. This involves sequential addition of a-amino and side chain protected amino acid 
residues to an insoluble polymeric support (resin bead). After removal of the N-
o, protecting group, the next protected amino acid is joined to the peptide by a coupling 
reagent. This process is repeated until the desired peptide length is reached, at which point 
the product is cleaved from the resin. The two most common protecting groups used for 
SPPS are the acid labile Boc group and the base labile Fmoc group. Of the two, Fmoc was 
chosen as more suitable due to the hazardous use of HF for the final cleavage of the Boc 
strategy and also concerns about the alteration of sensitive peptide bonds with the repetitive 
acid treatment used for Boc deprotection. Fmoc SPPS154 utilises piperidine (mild base) to 
remove the protecting group and TF A to cleave the peptide from the resin. 
4.3.1.2 Synthesis of Fmoc-Gly-Phe-Leu-Gly-OH 
The aim of this experiment was to produce the tetrapeptide Fmoc-Gly-Phe-Leu-Gly-OH for 
use with the various synthetic strategies utilising this biolinker. The glassware apparatus 
used for SPPS allowed the resin to be bubbled in solution with N2 over a frit and 
subsequently switched to vacuum to allow drainage and rinsing at the various stages of the 
synthesis. Fmoc-Gly-Wang resin (3 g, 0.897 meq/g) was bubbled in DMF for 30 min to 
pre-swell the beads allowing greater access for reagents in solution. The DMF was drained 
and a 20% piperidinelDMF solution (30 mL) added, with bubbling, to deprotect the glycine 
residue. After 10 min the reaction mixture was drained and washed with DMF and then 
IP A. At this stage a couple of resin beads were removed from the apparatus, washed with 
EtOH and submitted for Kaiser test analysis (discussed in section 8.1) to determine the 
presence of free amine. A positive test was obtained (blue resin beads) and the synthesis 
was allowed to continue. Once washed thoroughly, a DMF solution containing Fmoc-Leu 
(2 equiv.), HBTU (coupling reagent, 2 equiv.), HOBt (to prevent racemisation, 2 equiv.), 
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DIPEA (base, 4 equiv.) was added and bubbled for 60 min. After rinsing with DMF and 
again performing a Kaiser test (this time negative) the resin was ready for the procedure to 
begin again from the deprotection of the Fmoc group to the coupling of the remaining two 
amino acids (Fmoc-Phe and then Fmoc-Gly). After the final amino acid was coupled to the 
peptide the Fmoc-protected biolinker was left drying overnight in the presence of P20 5 
under vacuum. The peptide was now ready for cleavage from the resin with 95% TF A, 
2.5% H20, and 2.5% triethylsilane (TES, scavenger). After 20 min of bubbling, the 
solution was drained, rinsed with fresh TF A and collected into a flask. This solution was 
then concentrated on a rotary evaporator. Water was added to precipitate the peptide out of 
the acidic solution. The solution was next evaporated to remove more TF A and this 
process repeated with fresh additions of water each time to dilute out the acid solution. 
Water was added one last time and the resulting precipitate filtered on a sintered glass 
funnel. The Fmoc-Gly-Phe-Leu-Gly-OH (49) solid was then dried and weighed. (1.17 g, 
71 %). Small amounts of the product were detected in the aqueous wash by F ABMS, but 
the purity was very low and made recovery unworthwhile. 
4.3.1.3 Characterisation of Fmoc-Gly-Phe-Leu-Gly-OH 
The IH and l3C NMR spectra of 49 were readily assignable with reference to COSY, 
HSQC and HMBC 2D NMR experiments. The chemical shifts for the IH and l3C NMR 
spectra are shown in Table 4.5 with the structure and major HMBC correlations shown in 
Figure 4.7. The unique binding of amino acids in peptides allows 2D NMR techniques, 
particularly HMBC, to bridge across the amide bond of the peptide allowing a complete 
unambiguous assignment of structure. 
A good starting point for the structural elucidation was to use the readily assigned methyls 
ofC15 and C16 at 0.79 ppm. HSQC correlations confirmed the respective l3C resonances, 
while HMBC and COSY correlations from the methyl protons allowed assignment of C14 
and Cl3. A COSY correlation from the Hl3 resonances allowed assignment of the leucine 
a-proton, H5. From H5, a COSY correlation to the amide NH6 gave full assignment of all 
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Fmoc-Gly-Phe-Leu-Gly-OH (49) 
Table 4.5 j; H and 13C NMR data for Fmoc-Gly-Phe-Leu-Gly-OH (49) 
IH 0 (ppm)a De 0 (ppm)b IH 0 (ppm)a 
1 171.2 16 0.79 (d , J=5.9 Hz) 
2 3.79 (m) 40.7 17 2.97 (m) 
3NH 7.1 4c 18 
4 172.6 19 7.09 (m) 
5 4.33 (m) 51.4 20 7.12 (m) 
6NH 7.64 (m) 21 7.09 (m) 
7 171.2 22 
8 4.53 (m) 54.3 23 4.25 (m) 
9NH 7.4 (d, J=7.3 Hz) 24 4.12C 
10 170.2 25 
11 3.68 (m) 43.9 26 7.52 (d J=6.8 Hz) 
12NH 6.61 (m) 27 7.23 (t, J=6.8 and 7.5 Hz) 
13a 1.44 or 1.53 (m) 39.9 28 7.32 (t, J=7.5 and 7.5 Hz) 
13b 1.44 or 1.53 (m) 39.9 29 7.69 (d J=7 .5 Hz) 
14 1.44 (m) 24.2 30 
15 0.79 (d , J=5.9 Hz) 22.6 or 21 .0 
a Data recorded at 23°C in CDCI3 at 300 MHz with chemical shifts in ppm and referenced to CHCI3 , IiH 7.26 
b Data recorded at 23°C in CDCI3 at 75 MHz with chemical shifts in ppm and referenced to CDCI3, Oc 49.3 
C peak obscured therefore no multiplicity available 
15 
Figure 4.7 Important HMBC correlations for Fmoc-Gly-Phe-Leu-Gly-OH (49) 
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of the protons of the leucine residue. H5 also showed two HMBC correlations to carbons 
in the carbonyl region of the l3C spectra but only one of these two was seen as an HMBC 
correlation from HI3. This therefore could be assigned as C4 as only the leucine carbonyl 
was able to show HMBC correlations from the H5 and H13 protons. Another HMBC 
correlation to this leucine carbonyl (C4) allowed assignment of the adjacent glycine a-
protons H2 and the amide 3NH. All HSQC correlations in the spectra were present 
therefore allowing immediate correlation of IH chemical shifts to their 13C counterparts. 
The second HMBC correlation from H5 to a carbonyl resonance allowed assignment of C7 
although this turned out to have the same l3C chemical shift as Cl. HMBC correlations to 
C7 from HI7 and H8 respectively gave their chemical shifts, confmned by COSY 
correlations from H17 to H8 and from H8 to hTH9. Access into the aromatic ring of 
phenylalanine was gained through HMBC correlations from H8 and HI7. The chemical 
shifts of H28, H29 and H30 were overlapped in the IH spectrum but HMBC analysis 
elucidated their distinctive 13C resonances. The carbonyl, CIO, was found from an HMBC 
correlation from H8 which gave access to the glycine adjacent to the Fmoc group. Another 
HMBC to this carbonyl identified the a-protons HII with a COSY from HII giving NHI2. 
Linkage of the Fmoc group could be confmned from two HMBC correlations to the 
carbonyl C22 from both HII and H23. From H23 and C23 it was possible to follow the 
HMBC correlations around the remainder of the Fmoc group with HSQC correlations 
elucidating the respective proton resonances. 
The molecular formula for 49, C3~3807N4 was obtained by HRFABMS as the sodiated 
adduct of mass 637.27 Da (2.93 ppm). An analytical isocratic HPLC injection (CI8, 80% 
MeOHIH20 (0.05% TFA)) yielded a single peak: only, at 7.6 min retention time with a 
characteristic UV chromophore representing primarily the Fmoc group ofthe tetrapeptide. 
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4.3.2 Fmoc-Gly-Phe-Leu-Gly-Coumarin 
The structure of 7-amino-4-methylcoumarin (50) is shown below. The direct attachment of 
the amine to an aromatic ring reduces the nUcleophilicity of this amine and led to initial 
problems in coupling the coumarin moiety to the C-terminal of 49. The delocalising effect 
CH3 
7-amino-4-methylcoumarin (50) 
of the aromatic ring on the nucleophilic potential 
of the coumarin amine meant it could not be 
coupled via a succinimidyl ester as planned for 
the halichondrin derivative. However, a search of 
the literature revealed a method for coupling the 
coumarin amine to the carboxyl of the 
tetrapeptide using POCh in pyridine. lss These conditions were obviously too harsh for the 
toxin to survive but this first reaction would be accomplished via a succinimidyl ester when 
incorporating a toxin molecule. 
4.3.2.1 Synthesis of Fmoc-Gly-Phe-Leu-Gly-Coumarln 
To a solution of 49 in freshly distilled pyridine was added 50 (1.1 equiv.) along with POCh 
(1.1 equiv.) (Figure 4.8). After stirring for 1 hour the solution was dried under vacuum. 
HPLC analysis on an analytical CI8 column (80% MeOHlH20 (0.05% TFA)) allowed 
identification of the product from the change in both retention time and UV chromophore 
from the starting material. This elution profile was then transferred to a preparative CI8 
column and the resulting peaks collected with identification of the product at a retention 
time of 27 min. The Fmoc-Gly-Phe-Leu-Gly-coumarin (51) product was obtained in a 
yield of 67%. 
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Figure 4.8 Synthesis of Fmoc-Gly-Phe-Leu-Gly-coumarin (51) 
4.3.2.2 Characterisation of Fmoc-Gly-Phe-Leu-Gly-Coumarin 
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o 
Compound 51 would not dissolve in CDCb for NMR analysis. CD30D was therefore 
used, but resulted in a loss of the amide signals after a short period of time. The change of 
solvent also made the direct comparison of the NMR spectra of the tetrapeptide starting 
material (49) and 51 more difficult. However, the full structural elucidation was completed 
through use of COSY, HSQC and HMBC experiments as for the starting material (Table 
4.6). The distinctive chemical shifts of the H3' and H11' were significant in identifying 
the other components of the coumarin section of the molecule. HMBC correlations were 
again significant in assigning the l3C NMR spectrum. High resolution ESIMS confirmed 
the mass of 772.3341 Da (MH+, 0.7 ppm) for C44Rt6N50S. 
27 
o 17 
H~l o 22 N l(12 10 ~ 
o 12' 
~0~~~ 
13~16 
114 
15 
Fmoc-Gly-Phe-Leu-Gly-coumarin (51) 
l' 
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Table 4.6 IH and 13C NMR data for Fmoe-Gly-Phe-Leu-Gly-eoumarin (51) 
lH;) (ppm)a 13e ;) (ppm)b lH;) (ppm)a 13e ;) (ppm)b 
1 169.4 21 7.1 (m) 127.7 
2a 3.85 (d,J=17.1 Hz) 44.0 22 158.4 
2b 4.06 (d,J=17.1 Hz) 23 4.25 (m) 68.1 
3NH c 24 4.14(m) 47.6 
4 174.3 25 144.3 
5 4.26 (m) 53.8 26 7.51 (m) 125.9 
6NH c 27 7.22 (m) 128.1 
7 173.3 28 7.34 (m) 128.5 
8 4.57 (1, J =5.8 Hz) 55.5 29 7.70 (m) 120.6 
9NH c 30 141.9 
10 172.0 l' 
11 3.76 (bs) 45.0 2' 163 
12NH c 3' 6.15(s) 113.4 
13a 1.51 or 1:61 (m) 40.2 4' 154.4 
13b 1.51 or 1.61 (m) 40.2 5' 7.63 (m) 127.6 
14 1.51 (m) 25.3 6' 7.65 (m) 125.7 
15 0.85 or 0.87 (d, J =5.9 Hz) 21.9 or 23.4 7' 144.4 
16 0.85 or 0.87 (d, J =5.9 Hz) 21.9 or 23.4 8' 7.66 (s) 108.0 
17a 3.01 (dd,J=7.1 and 14.0 Hz) 37.7 9' 154.5 
17b 3.12 (dd, J=6.1 and 14.0 Hz) 10' 116.8 
18 136.6 ii' 2.37 (s) 19.0 
19 7.09 (m) 129.8 12'NH c 
20 7.12(m) 129.2 
a Data recorded at 23°C in CDsOD at 300 MHz with chemical shifts in ppm and referenced to CD2HOD. OH 3.31 
b Data recorded at 23°C In CD30D at 75 MHz with chemical shifts in ppm and referenced to CD30D. Oc 49.3 
C The amldes were only partially observed in the lH spectrum but had exchanged before characterisation from 
other experiments could take place 
4.3.2.3 Fmoc Removal to form H1N-Gly-Phe-Leu-Gly-Coumarin 
The suggested solvent for removal of the Fmoe group is DMF which is much less volatile 
and hence, much more difficult to remove than CH3CN. Mild conditions for solvent 
removal would be needed when the toxin was present. Therefore, this reaction was 
attempted in CH3CN (Figure 4.9) and was, therefore a test of whether the Fmoc group 
could be removed under these conditions. The Fmoc-Gly-Phe-Leu-Gly-coumarin (51) was 
dissolved in 20% piperidine/CH3CN and left for 30 min. The solvent was removed and the 
THE LIBRARY 
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sample dried under vacuum. The solid was dissolved in DCM and chromatographed on a 
small silica column. Three fractions were collected, eluting DCM, EtOAc and fmally 
MeOH. The Fmoc-adduct (52), eluted in the EtOAc fraction while the product (53) was 
not eluted until the MeOH fraction. 
o 
piperidine 
CH3CN 
~ 0 (53) 
~~'l) 
Y 
Figure 4.9 Removal of Fmoc group from Fmoc-Gly-Phe-Leu-Gly-coumarin (51) 
Characterisation of HzN-Gly-Phe-Leu-Gly-coumarin (53) was by direct comparison of the 
IH NMR spectrum with 51 and by ESIMS analysis. The removal of the Fmoc group made 
the characterisation much easier as the many aromatic resonances of Fmoc were removed 
from the spectrum. There was also a significant downfield shift of the N-terminal glycine 
a-proton resonances. This was expected from conversion of the adjacent amide to an 
amine. 
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4.3.3 Succinimide Activation of HzN-Gly-Phe-Leu-Gly-Coumarin 
The initial strategy at this stage was to activate the free terminal amine with a succinimidyl 
ester in order to react it with CV-N (15). The reagent N,N'-disuccinimidyl carbonate 
(DSC, 54)143 is capable of converting amines to succinimidyl esters, as shown in Figure 
4.10, forming a carbamate or urethane bond. Once the carbamate ester reacts with CV-N 
(15) a stable urea bond would be formed. 
DSC (54) 
Q-~~ 
o a 
+ HO~ 
a 
R-NH2 
Figure 4.10 Activation of amines by DSC (54) 
The reaction between DSC (54) and H2N-Gly-Phe-Leu-Gly-coumarin (53) was attempted 
many times with varying solvents and conditions. Although the correct product was seen 
by 1 H NMR spectroscopy and ESIMS analysis of the crude samples, purification 
predominantly led to a compound with a mass 26 Da higher than that for the amine, but 
115 Da less than that required for the succinimidyl ester. The presence of the succinimidyl 
ester in the crude sample was relatively easy to identify in the 1H NMR spectra (singlet of 
integral 4, at "'2.8 ppm). However, the intensity of the corresponding resonance decreased 
no matter what method was attempted for purification (e.g. column chromatography or 
HPLC). The other striking features of the resulting IH NMR spectrum after 'purification' 
when compared to the starting material amine (53) was the downfield shift of the a-proton 
of phenylalanine by 0.50 ppm and the p-protons by 0.16 ppm respectively. This data, in 
combination with a shift in the N-terminal glycine a-protons of 0.22 ppm provided 
evidence for a dramatic change in the molecule. Possible adducts of the succinimidyl 
esters were investigated that matched both the NMR data and the ESIMS results. One 
proposal examined was that the phenylalanine amide had attacked the activated 
succinimidyl ester and produced a five membered imidazolidine ring as in Figure 4.11. 
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Figure 4.11 Postulated reaction of succinimidyl ester ofbiolinker-coumarin conjugate 
This would explain both the increase in mass from the parent amine by 26 Da and also the 
downfield IH NMR shift in the phenylalanine and glycine protons. An HMBC was 
attempted on the material but the sample was not completely pure and there was not 
enough material to resolve the signals representing the a-proton of phenylalanine 
correlating to three distinct carbonyls or from the N-temlinal glycine a-proton to two 
distinct carbonyls. This would have gone a long way to proving the postulated adduct was 
indeed present. 
4.3.3.1 Chain Extension Reaction with Succinic Anhydride 
To circumvent this problem, 53 was reacted with succinic anhydride (1.2 equiv.) and 
DMAP (l equiv.) in pyridine to extend the chain and convert the amine to a carboxyl in the 
hope that this would prevent the ring fOmIing reaction (Figure 4.12). The succinic acid 
adduct was duly purified (HPLC, CI8, 40% CH3CNIH20 (0.05% TFA)) and again reacted 
in the same way as above, with DSC (54) and pyridine in CH3CN. LCMS analysis using 
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the same elution conditions showed fonnation of the succinimidyl ester of the succinic-
biolinker-coumarin. However, as the reaction progressed a new peak began to be visible 
after some time, representing the product shown in Figure 4.12. The succinimidyl ester 
did fonn, but as before, it subsequently reacted internally displacing the ester in favour of 
this time, a succinimide ring. This was further proof of the postulated 'ring closing' 
reaction which made this particular reaction pathway unfavourable. The results of these 
reactions were unacceptable in tenns of transferring this strategy to incorporate the toxin 
molecule, therefore the strategy was modified (section 4.3.4). Precedents for this type of 
intramolecular reaction were found in the literature particularly with the succinic spacer 
present, although the leaving group was usually a drug (not NBS as in this case ).156-158 
o~ 
o 
HN II 2~N 
H 
pyridine 1 
DMAP 
y~ ~I ~ 0 o ~'¢~~ 
o 
H3 
Figure 4.12 Succinic anhydride reaction and subsequent activation and 'ring closure' 
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4.3.4 Adipic Anhydride Reaction with HzN-Gly-Phe-Leu-Gly-Coumarin 
An analysis of the two previous reactions demonstrated that in order for the 'ring closing' 
reaction to occur the amide needed to be four atoms away from the activated carbonyl. 
Therefore, an obvious solution was to extend the chain by greater than four atoms. A chain 
length of 3 CH2's would still afford the possibility of a six-membered ring, therefore adipic 
anhydride (55) was chosen to react with 53 as any ring closing reaction would have to form 
a less favoured 7-membered ring. 
4.3.4.1 Adipic Anhydride Synthesis 
Adipic acid (5 gm) and acetic anhydride (9.7 mL) were refluxed under argon for two hours 
at 160°c.159 The excess acetic anhydride and the acetic acid formed were distilled off at 
atmospheric pressure. The remaining liquid solidified on cooling and was distilled under 
reduced pressure on a Kugelrohr (Biichi GKR-50). The resulting liquid, which solidified at 
room temperature was analysed by IH NMR spectroscopy. The two peaks in the IH NMR 
spectrum matched closely to published data and an ElMS analysis confIrmed the correct 
mass (128 Da). 
4.3.4.2 Adipic Anhydride Reaction with H2N-Gly-Phe-Leu-Gly-Coumarin 
This approach required the terminal amine of the biolinker-coumarin to attack the reactive 
adipic anhydride (55) to form a pendant chain at the end of the biolinker (Figure 4.13). 
The H2N-Gly-Phe-Leu-Gly-coumarin (53, 5.6 mg) was dissolved in CH3CN and adipic 
anhydride (55, 1.1 equiv.) added and left for 24 hours. The reaction solvent was removed 
and the remaining solid dried under vacuum. ESIMS analysis of the crude residue showed 
the correct mass of 678 Da (MH+). Preparative HPLC (C18, 50% CH3CNfH20 (0.05% 
TFA)) eluted a compound (56) at a retention time of 11.6 min with the correct UV 
chromophore (coumarin like). The IH NMR spectrum was readily assignable, with a 
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COSY analysis allowing assignment of the CH2' s of the adipic acid group. ESIMS 
analysis of the purified sample confinned the molecular formula of the product. 
U 
~I 
(53) 
0 ~ 0 
+ H2N~lN ~0~~~ H 
(55) Y 
CH,CN 1 
~I 
0 ~ 0 
~~lN ~0~~~ 0 HO H 
Y CH3 
Figure 4.13 Adipic anhydride reaction with H2N-Gly-Phe-Leu-Gly-coumarin (53) 
4.3.5 Activation of Adipic-Gly-Pbe-Leu-Gly-Coumarin 
This reaction was the crucial step, as this was the point at which the previous strategies had 
failed with the 'ring closing' mechanism. Initial reactions using DSC (54) as the activating 
agent showed very little formation of the expected product (Figure 4.14) by ESIMS 
analysis of the crude reaction mixture. Therefore, DCC (1 equiv.) and N-
hydroxysuccinimide (NHS, 1 equiv.) were added to 56 in DMF and left stirring at room 
temperature (Figure 4.14). An ESIMS sample analysis from the reaction mixture did show 
significant formation of a compound representing the correct mass for succinimidyl-adipic-
Gly-Phe-Leu-Gly-coumarin (57). After 12 hours reaction time preparative HPLC (CI8, 
45% CH3CNIH20 (0.05% TFA)) was used to separate the starting material from the 
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Figure 4.14 Activation of adipic-Gly-Phe-Leu-Gly-coumarin (56) 
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product (retention time 14.1 min), both of which showed the correct masses for their 
respective peaks. There was not enough material for any meaningful NMR analysis and 
previous experience with the succinimidyl esters had shown that they were best used 
immediately, before hydrolysis or other side reactions could destroy the ester. Therefore, 
the fmal reactions with CV-N (15) were carried out immediately. 
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4.3.6 Reaction ofCV-N with 57 
Based on the experience gained with reaction of CV-N (15) with the fluorescent dye 
derivatives in section 4.2, the best approach for generating these conjugates was to load as 
much 'coumarin' onto each CV-N (15) as possible to ensure the best fluorescent response 
for later testing. Therefore, dual reactions of 25 equiv. of 57 with CV-N (15) were reacted 
in NaHC03 buffer with two reaction times of 15 and 60 min (Figure 4.15). After each 
reaction time was completed the samples were chromatographed on a G25 column eluting 
water. Detection at 276 run ensured collection of the protein material separated from the 
lower molecular weight components. The protein containing fractions were then freeze 
dried. 
+ 
-NH2 represents lysine chain , 
and N-terminal amines 
o 
~~N 
H 
NaHC03 buffer 
a) 15 min 
b) 60 min 
coupling may occur at more than one site 
Figure 4.15 Reaction ofCV-N (15) and 57 
o 
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4.3.6.1 Analysis of 15 minute Reaction 
The product from the 15 min reaction (58) was dissolved in water and analysed by LCMS 
with injection onto a reverse phase C3 column running a gradient from 20-50% 
CfbCN/H20 (0.5% fonnic acid) over 15 min. Elution of the native CV-N (15) peak at 9.3 
min was followed by the singly-conjugated CV-N (11.1 min) and the doubly-conjugated 
CV -N (12.7 min). The specific ESIMS spectra at these times are shown in Figure 4.16. 
The combined, transformed data (from 9.1 to 12.7 min) is shown in Figure 4.17 and 
represents the relative amounts present of the full mass of the protein conjugates derived 
from the individual spectra. The effectiveness of the LCMS analysis over the direct inject 
ESIMS analysis can be seen in the increased signal intensity of the peaks resulting in a flat 
baseline and more accurate results compared to Figures 3.4 and 3.5. The mass difference 
observed between series 'A', 'B' and 'C' in Figure 4.16 corresponds to the added mass 
(~659 Da) of the adipic-Gly-Phe-Leu-Gly-coumarin conjugate as expected. The ratio of 
the three products as shown in Figure 4.17 demonstrates only partial conjugation had taken 
place after only 15 min reaction time as the major component was still native CV -N (15). 
100 · 
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Figure 4.16a) LCMS spectrum ofCV-N (15) plus 57 
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Figure 4.16b)-c) LCMS spectra ofCV-N (15) plus 57 
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Figure 4.17 Transformed mass spectrum of CV -N (15) plus 57 
4.3.6.2 Analysis of 60 minute Reaction 
The analysis of this sample (59) was performed as above. The individual components of 
the LCMS spectrum are shown in Figure 4.18 with the combined, transformed data in 
Figure 4.19. The retention times for the peaks differ slightly from those of Figure 4.16 as 
the samples were run on different days. The extended reaction time has allowed a greater 
degree of conjugation to the CV -N (15) molecule with up to four additions of the coumarin 
derivative. The transformed spectra (Figure 4.19) established the major component as the 
singly-conjugated CV -N with steadily decreasing amounts of the more conjugated species. 
There was still a substantial amount of native CV-N (15) present which ideally would be 
completely reacted in order to provide fully conjugated protein. In order to increase the 
rate of conjugation, the reaction time could be increased although hydrolysis of the 
succinimidyl ester could become significant. The second alternative would be to increase 
the ratio of succinimidyl ester (57) to CV -N (15). 
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Figure 4.18a)-b) LCMS spectra ofCV-N (15) plus 57 
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Figure 4.19 Transformed mass spectrum of CV -N (15) plus 57 
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Both the CV-N conjugated coumarin samples underwent further testing (section 6.4). The 
XTT assay results from these tests indicated, that like the CV-N-dye conjugates, these 
coumarin derivatives also bound gp120 in a comparable manner to the native CV-N (15). 
This confirmation of the binding meant that the final toxin conjugate synthesis could 
proceed as planned. 
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4.4 Succinimidyl ... Biolinker-Toxin Constructs 
The synthetic strategy developed in the previous section was now applied to construction 
of the identical conjugates with the replacement of the coumarin moiety with the 
halichondrin toxin. The harsh conditions required to attach the coumarin amine to the C-
terminal of the biolinker were not needed for this conjugate as the aliphatic nature of the 
homohalichondrin B amine (28) would provide a greater degree ofnudeophilicity. 
4.4.1 Synthesis of Fmoc-Gly-Phe-Leu-Gly-Succinimidyl Ester 
The carboxyl end of the Fmoc-biolinker needed to be activated in order for the amine of the 
halichondrin to be attached. The succinimidyl ester was chosen as a suitable activating 
functional group as the displacement reaction takes place under mild conditions with 
formation of an unreactive side-product (NBS). Reactions to activate the carboxyl were 
first attempted with DSC (54) but much better results were obtained with the following 
synthetic procedure shown as the first reaction in Figure 4.20. 
The Fmoc-Gly-Phe-Leu-Gly-OH (49, 1.12 mg) was dissolved in fresh, dry, THF with DCC 
(2 equiv.) and NHS (2 equiv.). The reaction vessel was flushed with argon, sealed and left 
stirring. Analysis of samples at various time intervals by HPLC (C18, 60% CH3CNIH20 
(0.05% TF A)) and ESIMS indicated that complete conversion had been achieved in six 
hours. Attempted purification of the Fmoc-Gly-Phe-Leu-Gly-succinimidyl ester (60) by 
either normal phase column chromatography or preparative reverse phase HPLC led to 
hydrolysis of the ester to return the starting material. Therefore, as the activated ester 
appeared quite labile, the next reaction was undertaken in situ without prior purification. 
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Figure 4.20 Synthesis of Fmoc-Gly-Phe-Leu-Gly-norhomohalichondrin B (61) 
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4.4.2 Synthesis of Fmoc-Gly-Phe-Leu-Gly-Norhomohalichondrin B 
To the solution containing the activated ester 60, was added norhomohalichondrin B amine 
(28,0.5 equiv) in THF. The excess of the ester was to ensure complete reaction of all toxin 
amine which was more precious than the more readily synthesised peptide bio1inker. The 
reaction progress was followed by ESIMS analysis which gradually showed the 
disappearance of the halichondrin amine and formation of the Fmoc-Gly-Phe-Leu-G1y-
norhomohalichondrin B product (61) shown in Figure 4.20. The reaction was quite slow, 
taking 24 hours before all 28 had reacted. At this stage, HPLC (CI8, 85% CH3CNfH20) 
purification separated the product which was collected and dried. ESIMS analysis of the 
purified sample gave an accurate mass corresponding to the molecular formula of the 
product ((MH2i+, C94H123Ns023) within 4.7 ppm error. 
The ESIMS spectra of 61 is shown in Figure 4.21, the top spectrum representing the full 
mass range with the doubly charged region in the spectrum below. ESIMS analysis allows 
formation of adducts of sodium and potassium where the samples have been stored in 
glass. This leads to the many ion species represented in Figure 4.21. The three lowest 
doubly charged states shown (817.9, 826.9 and 835.9 Da) result from consecutive loss of 
H20 in the mass spectrometer as this leads to conjugation and charge stabilisation, hence is 
favourable. The isotopic pattern for each species was due to the elemental composition of 
61, with the M+ I isotope peak dominating the pattern observed for the ions generated 
during ESIMS analysis. This is because as the number of carbons in a compound increases 
the natural 13C abundance (-1 %) becomes significant. 
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Figure 4.21 ESIMS spectrum of Fmoc-Gly-Phe-Leu-Gly-norhomohalichondrin B (61) 
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4.4.3 Fmoc Removal from 61 
The next three synthetic steps are shown in Figure 4.22 and represent conversion of the 
Fmoc-Gly-Phe-Leu-Gly-norhomohalichondrin B (61) to the activated succinimidyl ester 
after lengthening of the chain with adipic anhydride. The standard conditions for removal 
of an Fmoc group are a solution of 20% piperidine but in an effort to keep reaction 
conditions mild for the halichondrin moiety, it was discovered that a 2% piperidine/CH3CN 
solution was sufficient. The Fmoc protected biolinker-halichondrin 61 was dissolved in 
2% piperidine/CH3CN and left at room temperature for 30 min. The solvent and piperidine 
were removed and the sample dried. An ESIMS analysis of the sample showed the correct 
mass for the H2N-Gly-Phe-Leu-Gly-halichondrin species (62) with no sign of the starting 
material. The Fmoc-piperidine side product present was inert with respect to the next 
reaction and so the mixture was further reacted without purifIcation. 
4.4.4 Adipic Anhydride Reaction with 62 
Fresh adipic anhydride was prepared (as per section 4.3.4.1) and 1.1 equiv added to the 
H2N-Gly-Phe-Leu-Gly-halichondrin (62) in dry CH3CN. The sample was flushed with 
argon, sealed and left at room temperature. Consecutive ESIMS sample analyses (Figure 
4.23) after 10, 20, 60, 120 min, and 26 hours, showed the slow conversion of amine to 
carboxyl (63) via the ring-opening adipic anhydride reaction. The MHNa2+ and MNa/+ 
adducts of the starting material were the predominant ESI ion species initially seen, while 
the product formed primarily the MNa22+ ion. These data indicated that full conversion had 
taken place. 
Purification of 63 was needed at this stage to remove unreacted adipic anhydride andlor 
adipic acid that was present in the product. The product was dissolved in minimal MeOH 
(-200 uL) and 50 uL aliquots chromatographed on a C18 cartridge (100 mg) with the 
empty space above the packing filled with H20 (~ 5 column volumes) to dilute out the 
MeOH when added. Each aliquot was loaded on to the column in this way and then 
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washed with water. The cartridge was then washed with MeOH to elute 63 which was 
dried under vacuum. An accurate mass ESIMS analysis confirmed the molecular formula 
ofthe product (C85H119N502~a2' 1.93 ppm error). 
o 
H II H 
NY"~~Ni norhomohalichondrin B ) 
o 
(61) yo 
2% piperidine/CH3CN 
o 
H II ' H 
NY"~~Ni norhomohalichondrin B ) 
(62) Y 0 
o 
~~N 
H 
(63) 
0 1 /'- /'- /~~ 
I' ~ ~ lr H 
0VN):~~.o 0 U (64) 
adipic anhydride 
CH3CN 
DCC 
NHS 
CH3CN 
o 
H II H 
NY"~~Ni norhomohalichondrin B } yo 
Figure 4.22 Synthetic scheme for conversion of 61 to 64 
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Figure 4.23 ESIMS time resolved formation of adipic-Gly-Phe-Leu-Gly-norhomohalichondrin B (61) 
Chapter 4 Succinimidyl methodology 122 
4.4.5 Activation of Adipic-Gly-Phe-Leu-Gly-Norhomohalichondrin B 
The final reaction before coupling of the conjugate with CV-N (15) was to activate the free 
carboxyl of 63 with a succinimidyl ester. To the carboxyl derivative (63, 0.62 mg) was 
added DCC and NHS (5 equiv. each) in dry CH3CN. An ESIMS spectrum after 48 hours 
showed complete conversion of the starting material to the succinimidyl ester (64). This 
product was purified by reverse phase C18 HPLC (65% CH3CNIH20) (retention time of 
6.5 min). After drying, the mass and molecular formula was confirmed by ESIMS analysis. 
4.4.6 Reaction of 64 with CV-N 
In the final reaction (Figure 4.24), CV-N (15,50 Ilg) was dissolved in 150 ilL ofNaHC03 
buffer (0.1 M) and 64 (20 equiv.) added in 50 ilL of CH3CN. The reaction was left at room 
temperature for 1 hour and an aliquot analysed by LCMS. The gradient was 20-60% 
CH3CNIH20 (0.5% formic acid) over 20 min. Formation of the product was observed 
although only one adipic-biolinker-toxin conjugate had been added. The separation of the 
compounds was excellent. A retention time of 9.5 min was observed for CV-N (15) with 
elution of the conjugate at 13.1 min. A further LCMS analysis after 15 hours showed a 
slight increase in the amount of the conjugated product present, but this was still far below 
the amount of native CV-N (15) present. Therefore, a further 20 equiv. of 64 was added to 
improve the yield of the reaction. LCMS analysis 15 hours after the addition of the extra 
toxin construct did show increased formation of the singly-conjugated product. A 
comparison of the ion series for each of the two components of the reaction mixture 
(Figure 4.25) shows the change from a mass of 11 ,009 Da (CV-N, 15) to that of the 
product, 1,576 Da higher at 12,585 Da. The advantage of having such a large non-polar 
biolinker-toxin molecule attached was the dramatic shift in HPLC retention time of the 
constructs allowing separation of the ion series, as well as ready physical separation of the 
compounds themselves. Therefore, preparative HPLC on a C3 column with the same 
gradient profile as for LCMS, (except for 0.001% formic instead of 0.5%) separated the 
product from unreacted CV-N (15). 
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Figure 4.25 LCMS spectra of CY -N (15) plus 64 
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4.4.7 Conclusions from the Toxin Conjugate Synthesis 
The strategy ultimately used for the successful synthesis of the CV-N-toxin conjugate 
involved more steps than was initially envisaged. There was little choice but to lengthen 
the chain using adipic anhydride as any kind of intramolecular 'ring closing' as observed 
for the equivalent coumarin synthesis would have been undesirable. The enforced chain 
extension can in fact be seen as advantageous with the increased distance between the large 
toxin and the surface of the CV -N providing flexibility in allowing CV -N to still bind to 
gp120. Also, the reactions chosen were effective in that they did not interfere with the 
halichondrin structure by forming unwanted side products or by degrading the toxin. This 
has been an important consideration in determining viable strategies. Separation of the 
conjugated CV -N from the native protein was afforded by the relatively non-polar nature of 
the adipic-biolinker-halichondrin conjugate and although unforeseen was a welcome 
outcome of attaching such a large molecule. 
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Chapter 
MALE IMIDE METH DOLOGY 
5.1 Introduction 
The complementary approach to the use of succinimidyl esters in developing CV-N-
conjugates, was to utilise maleimide functionalities (Figures 2.4 and 2.5) and react them 
with thiol groups either present in CV-N-Cys, or synthetically added via iminothiolane 
(27). The production ofCV-N-Cys (section 3.3) and the development ofCV-N (15) lysine 
amine conversion to thiols via iminothiolane (27) (section 3.4) have been previously 
discussed. The other side of these strategies is the linking of the maleimido, biolinker, and 
toxin moieties together in an efficient synthetic scheme. The strategy to achieve this was 
the basis of this chapter. 
Before full-scale male imide derivative development could take place the reactivity of the 
maleimide group towards thiols was tested. The viability of the maleimido-thiol reaction 
was carried out first with a lysozyme model. The thiolated-Iysozyme (formed in section 
3.4.1) was reacted with a simple maleimide derivative and the product analysed by ESIMS. 
The maleimide chosen for the equivalent reaction with thiolated-CV-N was a fluorescent 
compound (F-lS0, Molecular Probes Inc.) incorporating a maleimido-activating group and 
the same fluorescein dye moiety utilised in section 4.2. 
As with the development of the succinimidyl methodology, a test compound was frrst 
synthesised using the coumarin moiety in place of the toxin derivative. A method was 
adapted from the successful succinimidyl strategy to produce a maleimido-biolinker-
coumarin adduct. The product formed was then reacted with thiolated-CV-N to produce 
CV-N constructs containing a dye attached through a biolinker. 
Finally, the synthesis of the toxin equivalent was undertaken with the norhomohalichondrin 
B amine (28) and reaction with both CV-N-Cys and thiolated-CV-N carried through. 
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5 .. 2 Thiolated Proteins with Maleimides 
5.2.1 Thiolated-Lysozyme Reaction with a Maleimide 
Maleimidobutyric acid (65) was chosen to react with the model protein, lysozyme, after 
conversion of the lysozyme lysine side chain amines to thiols using iminothiolane (27). 
The reaction mixture synthesised in section 3.4.1 contained mUltiple thiol groups and the 
reaction of these with a maleimide functionality was important to ensure that this reaction 
would be viable for CV-N (15). The reaction is outlined in Figure 5.1. 
-NH2 represents lysine Side! 
chairiand N-terminal amine 
k~ (27) 
10 equiv. 
Figure 5.1 Lysozyme-thiolated model plus maleimido butyric acid (65) 
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Maleimidobutyric acid (65, 10 equiv.) in reaction buffer (50 !J.L, 0.1 M sodium borate, 
0.001 M EDTA, 0.15 M NaCI, pH 8.0) was added to the thiolated-lysozyme mixture and 
the reaction left for 5 min. In contrast to the relative ease with which the thiolated-
lysozyme ionised in the ESI mass spectrometer, after reaction with maleimidobutyric acid 
(65) the ion signal was markedly decreased. Addition of neat formic acid to the sample 
when injected assisted ionisation of the protein adducts to some degree and a transform of 
the spectrum is shown in Figure 5.2. The baseline is poor, but the consistent mass gap of 
284 Da between components 'A', '8', 'D', and 'E' corresponds to sequential addition ofa 
maleimidobutyric acid group to a thiol on the lysozyme. Component 'C' corresponds to a 
lysozyme molecule having two thiols, only one of which has reacted with a maleimide. 
A 
14305 
B 
14589 
C 
1468900 
A = lysozyme 
B = lysozyme + 1 thiol + 1 maleimide 
C = lysozyme + 2 thiol + 1 maleimide 
o = ysozyme + 2 thiol + 2 malelmide 
E = lysozyme + 3 thiol + 3 maleimide 
o 
14873 
E 
15157 
o 
13600 13800 14000 14200 14400 14600 14800 15000 15200 15400 15600 15800 
mass 
Figure 5.2 Transformed ESIMS analysis of lysozyme-thiolated plus maleimidobutyric acid (65) 
The reaction between thiols and the maleimide group was fast with the majority of 
thiolated-Iysozyme converted within 5 min. The relatively small size of the 
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ma1eimidobutyric acid undoubtedly played a role in this aspect of the kinetics of the 
reaction. The significant loss of ionisation of the protein conjugates after addition of the 
maleimide could be due to the side reaction of a hydrolysed iminothiolane with a 
maleimidobutyric acid molecule. This small side-product, very likely present in excess, 
could effectively quench the ionisation of the larger protein adducts. Therefore, this 
reaction points towards the use of LCMS andlor G25 column chromatography to more 
accurately survey the outcome of these type of reactions. The trade off is the length of time 
taken for the chromatography to take place for either method. However, the benefits of 
product separation and increased ionisation, hence a better signal to noise ratio, outweigh 
the 'speed' advantage of direct injection ESlMS analysis. This knowledge was applied in 
later reaction schemes. 
5.2.2 Thiolated-CV -N Reaction with F -150 
Having established that the model lysozyme system reacted successfully with the 
maleimidobutyric acid (65), the same reaction was attempted on thiolated-CV-N to more 
fully test the viability of the maleimide approach. The maleimide selected for reaction with 
the thiolated-CV-N mixture synthesised in section 3.4.2.1 was F-150 (66), a fluorescein 
derivative with a maleimide activating group. The synthetic scheme in Figure 5.3 depicts 
the reaction with CV-N (15) after initial conversion of the lysine side chain amines to thiols 
(section 3.4.2.1). 
The F-150 dye (66, 70 equiv.) was added to the thiolated-CV-N (200 Ilg). After reaction 
for 1 hour the mixture was separated by G25 column chromatography (with monitoring at 
276 nm) to remove the overwhelming excess of small molecules present The protein-
containing fraction was analysed by ESIMS. The resultant transformed spectrum is shown 
in Figure 5.4. There was still unreacted CV-N ('A') and thiolated-CV-N with 1 and 2 
thiols added ('B' and 'C') although the majority of the thiolated-CV-N had reacted to form 
the F-l50 fluorescent conjugates 'D', 'E' and 'F'. Although the number of equivalents of 
the F-150 dye was equal to that of the iminothiolane (27) eventually added to the CV-N 
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-NH2 represents lysine side 
chain and N-terminal amines 
(15) 
+ 
HO 
H02e F-150 (66) 
Figure 5.3 Reaction ofthiolated-CV-N with F-150 (66) 
130 
(15), the presence of unreacted thiols was a cause for concern as potentially the toxin-
loaded maleimide could be 'wasted' on reaction with hydrolysed iminothiolane, leading 
indirectly to incomplete conversion of the protein thiols. It was therefore concluded that 
the thiolated-protein should first be purified by G25 chromatography before reaction with 
the maleimide. This would remove the majority of the excess lower molecular weight 
compounds present and allow just the protein thiols to be reacted with the excess of the 
specific maleimide derivative. 
The reactions ofmaleimides with thiolated-Iysozyme, and then thiolated-CV-N, confirmed 
the validity of this approach for the attachment of conjugates to proteins. The results also 
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Figure 5.4 Transformed ESIMS analysis of thiolated-CV -N plus F-150 (66) 
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14000 
showed that direct injection ESIMS analysis is suitable only up to the point of addition of 
the maleimide to the thiolated-protein. This led to the more important consideration of 
utilising G25 chromatography for separating the excess hydrolysed iminothiolane (with a 
free thiol capability) from the thiolated-protein before addition of an overwhelming excess 
of maleimide to ensure complete reaction of the thiolated-protein. The products of the 
reaction would then be purified by G25 chromatography and/or analysed by LCMS. 
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5 .. 3 Maleimido-Biolinker-Coumarin Constructs 
Although the model reactions reinforced the applicability ofthe maleimide-thiol reaction to 
the design of CV-N conjugates, the synthesis of the biolinker-toxin had to be addressed. 
Unlike the succinimidyl esters, the activating group (maleimide) could be introduced early 
on in the synthesis as the introduction of the amino toxin would cause no reactivity 
problems. The succinimidyl ester strategy required early toxin addition and then 
subsequent modification to allow introduction of the activated ester. The advantage of 
utilising the male imide was that the sensitive toxin would only be exposed to the reaction 
conditions to introduce it, and then followed immediately by reaction with thiolated-CV-N 
or CV-N-Cys. 
The coumarin fluorescent dye was again utilised to provide a toxin substitute and the 
tetrapeptide biolinker was also retained. The maleimide derivative chosen was 
maleimidocaproic acid (67) which would give a (CH2)s pendant chain separating the 
biolinker from the protein, comparable to the adipic acid moiety in the succinimidyl 
strategy. This gives a degree of flexibility to the whole conjugate and, importantly, keeps 
the toxin distal from the surface of the CV-N molecule. There was one obvious method for 
synthesis of the maleimido-Gly-Phe-Leu-Gly-coumarin (68), shown in Figure 5.5. The 
carboxyl of the maleimidocaproic acid (67) allowed a simple coupling reaction to take 
place to the free amine of the biolinker-coumarin construct. 
5.3.1 Synthesis of Maleimido-Caproic-Gly-Phe-Leu-Gly-Coumarin 
Synthesis of the maleimide derivative utilised the H2N-Gly-Phe-Leu-Gly-coumarin (53,2.0 
mg) already synthesised in section 4.3.2.2. To this was coupled maleimidocaproic acid 
(67, 1 equiv.) with the coupling reagent DCC (1.5 equiv.) in DCM (plus 3 drops of DMF 
for solubility). The reaction mixture was left stirring overnight. TLC analysis (20% 
MeOHlEtOAc) confirmed formation of a fluorescent compound less polar than the 
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starting materials. The solution was dried, taken up again in MeOH and purified by 
preparative HPLC (C18, 45% CH3CNIH20 (0.05% TFA), 324 nm) to yield 68. HRESIMS 
analysis indicated a molecular fonnula of C39~6N609 as required for 68. 
~~H 
(67) . 
DCC 
DCM 
3 drops DMF 
Figure 5.5 Synthesis of Maleimido-caproic-Gly-Phe-Leu-Gly-coumarin (68) 
5.3.2 Thiolated-CV -N with 68 
The thiolated-CV-N fonned in section 3.4.2.2 had been purified by G25 column 
chromatography and was ready for reaction with a maleimide. The coumarin adduct (68, 
20 equiv.) in DMF was added to the thiolated-CV -N. (200 Ilg) in reaction buffer and left at 
room temperature. After 2 hours the solution was concentrated under a stream of N2 and 
analysed by LCMS (20-50% CH3CNIH20 (0.5% fonnic) over 15 min). Native CV-N (15) 
that had not been thiolated was still present but sufficient quantities of the singly (11,853 
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Da) and doubly (12,696 Da) conjugated products could be identified with concomitant 
disappearance of the thiolated-CV-N species. 
The synthesis and subsequent reaction with CV-N of the maleimide derivatives has 
demonstrated the simplicity of this strategy in comparison to that of the succinimidyl ester 
approach. To achieve the synthesis of the final activated species for reaction with CV-N 
(or derivatives) required much fewer reaction steps for the maleimides than for the 
succinimidyl esters. There is the additional step required for conversion of the CV-N (15) 
amines to thiols, but this was achieved simply and efficiently. 
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5.4 Maleimide-Biolinker-Toxin Constructs 
The major difference in the synthetic strategy for the maleimido toxin derivatives 
compared to the equivalent coumarin constructs was that the starting material for this 
strategy needed to be maleimido-caproic-Gly-Phe-Leu-Gly-OH (69). The simple approach 
to this compound was to synthesise the entire structure by SPPS and simply cleave the 
peptide derivative from the resin. Attaching the toxin molecule to the maleimide-biolinker 
would then only require a single step of C-terminal activation and in situ displacement by 
reaction with norhomohalichondrin B amine (28). This strategy is shown in Figure 5.6. 
5.4.1 Synthesis of Maleimido-Caproic-Gly-Phe-Leu-Gly-OH 
The SPPS method used was identical to that for Fmoc-Gly-Phe-Leu-Gly-OH (49, section 
4.3.1.2) with removal of the terminal Fmoc group while still on the resin, and subsequent 
coupling of the maleimidocaproic acid (67) to the peptide chain. The removal of the 
peptide derivative with the TF A solution and subsequent purification was also identical. 
An ESIMS analysis of the crude product showed the correct mass, but HPLC analysis 
(CI8, 60% MeOHlH20 (0.05% TF A» indicated the presence of several minor impurities. 
The product was purified by preparative HPLC using the same elution conditions. 
Analyses by HPLC and ESIMS were consistent with the structure. IH NMR chemical 
shifts were assigned from comparison to previously assigned biolinker derivatives. [It was 
noted that this product could also be used to prepare the coumarin derivative as an 
alternative to the synthesis in section 5.3.1. This was indeed done but yields were lower 
than those for the synthesis detailed in section 5.3.1.] 
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5.4.2 Synthesis of Maleimido-Caproic-Gly-Phe-Leu-Gly-Toxin 
The activation of the carboxyl by fonnation of the succinimidyl ester and subsequent 
reaction with the toxin amine was carried out in the same reaction vessel to avoid 
hydrolysis of the succinimidyl ester. Maleimido-caproic-Gly-Phe-Leu-Gly-OH (69, 1.07 
mg) was dissolved in dry THF with DCC and NHS (2 equiv. each). Several drops ofDMF 
were added to aid dissolution of the maleimide and the solution stirred under argon. After 
24 hours ESIMS analysis showed approximately 50% conversion to the succinimidyl ester 
(70) At this stage norhomohalichondrin B amine (28,0.5 equiv.) was added in CH3CN to 
the reaction mixture. The reaction was continuously monitored by ESIMS analysis until 
complete disappearance of the toxin amine peak and fonnation of the product (71) after 60 
hours. A gradient HPLC elution profi~e (25-85% CH3CNIH20) was used to purify the 
maleimido-caproic-Gly-Phe-Leu-Gly-norhomohalichondrin B product (71) from 
maleimido-caproic-biolinker-OH (69). 
An accurate mass was obtained by HRESIMS analysis of the purified sample (Figure 5.7). 
As noted earlier for the Fmoc-Gly-Phe-Leu-Gly-norhomohalichondrin B (Figure 4.21), the 
compound had produced sodiated adducts resulting in a range of ions, both singly and 
doubly charged. To fonn the product required a reaction time of greater than 48 hours, 
longer than that required for the equivalent Fmoc-biolinker. These long reaction times 
were almost certainly due to the steric bulk of two large molecules having to orientate 
themselves correctly in solution for reaction to occur. 
The major advantage of ESIMS analysis of reactions such as this is the small sample 
amount required to monitor the reaction progress. This must be balanced by the fact that 
not all compounds ionise identically so that the 'ion count' for each component of the 
spectra may not be indicative of the relative quantity of each species present. 
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Figure 5.7 ESIMS spectra ofmaleimido-caproic-Gly-Phe-Leu-Gly-norhomohalichondrin B (71) 
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5 .. 5 Maleinlide-Toxin Reaction with CV-N Adducts 
The utility of the maleimide-toxin derivative was that two methods were developed for its 
use. The first was reaction with CV-N-Cys where the free side chain of the extra cysteine 
residue provides a thiol for reaction at a single defmed position. This would seem to be the 
most advantageous application of the maleimido-toxin derivative as the product formed 
would be a homogeneous compound. However, the alternative of pre-forming the thiols 
through conversion of the lysine amines to thiols would provide greater coverage of the 
CV-N with toxin molecules and give the potential for an increased cell killing ability. As 
was discovered in section 3.4.2.3 there was also the possibility of halting the thiolation 
reaction at a designated time when just a single thiolation adduct had been formed. The 
reaction for both CV-N substrates was identical as both were a maleimide-thiol interaction. 
5.5.1 Maleimide-Toxin Reaction with CV-N-Cys 
The recombinant production ofthe CV-N-Cys (section 3.3) produced the correct compound 
but subsequently glutathione had coupled to the free thioI. The attempts at removal of the 
glutathione were partially successful in that the unwanted addition was easily removed but 
the refolding of the CV-N-Cys showed a loss of bioactivtiy suggesting that the refolding 
had not produced the correct tertiary structure of the CV-N. However, subsequent work at 
the LDDRD based on the reactions in section 3.3.3 did produce CV-N-Cys that was 
bioactive by ELISA studies (gp120 binding) and XTT assay (anti-HIV) results. This 
material was free of glutathione, but did contain several impurities which seemed to be 
addition of methyl groups (14 Da increase in mass) at indeterminate sites on the CV -N-Cys 
protein. The exact method of attachment of these 'methyl' groups was not determined. 
The fact that the material contained the free cysteine thiol and that the activity was 
equivalent to native CV-N (15) was enough to utilise this CV-N-Cys for reaction with the 
male imide-toxin adducts. 
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Maleimido-caproic-Gly-Phe-Leu-Gly-norhomohalichondrin B (71,10 equiv.) was added to 
CV -N-Cys (72, 100 Ilg) in PBS buffer. The reaction was left overnight and LCMS analysis 
after 24 hours showed formation of about 15% product. The mixture was left for a further 
24 hours before further LCMS analysis. The yield of product had not significantly altered, 
so the starting material and product were separated by reverse phase HPLC (C3 Zorbax, 
20-60% CH3CN/H20 (0.001 % formic) over 20 min). The fractions were dried and 
analysed separately by LCMS analyses to confirm the presence and identity of CV -N -Cys 
and the CV -N-Cys-biolinker-toxin construct. 
The transformed LCMS spectra of the two compounds is shown in Figure 5.8 with the a) 
spectrum representing the starting material CV-N-Cys CA') and 'methyl' adducts ('B' and 
'C') while the b) spectrum shows the product ('0') also with methyl adducts ('E' and 'F'). 
The fact that product formed meant that at least some of the CV -N-Cys had a free thiol on 
the cysteine as opposed to being S-methylated. The full potential of this strategy for 
forming CV -N-toxin conjugates will only be realised if CV -N-Cys can be formed free of 
impurities (such as glutathione or 'methyls'). In these circumstances a single homogeneous 
compound would be formed . 
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Figure 5.8b) Transfonned LCMS spectrum ofCV-N-Cys plus 71 
5.5.2 Maleimide-Toxin Reaction with Thiolated-CV-N 
The thiolated-CV -N (section 3.4.2.3) was primarily mono-thiolated as the reaction was 
halted after 30 min at which time this was the predominant species present. To this 
thiolated-CV -N (100 /-lg) in H20 was added maleimido-caproic-Gly-Phe-Leu-Gly-
norhomohalichondrin B (71) in DMF (25 /-lL). The reaction was left for 90 min and then 
analysed by LCMS utilising a 20-60% CH3CN/H20 (0.5% fonnic acid) gradient over 20 
min. The starting material mixture of unreacted native CV-N (15) and thiolated-CV-N 
eluted at 9.7 min with the conjugate eluting at 13.1 min. Unreacted maleimide-toxin 
construct was also still present (eluting at 19.4 min) and so the reaction was left for a 
further 24 hours. LCMS analysis under the same conditions showed an increase in the 
product peak and the complete disappearance ofthe maleimide-toxin starting material. The 
LCMS spectrum of the starting material peak at 9.7 min was identical to that shown in 
Figure 3.6. A transfonned spectrum of the product peak eluting at 13.1 min is shown in 
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Figure 5.9. The 'A' peak shows the addition of one iminothiolane group to CV-N with 
subsequent addition of a single maleimido-caproic-Gly-Phe-Leu-Gly-norhomohalichondrin 
B (71) group with a total mass of 12,771 Da. Therefore, the aim of stopping the initial 
thiolation reaction in order to obtain primarily a mono-thiol on CV -N and hence a single 
addition of toxin had been successful. HPLC under the same conditions (except 
replacement of TFA with 0.001 % formic) separated the product from the remaining CV-N 
(15) and thiolated-CV-N. 
100 
0 \.: -
12550 12600 12650 12700 
A 
12771 
\ 
\ 
vt 
12750 12800 
A = CV-N + 1 thiol + 1 toxin 
8 = CV-N + 2 thiol (-17 Oa) + 1 toxin 
B 
12855 
~ 
JI 
t~1 f.~ ~ A III • r : ~ \. 1\ \ 
12850 12900 12950 13000 13050 13100 
Figure 5.9 LCMS transformed spectrum ofthiolated-CV-N plus 71 
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The second ('B ' ) peak in Figure 5.9 had an interesting derivation. It was expected that 
there would be present a proportion of CV -N with two iminothiolane adducts and a single 
toxin derivative of total mass 12,882 Da. However, the peak seen in the spectrum is 17 Da 
less than this at 12,855 Da. Peaks 17 Da less than the mass for an iminothiolane addition 
had been seen previously at much lower levels in reactions of CV -N with iminothiolane 
(27). A potential structure for the side product is shown in Figure 5.10. This compound 
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matches the mass spectral data with a loss of 17 Da from the thiolated-CV-N although 
obviously there are other potential compounds that fit this criteria. It is suggested that this 
entity is formed by intramolecular reaction as indicated. It would be difficult to prove such 
CV-N + 101 Da CV-N + 84 Da 
Figure 5.10 Postulated side product from thiolation of CV-N 
a mechanism for the formation of the by-product and more work would need to be done to 
fully explain such a reaction. (This ~oss of 17 Da was only observed for thiolation 
reactions of CV-N (not lysozyme) and only occurred after successful formation of the 
correct thiolated product.) Evidence that supports this postulated structure is the absence 
of products containing two attached toxins. The presence of this non-reactive transformed 
lysine did not inhibit formation of the desired product and was therefore not further 
investigated. 
It is crucial to note that by LCMS analysis, all the toxin adduct starting material had reacted 
after 24 hours confirming the inherent reactivity of the maleimide with thiols. The size and 
relatively non-polar nature of the biolinker-toxin construct again made separation of the 
product a simple task. A smaller toxin may not have contributed as much to the change in 
retention time and may not have led to complete separation by HPLC. 
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5.6 Conclusions from Maleimide Methodology 
The early reactions with both lysozyme and CV-N with lower molecular weight 
maleimides demonstrated the speed and selectivity of the thiol-maleimide reaction. The 
synthesis of the maleimido-caproic-biolinker-coumarin conjugate was rendered effective 
through adaptation of the previously derived H2N-biolinker-coumarin compound. The 
extension of the chain through the caproic linker mimicked the adipic section of the 
succinimidyl ester equivalent synthesis. As a result, the CV-N conjugates formed from 
each method were not significantly different from each other. 
The synthesis of themaleimide-biolinker-toxin was also relatively straightfoward using a 
solid phase approach. The attachment of the toxin amine via the succinimidyl ester was 
successful with purification by HPLC providing the final product. The two reactions of 
this toxin construct with the two different forms of thiol containing CV-N were 
understandably similar and with the halting of the thiolation of CV-N (15) at 
predominantly the mono-thiol stage the products were both primarily a protein with a 
single attachment of toxin. The difference lies in the 'known' position of the CV-N-Cys 
toxin while the thiolated-CV-N toxin could be on anyone of the lysine side chains, or as is 
more probable, on several different ofthe available lysines per CV-N molecule. 
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Chapter 6 
TESTING OF CV-N CONJUGATES 
I 
6.1 Introduction 
Although the synthesis of the various CV -N constructs was ultimately successful, the 
determining factor in deciding their therapeutic potential could only be evaluated by 
extensive biological testing. There were several distinct aspects of the interaction between 
CV-:-N (15) and gp120 expressing cells that needed to be explored with respect to 
modifying the CV-N (15) skeleton. 
The first phase of interaction is the initial binding of the CV-N (15) molecule to the gp120 
on the outer surface of infected cells. With the attachment of large molecules such as the 
toxin conjugates to CV-N, there was the potential to block the CV-N binding (15) to 
gp120. This was presumed to be the case for the CV-N-PE38 conjugate previously 
constructed and tested by Mori et ai. IOB where the gp120 binding affInity of the conjugate 
was significantly reduced. The same method of testing using an ELISA system, developed 
by the LDDRD, was used to determine the relative affinity of the synthesised CV-N 
constructs for gp120. This assay was critical in determining if the conjugation of 
compounds to the amines in CV-N resulted in any loss of binding affInity. If a high 
loading of conjugates onto CV-N resulted in a loss of gp120 binding then this would have 
to be taken into account in the synthetic strategy with perhaps minimal loading of the CV-
N (15) protein. 
The XTT anti-HIV assay detects drug-induced suppression of viral cytopathic effects by 
generation of a soluble fonnazan in surviving cells. For the CV-N-conjugates produced, 
this analysis tests the binding of the CV-N to the gp120 on the outer surface of the virus. 
This effectively 'protects' the uninfected cells which therefore continue to metabolise the 
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XTT to the fonnazan. Therefore, the results from this assay demonstrate whether or not 
the CV -N constructs can still productively inhibit the binding of virus to cell even with the 
addition of the dye molecules. 
The ftrst conjugates tested were those from section 4.2 where CV-N was conjugated to two 
fluorescent dye derivatives under a variety of reaction conditions. Several of these CV-N 
samples were very heavily loaded with dye molecules and therefore provided a good model 
for whether conjugated CV-N proteins would still interact effectively with gp120. These 
dye conjugates were tested using both the ELISA and XTT assays. Further constructs 
tested were the CV-N-biolinker-coumarin conjugates derived from the succinimidyl ester 
strategy (section 4.3.6). These were tested using the XTT assay system to determine if the 
biolinker derived constructs in any way interfered with the binding of CV-N to gp120. 
These coumarin conjugates were also 'fed' to productively infected cells to detennine if the 
constructs became internalised into the cell through gpl20 binding. Once inside the cell 
the biolinker should cleave, releasing the free coumarin dye whose fluorescent maxima 
would change as the amide bond previously linking it to the biolinker would now be an 
amine. These tests were designed to examine the effectiveness of the biolinker in releasing 
the coumarin (toxin substitute) internally in infected cells. 
The ultimate testing is of course with the CV-N-toxin conjugates themselves to determine 
if the cell-killing ability of the halichondrin moiety can be selectively applied to 
productively infected cells. These conjugates have been sent for such biological testing. 
The results are not yet known. 
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6.2 Assay Systems 
A discussion of the particular assay techniques used for testing is important to clearly 
understand exactly what properties of CV-N's interactions are being tested. Only in this 
way can the results be evaluated effectively. The two assays (ELISA and XTT) although 
both testing the binding of CV-N (or CV-N conjugates) to gp120, do so in very different 
ways providing different perspectives on the binding process. 
6.2.1 ELISA Assay 
Immunoassays form the backbone of tests used in the study of infectious diseases such as 
mv. The ELISA method provides a highly sensitive and precise method for the estimation 
of biological parameters with the added advantage of being able to handle large numbers of 
samples rapidly. Since the first effective enzyme-labelled assay was described in 1971160 
there have been thousands of applications published dealing with the quantification of 
antigens and antibodies for research. 
There are many different categories of ELISA utilising different binding patterns. The 
particular ELISA for testing CV-N (15) binding is based on the 'Sandwich ELISA' with 
indirect detection of the binding.161 An outline of the binding process is shown in Figure 
6.1. The assay is performed in a 96-well plate with initial binding of gp 120 to the plate 
itself. Incubation for two hours is followed by thorough washing of the plate. The 
resulting sites that are unfilled by gp120 are 'capped' by introduction of Bovine Serum 
Albumin (BSA) and left incubating overnight. After washing, the CV-N (15) or CV-N 
conjugates are introduced and selectively bind to the gp120. Excess compounds are again 
washed away and then antibodies introduced that are directed specifically to CV-N (anti-
Rabbit-anti-CV-N Ab). These are in tum bound by a second antibody (anti-Rabbit-IgG-
Ab-AP) leaving an alkaline phosphatase (AP) enzyme exposed at the terminal. The fmal 
step, after again washing, is to add the substrate buffer (10% diethanolamine, 10 mM 
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Figure 6.1 ELISA testing of CV -N conjugates 
substrate buffer 
containing colourising 
reagent 
MgCh, 4 mglmL p-nitrophenyl phosphate (PNPP), pH 9.8). The colour development (due 
to substrate binding) is halted after 15 min with addition of EDT A. The plate can now be 
read at 405 run in a plate reader. Any alterations to the binding of CV -N derivatives to the 
gp120 will cause fewer antibodies to bind at each step and hence the yellow colour will not 
be as intense as for the native CV -N (15). 
A sample plate layout is shown in Figure 6.2. The outer ring of wells is loaded with BSA 
at the same time as the rest of the cells are blocked with BSA after binding of gp 120 to the 
well walls. This gives a baseline reading to ensure the assay is working correctly. Rows B, 
C and D were used for native CV -N (15) as a standard reference for each plate. The 
concentration of CV -N loaded into each well increases from column 2 to II In a 
native 
CV-N 
CV-N 
conJ. 
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Figure 6.2 Sample ELISA plate 
logaritlunic fashion by a factor of 3.16 each time. This extensive range of concentrations 
allows an accurate graphical representation to be presented that gives a precise measure of 
the binding affinity of the CV-N (15) (or CV-N constructs). Each individual concentration 
of CV -N is assayed in triplicate in order to ensure uniformity of readings and to allow the 
easy identitication of 'erroneous' readings which can occur primarily due to cross-
contamination of the wells. A comparison of the data for the native CV -N (15) versus the 
CV -N conjugates gives an accurate indication of their relative binding affinities to gp 120. 
6.2.2 XTT Assay 
The particular XTT anti-HIV assay utilised for the analysis of the CV -N-constructs was 
originally developed in 1989 by the NCI to support and enhance the discovery of anti-HTV 
agents. 162 Viable cells (those metabolically active) convert the tetrazolium salt XTT into a 
soluble orange formazan (Figure 6.3) therefore giving the culture a high optical density 
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Figure 6.3 Metabolization of XTT to a water soluble fonnazan salt by viable cells 
(OD) at 450 nm. The cells used are lymphocytic CEM-SS cells, the choice of which is 
based on their sensitivity to the lytic, effects of HIV -1 infection and their ability to 
metabolically reduce XTT. CEM-SS cells that are not protected by drugs such as CV-N 
(15) are killed by the virus and/or do not proliferate, consequently producing less fonnazan 
and therefore lower optical densities. This assay is therefore a measure of CV-N's (15) 
ability to 'protect' cells from infection by binding to gp120 and preventing the HIV virus 
from entering the CEM-SS cells. Results obtained are treated graphically but also produce 
an ECso value which is the concentration of drug at which 50% 'protection' of the CEM-SS 
cells is obtained. The XTT assay also measures any direct cytotoxic effect the drugs tested 
may have to the CEM-SS cells in the absence of virus. 
The protocol is to initially dilute each drug in complete medium into a single column of a 
96 well plate ( dilution plate). An automated workstation then performs eight serial 
dilutions of each drug and transfers 100 ilL of each dilution to the test plate. Uninfected 
CEM-SS cells are then plated at a density of lx104 cells in 50 ilL of complete medium. 
Diluted virus is then added to the appropriate wells in 50 IlL to yield a total volume of 200 
ilL in each welL After addition of the cell, virus, and drug controls, the plate is incubated 
at 37°C in an atmosphere containing 5% CO2 for 6 days. Then 50 ilL of the XTT solution 
is added to each well of the test plate and incubated for 4 hours at 37°C. After incubation, 
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the plates are covered with adhesive plate sealers, shaken, and their optical densities 
detennined at a test wavelength of 450 I1ffi. 
A sample plate layout for this assay is shown in Figure 6.4. Two drugs are tested per plate 
(shown as blue and green) with rows B to E containing the active virus to test the 
infectivity. The cytotoxicity of the drugs to the CEM-SS cells is tested in rows F and G 
with standards of the drugs in the absence of cells or virus, in rows A and H. The standards 
of both CEM-SS cells and the virus are present on each plate to ensure the assay is 
perfonning correctly with viable cell growth and viral activity. Much like the ELISA 
assay, the use of 96 well plates allows extensive automation and the screening of large 
quantities of samples with high reproducibility. 
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Figure 6.4 Sample XTT plate 
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Figure 6.5a) shows a light microscope image (SOx) of how the CEM-SS cells appear in the 
absence of virus. The cells are small and well defmed with the vivid yellow colour 
reflective of the stain used to visualise them. The second image (Figure 6.5b»), shows the 
same CEM-SS cells after HIV virus has been introduced and the cells incubated for 7 days 
(as per the XTT assay protocol). The overwhelming formation of virus-induced multi-
nucleated giant cells (syncytia) and lack of small, well-defined cells is immediately evident. 
The HIV-induced cytopathic effects eventually result in the destruction of syncytia leading 
to suppression of both virion synthesis and formazan formation. A closer examination of 
these cell types is shown in Figure 6.5c) and d). The magnification has increased from 
SOx to 200x and the individual CEM-SS cells in c) can be seen more clearly. 
The protective effect CV-N (15) imposes on these CEM-SS cells is shown in Figure 6.6a)-
b) .. Both pictures have had the .same treatment with equal amounts of virus added to them 
and subsequent incubation for 7 days. There is no evident scyntium formation in the 50 
nM CV-N (15) treated cells in a) while the beginnings of multinucleated cells (as indicated 
by arrows), can be seen in b), at 0.5 nM concentration ofCV-N (15). Without the presence 
of CV-N (15) these pictures would appear as the cells in Figure 6.5b). The question 
regarding the CV -N-conjugates under investigation was whether or not the alterations 
made to the CV-N protein affected its binding, and hence protective qualities, in this XTT 
assay. 
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200 ~lm 
b) 
200 11m 
Figure 6.5a)-b) Light microscope image (SOx) of a) un infected and b) infected CEM-SS cells 
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c) 
d) 
Figure 6.5c)-d) Light microscope image (200x) of c) uninfected and d) infected CEM-SS cells 
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Figure 6.6a)-b) Light microscope image (50x) of a) CV-N (50 nM) and 
b) CV-N (0.5 nM) protected CEM-SS cells 
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6.3 Testing of CV-N-Dye Conjugates 
6.3.1 Initial ELISA Testing 
Before the CV-N-fluorescent dye derivatives could be tested effectively by the ELISA 
assay system the effect of the dye moiety (if any) on the assay system itself needed to be 
investigated. This was to prevent false positive or false negative results from influencing 
the analysis of the data. There were two issues in particular, the fIrst of which was whether 
the dye interfered with the binding of the antibodies, and secondly, whether the dye 
contributed to the substrate reading at 405 nm. The fIrst of these problems would give a 
false negative result as the CV-N-conjugates may bind to gpl20 adequately but if the 
antibodies did not bind, then there would be no response at 405 nm as the substrate would 
not have bound either. The second problem would be more subtle in that the result would 
still be positive although the intensity would be increased due to the 'addition' of the dye 
chromophore to the substrate response. This may lead to attributing a stronger binding 
affInity to the conjugates than would be strictly true. 
The fIrst issue was tested by performing the ELISA assay without the presence of gpl20. 
The first step was effectively coating the wells with the CV-N (15) (or CV-N-conjugate) in 
an increasing concentration. Without the gp120, the CV-N conjugates would bind to the 
well regardless of their 'loading' of dye. The remaining space in the well would be fIlled 
by BSA as for the standard ELISA. The antibodies would also be introduced as per the 
normal procedure. It was not necessary to test all the dye conjugates so only the most 
highly loaded samples for each dye from the pH 8.3 series were used (36 and 42). [At this 
stage it was not known that the BODIPY conjugate chosen for this test (42) was one of the 
samples that had not performed as expected, in that very little protein material was 
present] It was found that the CV-N-conjugates (particularly 36) did not interfere with the 
antibody binding as the results for the CV-N conjugates were comparable to the results 
obtained for the native CV-N (15) in the same procedure. Therefore, the presence of the 
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dye moieties did not prevent the antibodies from performing their task in binding to CV-N 
and ultimately producing a substrate response. 
The second issue, contributions to the absorption at 405 nm from the fluorescent tag, was 
also tested in the same experiment. This was done by reading the plates in the standard 
ELISA plate reader at 405 nm before addition of the substrate buffer. Without the buffer 
there should only be baseline response from any of the wells at 405 nm unless the dye was 
itself contributing to the absorption. There was no discernible detection of absorption at 
this wavelength for either dye tested even at the highest concentrations. This meant that 
the dye moieties would not interfere in any way with the response from the substrate in the 
ELISA experiment. 
As a check to determine if in fact there were samples of each dye conjugate present in the 
wells in increasing concentrations, the plates were exposed to a wavelength close to the 
absorption maxima of the respective dyes. The plate reader then recorded any response at 
the emission wavelength for the dyes. As the concentration of the conjugates increased 
across the plate, so did the fluorescent response as expected. This could also theoretically 
be used to determine the binding affmity of the fluorescent CV-N conjugates to gp120 if 
appropriate controls and standards were in place. 
6.3.2 ELISA Testing of 5-SFX and BODIPY CV-N-Conjugates 
Each of the mixtures of constructs synthesized during the reactions at pH 8.3 in section 4.2 
were tested using ELISA. [The samples from reactions at pH 7.1 were not tested as many 
contained a high proportion of native CV-N (15) and an ELISA assay would reveal little 
data of value.] Each sample tested was loaded onto a 96 well plate with native CV-N (15) 
also present as a control. The data from the response of the detection substrate at 405 nm 
has been converted into graphical form in Figure 6.7 for the CV-N-5-SFX conjugates and 
Figure 6.8 for the CV-N-BODIPY conjugates. With the exception of the 25 equiv. 
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Figure 6.7a)-b) ELISA ofCY-N (15) and CY-N-5-SFX conjugates 
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d) ELISA of 36 vs CV-N 
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Figure 6.7c)-d) ELISA ofCV-N (15) and CV-N-5-SFX conjugates 
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BODIPY conjugates (Figure 6.8c) and d)) the remainder ofthe samples can clearly be seen 
as comparable to native CV-N (15). As the sample concentration increased so did the 
substrate response as the amount of bound CV -N -conjugate to gp 120 had also increased. 
The binding affmities of 41 and 42 are markedly reduced due to the fact that for some 
undetermined reason the CV-N (15) (or conjugates) were not present in the fraction 
collected from the G25 purification. They do show some binding affinity at higher 
concentrations which may indicate the presence of smaller concentrations of CV -N (15) (or 
conjugates) that were undetected by LCMS analysis. 
Some samples still contained a reasonable percentage of native CV-N (15) and therefore 
one would expect that they would show binding affinities comparable to that of pure native 
CV-N (15). However, the samples with very little or no native CV-N (15) remaining and a 
high loading of fluorescent tags, also show binding comparable to the native protein. The 
precise position of the binding site(s) on gp120 and the corresponding region(s) on CV-N 
(15) have not yet been accurately determined. Preliminary fmdings tend to suggest that the 
binding sites are distant from the lysine residues but there remains a large degree of 
uncertainty. The results of O'Keefe et ai. 78 showed that the required ratio of CV-N (15) to 
gpl20 was 5:1 so there may be a variety of sites on CV-N (15) that bind to pockets on 
gp120. With 'blocking' of some sites by conjugation of the lysine side chains, the CV-N 
conjugate may bind at another, more accessible, site. Whatever the position of binding, the 
overall conclusion from these particular studies was that attaching relatively small 
molecules (MW ~450 Da) to the lysine side chains (or possibly the N-terminal) did not 
interfere with the binding affmity ofCV-N for gp120. 
6.3.3 XTT Assay Testing of CV-N-Dye Conjugates 
The concentrations of each of the CV -N-dye conjugates in solution differed. This was a 
consequence of differing volumes collected from the G25 colunm in each case during 
purification (section 4.2). The samples were each submitted for the XTT assay as 200 ~ 
aliquots from each of the eight conjugates tested (four for each dye at pH 8.2). Therefore, 
ns 
> 
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the concentrations of each sample in the wells of the test plates differed from each other 
making a comparison of the data misleading. However, the ECso values obtained were 
scaled according to the concentration of each sample and it is these values that can be 
directly compared with each other and with native CV -N (15) itself. Note that Figure 6.9 
does show the raw data obtained from the most heavily loaded CV-N conjugate (36). 
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Figure 6.9 XTT assay results for a) 36 and b) CV -N (15) 
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This data is shown in comparison to that of native CV-N (15) itself in order to show how 
the analysis took place. It should be carefully noted that sample 36 was almost exactly 
twice as concentrated as the native CV-N (15) sample. The data representing the 100% cell 
survival (green line) was obtained from an average of the standard cell blanks in the 96 
well plate. In contrast, the line representing the percent survival of cells completely 
infected by virus (purple line) without protection from any drugs was approximately 20% 
for sample 36 and 13% for native CV-N (15). The uninfected cells gave an approximately 
constant measure of cell viability as the concentration of the CV-N (or adduct) increased. 
The data for the infected cells started with a low percentage survival at a low concentration 
of CV -N (15) as there was no cell 'protection'. As the concentration increased, so did the 
protection afforded by CV-N (15) with a concomitant increase in percentage survival of the 
CEM-SS cells. Due to the higher concentration of 36 present (compared to native CV-N 
(15» the line representing the infected cells for 36 climbed at an earlier concentration than 
that for the native CV-N (15). 
The ECso value was obtained by correlating the 50% percent survival mark with the 
concentration as shown for CV-N in Figure 6.9a). The ECso values for the remaining 
samples were obtained in the same way. The corrected ECso's (i.e. taking into account the 
different concentrations ofthe CV-N-dye conjugates) are shown in Table 6.1. 
Table 6.1 EC50 results from XTT assay ofCV-N-dye conjugates 
Compounds 
5-SFX. 2eq, 15min (33) 
5-SFX, 6eq. 15min (34) 
5-SFX. 25eq, 15min (35) 
5-SFX, 25eg, 60min (36) 
BODfPY FLX, 2eq, 15min (43) 
BODfPY FLX, 6eq, 15min (44) 
BODIPY FLX, 25eq, 15min (41) 
BODIPY FLX, 25eq, 60min (42) 
ECso tfg/mL 
0.0026 
0.0085 
0.0054 
0.0034 
0.0064 
0.0110 
0.0897 
1.2133 
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The values for 41 and 42 were reflective of the lack of any CV -N type compound present, 
as the interpolated EC50 values were far above the value for native CV -N (15). The 
balance of the ECso values, representing those compounds with CV -N partially and fully 
loaded with dye molecules, were within a factor of three of the ECso value for native CV-N 
(15). With respect to the parameters of the XTT assay these results were very close and it 
can justifiably be claimed that there was no difference between the protection afforded by 
the CV -N conjugates or native CV -N (15) itself. This was further evidence that confirmed 
the ELISA assay results suggesting alterations to the amines of CV-N (15) did not inhibit 
the anti -HIV activity of the CV -N itself. 
cu 
> 
.~ 
:::l 
en 
~ 0 
Chapter 6 - Testing ofCV-N conjugates 166 
6.4 Testing of CV -N-Coumarin Conjugates 
The CV -N-coumarin conjugates synthesised in section 4.3.6 (58, 59) took the testing of the 
overall strategy a step further. They each contained the cleavable biolinker and so allowed 
a direct test of this facet of the strategy. Both compounds produced in section 4.3.6 were 
initially tested in the XTT assay to confirm that they bound adequately to gp 120 and 
protected CEM-SS cells from infection. 
6.4.1 XTT Assay Testing of CV-N-Coumarin Conjugates 
Unlike the CV-N-dye conjugates these CV-N-biolinker-coumarin adducts were both 
submitted at the same concentration as the native CV -N (15) allowing a direct comparison 
of the raw data (Figure 6.10a)-c). The trend shown for the infected cells (blue line) in the 
native CV-N (15) result (a) was closely mimicked by that of 58 (b) and 59 (c). This 
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Figure 6.10a) XTT assay results for native CV-N (15) 
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indicated that they both bound to gp120 and both protected the CEM-SS cells just as the 
native CV -N (15) did. The ECso results (Table 6.2) reflected how very close the two 
compounds tested were to CV-N (15) itself. The ECso value obtained for CV-N (15) 
Table 6.2 ECso results from XTT assay ofCV-N-coumarin conjugates 
Compound 
CV-N-Biolinker-Coumarin 15 min reaction (58) 
CV-N-Biolinker-Coumarin 60 min reaction (59) 
ECso llg/mL 
0.0210 
0.0200 
from this XTT assay was higher than that for the previous CV -N sample (Figure 6.9 and 
Table 6.1). Inevitably, there is variability in the assay from day to day as fresh CEM-SS 
cells may not have grown to exactly the level of a previous assay, or a multitude of other 
minor changes may have slightly affected the result. The controls in place ensured that 
these changes were within tolerable limits. An increase of 4 times the ECso is not 
statistically significant and the results can be considered identical. This result stressed the 
importance of incorporating a control such as CV -N (15) for each assay submission in 
order to have a reference point for analysing the performance value of the samples. This 
means that only the data in each submission can be accurately compared although obvious 
trends are evident through multiple XTT assay submissions. 
The conclusion from these successful results was similar to that for the CV-N-dye 
conjugates. That is, the addition of the biolinker-coumarin construct to the amines of CV-
N appeared to have had no effect on the binding affmity and subsequent anti-HN activity 
of CV-N. In particular, these results went a step further in that they also showed that the 
adipic-biolinker section of the construct in no way interfered with the binding ofCV-N to 
gp120. This was important for the overall strategy as the only difference between these 
conjugates and the final toxin derivatives was the substitution of the coumarin moiety by 
the haliamine toxin. There is an obvious increase in size between the coumarin and the 
haliamine toxin although the separation from the surface of the CV-N is considerable due 
to the adipic-biolinker portion. It was decided not to test these CV-N-coumarin conjugates 
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using the ELISA assay as the results would undoubtedly have shown acceptable levels of 
gp120 binding as had been noted with the XTT assay. 
6.4.2 Further Testing of CV-N-Coumarin Conjugates 
The prime reason for synthesising the coumarin derivatives was to establish that the 
biolinker portion of the constructs would in fact cleave under in vivo conditions. The 
cleavage of the biolinker should release free 7-amino-4-methy1coumarin (50) from the 
conjugate. The CV-N-coumarin conjugate was added to gpI20-producing, productively 
infected CEM-SS cells. In theory the CV-N portion should bind to the expressed gp120 
(just as in the XTT assay) with the whole conjugate subsequently taken into the cell as the 
receptors are recycled. l3S This would in turn lead to enzymatic cleavage of the biolinker at 
-pH 5.5 in the lysosomes of the cells, releasing the coumarin amine into the lysosome 
where it can now diffuse into the cytoplasm. The coumarin when conjugated to the 
biolinker in an amide bond has an absorption maxima around 324 nm and an emission 
maxima at 390 nm in aqueous solution. In contrast to this, the amine absorbs at 342 nm 
and emits at 441 nm. Therefore, as the coumarin dye is cleaved from the conjugate the 
fluorescence at 441 nm would increase to reflect this cleavage. 
However, when this experiment was performed, no fluorescence was observed at the 
emission wavelengths for the conjugated or for the free coumarin. Unhydrolysed coumarin 
(conjugated) molecules are known to only fluoresce weakly149 and it was possible that the 
presence of the CV-N and biolinker had quenched the fluorescence of the dye. Also, 
aromatic amines such as 7 -amino-4-methylcoumarin (50) are partially protonated at low pH 
(""5) and this may also contribute to the absence of fluorescence with the pH of the 
lysosomes being around pH 5.5. In retrospect, a fluorescent dye with a larger extinction 
coefficient should have been used to provide for more sensitive detection to unequivocally 
establish that the biolinker can be cleaved by gpI20-producing, productively infected 
CEM-SS cells. 
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Testing of CV-N-Toxin Conjugates 
Three different CV-N-toxin conjugates were synthesised. The fIrst was derived from the 
succinimidyl ester strategy by coupling to the lysine side chain amines in CV -N (15). The 
second was made from reaction of the maleimide-derived toxin construct coupled to CV-
N-Cys. The last was reaction of the same maleimide-toxin construct with thiolated-CV-N. 
The overall structure of each was very similar with primarily a single attachment of the 
halichondrin toxin per CV -N molecule. It was unfortunate that the CV -N-coumarin 
conjugates did not reveal evidence about in vivo cleavage of the biolinker due to lack of a 
fluorescent response. The cleavage of the linker is vital as it is necessary to release the 
norhomohalichondrirt B amine (28) in order to kill the infected cells. 
The testing these toxin conjugates will undergo is very similar to that performed on the 
CV-N-PE38 conjugate produced by Mori et al. lOS The conjugates will be fed to separate 
batches ofuninfected H9 cells and H9/HIV-lInIb cells chronically infected with HIV-l in a 
modifIed XTT type assay. The infected cells (gp120 expressing) should be selectively 
targeted and killed by the CV-N-toxin conjugate while the uninfected cells would remain 
viable. Therefore, there should be a clear distinction between the two types of cell in terms 
of the XTT assay. The values derived from the data will be ICso's which are the effective 
concentration at which 50% of cells are killed (or disabled). The IC50 for the infected cells 
should be much lower than that for the cells that do not express gp120. This is what was 
found for the CV-N-PE38 conjugate. lOS 
In a similar assay, H9IHIV-lIIllb cells will be treated with the CV-N-toxin conjugate in the 
presence or absence of free native CV-N (15). The native CV-N (15) should compete with 
the CV-N-toxin conjugate and therefore raise the IC50 value obtained. This would arise as 
a consequence of a lesser number of cells being killed due to 'protection' from the native 
CV-N (15) binding to gp120. 
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The final test will be an ELISA assay to ensure that, unlike the CV-N-PE38 conjugate, the 
CV-N-halichondrin derivatives will effectively bind to gp120 at the same level as the 
native protein. The CV-N-PE38 conjugate bound gp120 several orders of magnitude less 
than the native CV-N (15), however, the very much smaller biolinker-halichondrin moiety 
should not inhibit gp120 binding to this extent. 
Chapter 6 - Testing of CV-N conjugates 172 
6.6 Conclusions from Testing 
The initial testing of the CV-N-dye conjugates containing the fluorescein and BODIPY 
fluorescent tags were both essential and informative for several reasons. The first crucial 
aspect was whether 'blocking' of the amines in CV-N would prevent binding of CV-N to 
gp120. All the results from the ELISA studies ofthese conjugates revealed that the derived 
EC50 values remained comparable to that of native CV-N (15), no matter how 'loaded' the 
protein became. It could have been expected that with conjugation of such molecules at 
distinct .sites around the CV-N that the binding affmity for gp120 would be affected to 
some noticeable extent. The fact that this did not happen was reflective of the unique, and 
as yet not understood, binding process between CV-N (15) and gp120. The XTT assay 
results from these CV -N-dye conjugates also reflected the lack of interference in the 
binding to gp120, but this time in a situation that more closely resembled the 'real' 
virucidal infection process. 
The CV-N-biolinker-coumarin conjugates much more closely resembled the fmal toxin 
conjugates in that they contained a pendant chain attached to the tetrapeptide biolinker. 
These conjugates also proved to bind to gp120 just as effectively as the native CV-N (15) 
in the XTT assay. The molecular weight of each coumarin construct per addition was 
approximately 660 Da which corresponded to the addition of an extra 6% (by weight) to 
the CV-N (15) protein. This was a significant increase in mass particularly if more than 
one construct was attached per CV-N molecule. However, these additions of mass to the 
outer surface of the CV-N (15) protein, which must extend some distance out from the 
protein surface, did not inhibit the gp120 binding in any perceivable manner. The lack of 
fluorescent response from these coumarin conjugates in the gp120-expressing cell assay 
proved little either way as to whether the biolinker can be cleaved as planned, as there are 
many factors that can interfere with the fluorescent response from the coumarin. 
It was unfortunate that the results from the toxin conjugates themselves could not be 
included. The testing and the timing of the testing is part of the collaborative effort with 
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the NCr. The questions left to answer are whether or not these toxin conjugates do 
selectively target and kill infected, as opposed to uninfected, cells. The other results from 
this chapter do point towards the toxin conjugates having little trouble binding efficiently 
to gp 120. Based on these results it would be surprising if the conjugates did not bind to 
gp120 in a comparable manner to native CV-N (15). Although the biolinker-toxin section 
of the conjugate is nearly three times larger than the biolinker-coumarin equivalent, the 
portion of the structure closest to the CV -N surface (pendant chain-biolinker) is essentially 
identical. The 'extra' mass comes from the toxin portion of the conjugate which is furthest 
from the protein surface. The experiments with gp 120-expressing infected cells treated 
with these conjugates is the ultimate test to determine the effectiveness of the toxin 
conjugates at selectively targeting and destroying HIV -infected cells. 
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Chapter 7 
CONCLUSIONS 
7 .. 1 Summary and Conclusions 
The aim of this project was to construct CV-N-toxin conjugates that would selectively 
target HIV-infected cells with subsequent release of the toxin, causing cell death. The 
early approaches outlined in Chapter 2 led to the choice of two complementary strategies 
that relied on the activation of toxin constructs by succinimidyl esters and maleiinides 
respectively. The cleavable biolinker provided a suitable method for release of the toxin 
once internalised in infected cells. The successful development of norhomohalichondrin B 
amine precipitated its use as the toxin component of the conjugates. The individual 
components of a construct: protein, activating moiety, bio1inker, and toxin had to be 
incorporated in a coherent strategy that also allowed for the sensitivity of the toxin to harsh 
chemical conditions. 
The native CV-N (15) was purified by reverse phase HPLC from a crude mixture obtained 
from the NCr. This process returned approximately 15% of the mass. Although time 
consuming, HPLC did effectively separate the CV-N from other proteins present. CV-N-
Cys was recombinant1y produced, but the presence of a glutathione molecule attached to 
the cysteine proved troublesome to remove without loss of the biological activity of CV-N. 
The final derivative of CV-N was produced via thiolation oflysine side chain amines. This 
degree of thiolation could be controlled by halting the reaction at whatever level of 
conversion was required. Therefore, these CV-N derivatives had varying degrees of 
'loading' capacity with the native CV -N (15) having the potential for conjugation at six 
sites, the CV-N-Cys at a single site and the thiolated-CV-N at whatever level in between 
that was required. 
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Three separate CV-N-toxin conjugates were ultimately synthesised, all similar in structure, 
although with slight changes in the coupling process. The succinimidyl ester derived 
synthetic scheme, although longer than initially planned due to the necessity for 
lengthening of the chain via adipic anhydride, did produce the desired product. The 
subsequent reaction with CV-N (15) was significantly slower than that observed for the 
model systems incorporating succinimidyl esters. However, the CV-N-toxin product was 
obtained utilising this methodology and therefore remains a viable strategy. 
The synthesis of the maleimido-toxin derivatives utilised a simpler strategy, primarily due 
to the orthogonal reactivities of the. toxin amine and the maleimide moiety. This allowed 
synthesis of the entire maleimido-caproic-biolinker structure by SPPS with only the 
carboxyl activation and reaction with the halichondrin amine outstanding. The simple 
nature of this strategy was a distinct advantage over the succinimidyl counterpart in terms 
of effort required and exposure of the halichondrin skeleton to stronger (adverse) reaction 
conditions. This maleimido-toxin conjugate was utilised with both CV-N-Cys and 
thiolated-CV-N. As noted, the CV-N-Cys provided a derivative with the toxin attached at 
a defmed position. In terms of the viability of CV-N-toxin conjugates as potential 
therapeutic agents, this homogeneity is of particular importance. However, it will be 
necessary for future work that CV-N-Cys be made without attached groups such as methyl 
and glutathione. The thiolated-CV-N reaction was also successful in producing a CV-N-
toxin conjugate. This method has the advantage of being able to control the degree of 
loading of toxin per CV-N molecule by monitoring and halting the thiolation reaction at 
whatever stage is required, but as yet the site, or most likely sites, of mono-thiolation are 
unknown. 
No matter what modifications were made to CV-N, the initial issue was whether those 
alterations would cause a decrease in binding affmity for gp 120. The results from testing 
of both the model CV-N-dye and CV-N-biolin1cer-coumarin conjugates clearly indicated 
that no discernible inhibition of gp 120 binding had taken place. Therefore, it was 
reasonable to infer that the unique binding properties of CV-N (15) to gp120, although not 
yet precisely understood, did not necessitate interaction between gp120 and at least the 
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majority of the freely accesible lysine side chains of CV -N (15). The extensive testing of 
these conjugates meant that there was a high degree of confidence that the equivalent toxin 
constructs would also bind gp120 in the same manner. The final testing of the CV-N-toxin 
conjugates with infected cells will reveal if the last phase of the strategy, cleavage of the 
biolinker and release of the toxin, will be successful and a new approach to anti-HIV 
therapy realised. 
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Chapter 8 
E ERI NTAL 
8.1 General Methods 
Nuclear Magnetic Resonance 
All proton detected NMR spectra were recorded on either a Varian Unity 300 or 500 
spectrometer at 23°C, operating at 300 MHz and 500 MHz respectively. Carbon detected 
NMR spectra were recorded on either a Varian Unity 300 or Varian XL300 spectrometer at 
23°C, operating at 75 MHz. Other NMR experiments described in this thesis viz COSY, 
and the reverse detected HSQC and HMBC experiments were recorded on either the Unity 
300 or 500 spectrometer, at 300 MHz or 500 MHz. For each experiment the selection of 
the particular spectrometer is stated. Chemical shifts in this thesis are described in parts 
per million (ppm), on the 0 scale, and were referenced to the appropriate solvent peaks: 
CDCb referenced to CHCh at OH 7.26 ppm eH) and CHCh at Oc 77.0 ppm (l3C); CD30D 
referenced to CHD20D at OH 3.31 ppm (lH) and CD30D at Oc 49.3 ppm (BC). IH NMR 
spectra were recorded using an acquisition time (AT) of 2.0 s; 13C NMR spectra were 
recorded using an AT of 0.878 s. COSY experiments were recorded using an AT of 
typically 0.215 s and a relaxation delay (D1) of 1.0 s. HSQC experiments with the Pulsed 
Field Gradient system were run with an AT of typically 0.14 s, a D1 of 1.0 sand JC-H of 
140 Hz. HMBC experiments were recorded with an AT of typically 0.18 s, a relaxation 
delay of 0.333 s, 30 Hz and a nJCH of 8.3 Hz. HMBC experiments with the Pulsed 
Field Gradient system were run with an AT of ca 0.2 s, a Dl of 1.0 s, J =140 Hz and a nJCH 
of 8.3 Hz. 
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Mass Spectrometry 
Mass spectrometry of some initial samples (stated) was perfonned on a Kratos MS80 RFA 
Mass Spectrometer operated at 4,000 V in either fast atom bombardment (F AB) or electron 
impact (El) ionisation mode. F AB was perfonned with an Ion Tech ZNIIFN ion gun using 
Xe as the reagent gas, operating at 8 kV and 2 rnA with an m-nitrobenzyl alcohol (NOBA) 
matrix. Ionisation was perfonned at 70 e V. 
The majority of LCMS samples were analysed with a Waters 2790 HPLC system and a 
Waters 996 photodiode array (PDA) detector coupled in parallel to a Micromass LCT mass 
spectrometer equipped with an electrospray ionisation (ESI) probe. Samples were analysed 
at a probe voltage of 3,200 V at 150°C with a nebuliser gas flow of 160 L/hr and 
desolvation gas flow of 520 LIhr with the source temperature at 80°C. The cone voltage 
was typically 25 V unless otherwise stated. The solvent flow from a syringe pump in direct 
injection ESIMS mode (LC disabled) was 20 ilL/min. 
LCMS ofCV-N containing samples used a Zorbax C3 column (150 x 2.1 rnm, 300A, 0.2 
mLlmin) with a 20%-60% CH3CNIH20 (0.5% fonnie) gradient over 20 minutes unless 
otherwise stated. 
Some samples (stated) were analysed by Dr Lewis Pannell (NIDDK, NIH) on a Hewlett 
Packard LCMS mass spectrometer. 
High Performance Liquid Chromatography 
The HPLC work described in tlus thesis was performed on one of two machines. A 
SlUmadzu LC-4A instmment equipped with a Shimadzu UV Spectrotometric Detector 
SPD-2AS and Hewlett Packard 3390A integrator was used for preparative reverse phase 
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work with the stated column, solvent mixture and flow rate. Solvents were degassed using 
a flow of helium. 
Analytical and small scale preparative work was performed on a Shimadzu VP system. 
The complete setup involved a Shimadzu LC-I OAC VP liquid chromatograph coupled to a 
SIL-IOA VP autoinjector, aCTO-lOA VP column oven set to 40°C, and a SPD-MIOA VP 
diode array detector. This system was controlled by Shimadzu CLASS-VP (Version 5.023) 
software. A Shimadzu degasser was utilised for the degassing of all solvents used in this 
machine. 
Columns and flow rates used included a Phenomenex C 18 column (250 x 4.6 mnl, 60 A, 5 
micron APD, 1 mLimin), a Zorbax C3 column (150 x 2.1 mm, 300 A, 0.2 mLimin), a 
Dynamax C4 (260 x 10 mm, 300 A, 3.5 mL/min) and a Dynamax C18 (270 x 20 mm, 60 
A, 12 mL/min). 
The solvents used were either mixtures of acetonitrile (BDH HiperSolv™ 'Far UV' grade) 
or methanol (BDH HiperSolv ™ grade) with water (purified using a MilliQ deionising 
system). 
HPLC purification of CV-N-Cys took place while a guest at the LDDRD, NCI, Frederick, 
Maryland, USA and used a BioCAD SPRINT Perfusion Chromatography System 
(PerSeptive Biosystems, Inc.) with a Dynamax CI8 column (250 x 10 mm, 300 A, 2 
mLlmin). 
Bradford Protein Assay 
The Bradford protein assay, first reported in 1976163 is a simple, rapid, and sensitive test 
for the presence of protein material in a sample. When Coomassie Brilliant Blue is in a 
dilute acid solution it appears red, but when mixed with protein the dye turns blue 
(maximum at 595 urn). Not all proteins are susceptible in the assay but CV-N-Cys was 
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known to provide a positive result. For this particular assay a standard curve was obtained 
from measuring the response from increasing concentrations of Bovine IgG with the 
Coomassie Brilliant Blue dye. The crude CV-N-Cys was also tested at two different 
concentrations. After reading the absorbance at 595 nm for the CV-N-Cys samples, the 
corrections were made for the dilution factors providing an average value of -75 mg of 
protein material in the crude CV-N-Cys sample. 
SDS-PAGE 
In PAGE, a gel made by polymerising acrylamide and bisacrylamide together forms a 
network of pores, the sizes of which are defmed by the initial acrylamide and bisacrylamide 
concentrations. When an electric field·is applied across the gel, protein migrates according 
to its charge and the distance that it migrates in the gel in a given time is determined by the 
pore size, the molecular size of the protein and its net charge. In SDS-P AGE, the anionic 
detergent sodium dodecyl sulphate (SDS) is used to completely suppress the native charge 
on the proteins, giving them a large negative coat of detergent molecules. Because SDS 
interacts with the hydrophobic core of proteins, it causes a rapid and irreversible unfolding 
that denatures the polypeptide chains which all now have a roughly equivalent charge/mass 
ratio. For this reason the separation in the gel is now purely dependent on the molecular 
mass of the protein, providing a useful and high resolution analytical method. 
The following general method was used for all SDS-PAGE analyses performed while at the 
LDDRD, NCI, Frederick, Maryland, USA. 16% Tricine Gels were used which are ideal for 
low molecular weight proteins such as CV-N-Cys. 
The comb was removed from the gel and the wells rinsed with 3x 1 mL of Tricine Running 
Buffer. The gel cartridge was placed into the XCell II Mini-Cell and buffer poured to 
cover the gel and one third fill the outer reservoir. To 10 JlL of each sample was added 15 
JlL of Tricine Sample Buffer (see below) which was then vortexed and boiled for 2 min. 
The samples were loaded into the wells with (usually) a Prestained Marker (see below) in 
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wells on each end of the gel. The power supply was switched on and the gel run for 75 
min. At this time the cartridge was cut open to release the gel and the wells sliced off and 
removed. The gel was placed in fixative solution (400 mL MeOH, 100 mL CH3C02H, 500 
mL de-ionised water) for 30 min then stained with a solution containing CH3C02H (100 
mL), Coomassie Blue G-250 (0.25 g) and de-ionised water (900 mL) for 1 hour. The gel 
was then left overnight in CH3C02H (100 mL) and de-ionised water (900 mL). After 
washing with water (three times) the gel was placed in Gel-DryTM drying solution for 20 
min. The gel was then sandwiched between two cellophane sheets soaked with Gel-DryTM 
and left in a stand overnight to dry. 
The Tricine Sample Buffer contained:-
Deionised water (4.0 mL) 
0.5M Tris-HCI, pH 6.8 (2.0 mL) 
Glycerol (2.4 mL) 
10% SDS (1.0 mL) 
~-mercaptoethanol (0.2 mL) 
0.5% Coomassie G-250 (0.4 mL) 
The Prestained Marker contained the following standards:-
Protein 
Triosephosphate isomerase 
Myoglobin 
a-Lactalbumin 
Aprotinin 
Insulin ~ chain, oxidised 
Bacitracin 
Molecular Weight (Da) 
26,625 
16,950 
14,437 
6,512 
3,496 
1,423 
Any changes made to this protocol are stated. 
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ELISA Assay 
A general outline of the principle and procedure of the gp 120-mediated ELISA is discussed 
in section 6.2.1. The exact methodology is outlined below. 
Each well of a 96-well plate was incubated with 100 ilL/well of a 1 Ilg/mL solution of 
gp120 (8.3 nM) in PBS for 2 hours at room temperature. Plates were then washed with 
100 JlL of wash buffer (pBS (without Ca and Mg), 0.01 % Tween 20). Incubation with 200 
ilL of 2% BSA in PBS (sonicated) overnight at 4°C blocked any unused space in the wells. 
Plates were then washed twice with 100 JlL of wash buffer. The appropriate wells (shown 
in Figure 6.2) were incubated with 100 ilL/well of variable concentrations of either native 
CV-N (15) or CV-N conjugates for 1 hour at room temperature. The plate was again 
washed 3 times with 100 jlL of wash buffer and further incubated with 100 ilL/well of anti-
Rabbit-anti-CV-N Ab for I hour at room temperature. After a further 3 washes the plate 
was incubated with 100 Ill/well of anti-Rabbit IgG-Ab-AP for 1 hour at room temperature. 
The plates were then washed 3 times and incubated with 100 jlL of substrate buffer (10% 
diethanolamine, 10 mM MgCh, 4 mg/mL p-nitrophenyl phosphate (pNPP) for 
approxinmtely 15 min - dependant on visual colour change. The final step was to add 100 
JlL of EDT A (0.5 M, pH 8.0) to each well (without washing of the buffer). The plates were 
then stored at 4°C until ready to read at 405 nm in a plate reader. 
XTT Assay 
After adding each sample for testing to a single colunm of a 96 well plate at a known 
concentration the rest of the procedure was primarily automated as described in section 
6.2.2. For further detailed information see Weislow et al. 162 and Gulakowski et al. 164 
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Column Chromatography 
All column chromatography was performed using glass columns of stated dimensions. 
Solvents were all of commercial grade, distilled once in glass distillation apparatus, except 
MeOH, which was distilled twice. 'Flash' columns were run under N2 gas (oxygen free) 
pressure (0.5 kPa). 
Silica flash chromatography was performed on Merck silica gel 60 (230-400 mesh). 
Reverse phase C 18 chromatography of halichondrin containing compounds used 
Bakerbond spe ™ Octadecyl (C 18) disposable extraction columns (40 11m APD, 60 A) of 
either 100 mg or 500 mg size. Chromatography ofCV-N conjugates used Bakerbond C4, 
Pharmacia G25 or G 100 in appropriate solvents (stated). 
Kaiser Test 
For SPPS of peptides the Kaiser test was used to determine the presence (or not) of free 
amines. Several beads from the resin synthesis were removed and washed with 3x 1 mL 
EtOH in a small glass vial. The following three stock solutions were made and 3 drops 
from each added to the beads ensuring all beads were completely covered in solution. 
1) 2.5 g of ninhydrin in 50 mL ofEtOH 
2) 40 g phenol in 10 mL ofEtOH 
3) 0.001 M KCN (6.5 gin 100 mL water) and 12 mL of pyridine 
The vial was capped and placed in an oven (100°C) for approximately 5 min. A positive 
result was indicated by the beads turning blue while a negative result was shown by no 
change in colour (beads remain yellow). 
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Solvents 
All Technical grade solvents were distilled prior to use. MeOH was distilled twice. Dry 
solvents were obtained using the following standard methods. MeOH was distilled from 
magnesium metal and iodine and stored over activated molecular sieves (4 A). Pyridine 
was refluxed over CaH2 before distillation. Tetrahydrofuran (THF) was refluxed over 
sodium metal and benzophenone before distillation directly prior to use. Dichloromethane 
(DCM) was refluxed over calcium hydride before distillation. DMF was dried by treating 
twice overnight with 4 A molecular sieves, followed by storage over 4 A sieves. Isopropyl 
alcohol (IP A) was refluxed over calcium hydride for 3 hours before distillation and stored 
over 4 A sieves. 
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8.2 Work Described in Chapter 2 
2.6.2.1 Reductive Amination of Norbomohalicbondrin B Aldebyde 
To a solution of 29 (1.0 mg, 9.17xlO"4 mmole) in dry MeOH (200 j..1L) was added 
ammonium acetate (7.06 mg, 0.0917 mmole) and NaCNBH3 (0.0403 mg, 6.42xlO-4) with 
stirring under argon at room temperature. TLC analysis (Si02, Merck, lO% MeOHlDCM) 
after 4 hours showed formation of a ninhydrin and phosphomolybdic acid (PMA) active 
spot at Rr=0.2 compared to the Rr=0.8 of the PMA active 29. After 18 hours all signs of 
29 had disappeared (TLC) and the reaction mixture was loaded in 50 ~LL aliquots onto a 
C1S cartridge (100 mg) pre-filled with water (-5 column volumes) above the packing 
material. After all 4 aliquots had been diluted and rinsed through the cartridge in this way 
the column was washed with water (20 column volumes). Washing with MeOH (lO 
column volumes) eluted 28 in quantitative yield after drying. The lH NMR (Unity 500) 
spectrum of 28 was directly compared with that of the starting aldehyde (29) and amine 
synthesised previously via a different method.130 The disappearance of the aldehyde 
resonance at 0 9.70 ppm and the movement of resonances for H53 and H50 along with the 
correlation to the previously derived amine indicated successful product fonnation. 
Confinnation by ESIMS analysis showed a mass of 1092.48 Da. C6oH86N017 (MH+) 
required lO92.58. 
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8 .. 3 Work Described in Chapter 3 
Work in this chapter from sections' 3.3.1, 3.3.2, 3.3.3.1, 3.3.3.2, 3.3.3.3 was carried out 
while a guest at the LDDRD, NCI, Frederick, Maryland, USA. 
3.2 Native CV-N Purification 
Successive analytical HPLC injections (Phenomenex C18 column) of the crude CV-N 
(1.712 g) showed that the best method was a 20% to 50% CH3CNIHzO (0.05% TFA) 
gradient over 15 min with monitoring at 210 nm. The CV-N (15) eluted at 13.1 min, 
confirmed by ESIMS of the collected peak showing a deconvoluted mass of 11,009 Da. 
Preparative HPLC on the Shimadzu LC-4A utilised a 20% to 45% gradient over 25 min 
using the same solvents. The average injections were 200 ilL of a 25 mg/mL solution of 
crude CV-N onto a Dynamax C4 column with a flow rate of 4 mUmin. The CV-N (15) 
peak (22 min) was collected and after multiple injections dried under vacuum. The mass 
obtained for the CV-N (15) peak was 12% of the total mass injected. Re-injection of the 
collected peak on the analytical HPLC system confirmed the identity of the CV-N (15) with 
an identical retention time to a CV-N (15) standard and distinctive UV chromophore 
characteristic of protein material. A sample sent to Dr Lewis Pannell (NIDDK, NIH) for 
LCMS confIrmed the mass as 11,009 Da corresponding to C47oH743N1330164S4. 
3.3.1 Recombinant Production of CV -N-Cys 
Cultures of transformed E. coli containing the plasmid (PET26b(+)) with coding for CV-N-
Cys were grown in Super Broth (Quality Biological Inc., Gaithersberg, USA) with 
kanamycin (30 Ilg/mL), 0.5% glucose, and 1.6 mM MgS04 at 37°C overnight. 20 mL of 
this broth was added to each of eight 2L flasks containing 500 mL of Super Broth and 
incubated for a further 4 hours at 37°C. When the OD of the cultures (600 nm) had reached 
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a value of --4, IPTG was added to a final concentration of 1 mM for induction of gene 
expression. Cells were harvested after 2 hours of incubation at 37°C through centrifugation 
at 6,500 g for 15 min at 4°C. The pelleted cells were resuspended in Tris-HCI (30 mM, pH 
8.0), 20% sucrose, and EDTA (1 mM), incubated for 15 min at room temperature with 
stirring and centrifuged at 10,000 g for 10 min at 4°C. The resulting supernatant 
(periplasmic fraction) was freeze dried. 
3.3.2 Purification and Analysis ofCV-N-Cys 
The freeze dried solid (from above) was resuspended in water and chroma to graphed on a 
pad of reverse phase C4 in a 250 mL sintered glass funneL The sample was loaded in 
water and progressively washed with 100% water, 2: 1 waterlMeOH, 1:2 waterlMeOH and 
100% MeOH. The MeOH containing fractions were combined and dried under vacuum. 
A Bradford Protein Assay estimated the protein content to be 75 mg at this stage and SDS-
PAGE analysis showed, as the primary spot, a protein of approximately 11 kDa in size. 
Purification was achieved firstly by reverse phase C 18 preparative HPLC (BioCAD 
SPRINT Perfusion Chromatography System) running a 20% to 50% CH3CN/H20 (0.05% 
TFA) gradient over 30 min with monitoring at 210 nm and a flow rate of 2 mL/min. The 
CV -N-Cys eluted at 22 min, was collected over multiple injections and dried under vacuum 
to yield 43 mg. A further SDS-PAGE established that the sample had undergone 
significant purification with a single spot at approximate molecular weight 11 lilla. LCMS 
analysis by Dr Lewis Pannell (NIDDK, NIH) showed the molecular mass to be 11,417 Da, 
305 Da higher than would be expected for the CV-N-Cys protein. The extra mass was 
detelmined to be a glutathione molecule by comparison to previous samples analysed from 
the LDDRD that had contained smaller amounts of this product. 
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3.3.3.1 Dialysis Treatment of CV ~N-Cys-Glutathione 
The initial dialysis buffering solution (1 L) contained potassium phosphate buffer (20 mL, 
100 mM), EDTA (2 mM, pH 7.5) and DTT (100 JlL, 1 M). To 30 (250 JlL of 4 mg/mL) 
was added 2.25 mL of dialysis buffer and the solution injected into the inner membrane of 
the dialysis cartridge. The cartridge was left submerged in the larger volume at 4°C with 
gentle stirring for 6 hours at which time the outer solution was refreshed with 1 L of the 
same buffering solution. After a further 12 hours, the outer solution was changed to I L of 
buffer (no DTT) and left stirring for 6 hours with a final change to 1 L of buffer (no DTT) 
which was left stirring at 4°C for 12 hours. The inner solution was removed from the 
cartridge and chromatographed on a C4 column (30 x 10 mm) and washed with water (20 
column volumes). The protein was eluted with MeOH (10 column volumes) and dried 
under vacuum. An initial SDS~PAGE analysis under standard conditions revealed protein 
corresponding to approximately the monomer of CV-N-Cys but a further SDS-PAGE 
without boiling of the sample showed protein corresponding to the dimer. This was 
confirmed by LCMS analysis (Dr Lewis Pannell, NIDDK, NIH). Mass of 22,262.79 Da 
(dimer ofCV-N-Cys plus K+). An XTT assay showed an ECso 12x less than that of native 
CV-N (15). 
3.3.3.2 Repeat of Dialysis of CV -N-Cys-Glutathione 
The initial dialysis conditions were identical to those above. After stirring for 24 hours the 
inner solution was removed from the cartridge and diluted into water (500 mL) with slow 
stirring. After 1 hour the solution was progressively loaded into two 80 mL Centriprep 
filters (3,000 MW cut-off) which were centrifuged at 3,000 g for 20 min. After the 500 mL 
had been centrifuged through the filter the remaining small volume (""'5 mL in each filter) 
was further washed and centrifuged with water (3x 70 mL). The filter was then reversed 
and centrifuged at 250 g for I min. The samples from both filters were combined and 
freeze dried. SDS-P AGE analysis revealed monomer with pre-boiling of the sample, and 
dimer without boiling. LCMS (Dr Lewis Pannell, NIDDK, NIH) confirmed the presence 
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of dimer of mass 22,223.26 Da. XTT analysis gave an ECso 60 times greater than native 
CV-N (15). 
3.3.3.3 Chemical Removal of Glutathione from CV -N-Cys 
To 30 (10 mg, 8.76x10·4 mmole) in 250 flL of water was added guanidine HCI (750 flL, 8 
M) with gentle vortexing and addition of Tris HCI (33 flL of 3 M, pH 8.45) and DTT (20 
flL of 0.5 M). The sample was flushed with N2, sealed, left in the dark for 2 hours and then 
chromatographed on a GIOO column (400 x 25 mm) eluting with PBS at a flow rate of2.l 
mL/min with monitoring at 280 nm. The protein was collected between 32 and 52 min and 
concentrated on Centriprep filters (as described for the repeat dialysis experiment above) 
and freeze dried. SDS-P AGE analysis with pre-boiling showed monomer, and 'without 
boiling an approximate ratio of 1:2 monomer:dimer. LCMS analysis (Dr Lewis Pannell, 
NIDDK, NIH) showed only monomer of correct mass 11,112.04 Da. However, an XTT 
assay showed an ECso 668 times greater than native CV-N (15). 
3.4.1 Lysozyme Model with Iminothiolane 
Lysozyme (1 mg, 6.99xlO-s mmole) was dissolved in 1 mL of degassed (helium) reaction 
buffer (0.1 M sodium borate, 0.001 M EDTA, 0.15 M NaCI) with addition of 
iminothiolane (27, 96 flL of 1 mg/mL, 6.99xl0-4 mmole). Aliquots (5 flL) were removed 
after 5, 25, 45, 65 and 90 min, diluted 30 fold with water and injected into the ESIMS 
probe with 5 flL of a 10% formic acid solution. Progressive formation of increasing 
numbers ofthiolated amines was noted (see Figure 3.4 for all spectra) and after 90 min the 
solution was further reacted (section 5.2.1). 
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3.4.2.1 Preliminary Reaction to Test Effectiveness of Thiolation 
To CV-N (15, 200 Ilg, 1.82xlO-s mmole) in 200 ilL of a 0.9% saline solution was added 
200 ilL of reaction buffer (0.1 M sodium borate, 0.001 M EDTA, 0.15 M NaCl) with 
degassing (helium) followed by addition of iminothiolane (27, 25 ilL of 1 mg/mL, 
1. 82xl 0-4 mmole). Aliquots (10 JlL) were removed after 5 and 25 min, diluted 30 fold with 
water and injected into the ESIMS probe with 10 ilL of a 10% formic acid solution. The 
reaction was proceeding slowly so further iminothiolane (27, 50 ilL of 1 mg/mL, 3.64xlO-4 
mmole) was added with ESIMS analysis at a total reaction time of 30, 45 and 60 min. The 
conversion rate from amines to thiols was still slow, so further iminothiolane (27, 50 ilL of 
1 mg/mL, 3.64xlO-4 mmole) was added to the reaction mixture. A final ESIMS analysis at 
total reaction tinle of 80 min (see Figure 3.5 for all spectra) showed sufficient thiolation to 
proceed with the next reaction (section 5.2.2). 
3.4.2.2 Second Reaction with Modified Conditions 
To CV-N (15, 200 Ilg, 1.82xlO-5 mmole) in 200 ilL of a 0.9% saline solution was added 
200 ilL of reaction buffer (0.1 M sodium borate, 0.001 M EDTA, 0.15 M NaCl) with 
degassing (helium) followed by addition of iminothiolane (27,25 ilL of 5 mg/mL, 
9.10xl0-4 mmole). Aliquots (5 JlL) were removed after 60 and 105 min, diluted four fold 
with water and injected into the ESIMS probe with 15 JlL of a 10% formic acid solution. 
The reaction mixture showed formation of significant amounts of thiolated-CV-N and was 
chromatographed on a G25 colunm (400 x 10 mm) eluting with water at a flow rate of 0.9 
mL/min and monitoring at 276 nm. The separated protein fraction was further reacted 
(section 5.3.2). 
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3.4.2.3 Optimised Reaction of CV-N Plus Iminothiolane 
To CV-N (15, 200 Ilg, L82xlO-5 mmole) in 200 ilL of a 0.9% saline solution was added 
200 ilL of reaction buffer (0.1 M sodium borate, 0.001 M EDTA, 0.15 M NaCl) with 
degassing (helium) followed by addition of iminothiolane (27, 50 ilL of 5 mglmL, 
1.82xl0·3 mmole). ESIMS injections at 5 min and 25 min showed fOlmation of principally 
singly thiolated-CV-N. The solution was left for 30 min and then chromatographed on a 
G25 colul1m (400 x 10 mm) eluting with water at a flow rate of 0.9 mUmin and monitoring 
at 276 mn. The protein eluted between 10 and 14 min. ESIMS analysis confimled the 
formation of mostly singly thiolated-CV-N (see Figure 3.6 for spectrum). Half of this 
solution from the G25 colunm was reacted (section 5.5.2). 
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8.4 Work Described in Chapter 
Work in this chapter from sections' 4.2.2.1, 4.2.2.2, 4.2.3.1 and 4.2.3.2 was carried out 
while a guest at the LDDRD, NCI, Frederick, Maryland, USA. 
4.2.2.1 Reactions at pH 8.2 
Four reactions were performed on separate aliquots of CV-N (15, 200 Ilg, 1.82xlO-5 
mmole) dissolved in NaHC03 buffer (200 ilL, 0.1 M). The 5-SFX dye (1 mg) was 
dissolved in DMF (100 ilL) and aliquots (2 equiv, 2.14 ilL; 6 equiv, 6.41 ilL; 2 x 25 equiv, 
26.7 ilL) added to the CV-N solutions. The fIrst three reactions were left at room 
temperature for 15 min. The fourth reaction, with 25 equiv. was allowed to react for 60 
min. After completion, the samples were chromatographed on a G25 column (140 x 10 
mm) eluting PBS. Two coloured bands (light orange, bright yellow) for each column were 
observed and subsequently collected. The first bands eluting were the protein containing 
fractions which were submitted for LCMS analysis (Dr Lewis Pamlell, NIDDK, NIH). The 
results shown in Table 4.1 and Figure 4.1. 
4.2.2.2 Reactions at pH 7.2 
The same reactions as above were carried out with the only differences being the buffer 
(0.1 M PBS, pH 7.2) and the less intense colour of the eluted protein bands from the G25 
column. The results from LCMS analysis (Dr Lewis Pannell, NIDDK, NIH) shown in 
Table 4.2 and Figure 4.3. 
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4.2.3.1 Reactions at pH 8.2 
Reactions were as described in 4.2.2.1 above, but with the following quantities ofBODIPY 
FLX-SE (1 mg in 100 ilL of DMF) used in place of 5-SFX; (2 equiv, 1.83 ilL; 6 equiv, 
5.48 ilL; 2 x 25 equiv, 22.8 ilL). The colours of the eluted bands were orange and light 
green. The protein containing bands (orange) were also analysed by LCMS (Dr Lewis 
Pannell, NIDDK, NIH) with results shown in Table 4.3 and Figure 4.4. 
4.2.3.2 Reactions at pH 7.2 
The same reactions as above were carried out with the only differences being the buffer 
(0.1 M PBS, pH 7.2) and the less intense colour of the eluted protein bands from the G25 
column. The results from LCMS (Dr Lewis Pannell, NIDDK, NIH) shown in Table 4.4 
and Figure 4.5. 
4.3.1.2 Synthesis of Fmoc-Gly-Phe .. Leu-Gly .. OH 
The SPPS of 49 was achieved by standard solid phase techniques using a glass apparatus 
with a frit (porosity 3) allowing bubbling of the resin from below through flow of Nz, and 
subsequent vacuum removal of the solution after reaction at each stage. Fmoc-Gly-Wang 
resin (3 g, 0.897 meqlg) was bubbled for 30 min in dlY DMF, drained, and the Fmoc 
cleaved with bubbling of a 20% piperidine/DMF solution (30 mL) for 10 min. After 
washing with 3 x 15 mL of DMF and 3 x 20 mL IPA, several beads were removed and 
analysed using the Kaiser test (see General Methods, section 8.1). A positive result 
allowed washing with 3 x 15 mL DMF and changing of the flask containing all the 
washings (to remove the presence of the piperidine). A DMF solution (~15 mL) containing 
Fmoc-Leu (1.902 g, 5.382 mmole), HBTU (2.041 g, 5.382 mmole), HOBt (0.727 g, 5.382 
mmole), and DIPEA (1.875 mL, 10.764 mmo1e) was bubbled with the resin for 60 min. 
Washing with 3 x 15 mL DMF and 3 x 20 mL IPA was followed by removal of several 
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more beads for a Kaiser test, this time negative, indicating that all amines had reacted. The 
process of coupling and deprotection was repeated for addition of Fmoc-Phe (2.085 g, 
5.382 mmole) and Fmoc-Gly (1.600g, 5.382 mmole) with all other reagents the same as 
above. The tetrapeptide was left to dry overnight inside the glass vessel in the presence of 
PzOs under vacuum. A mixture of 45 mL of 95% TF A, 2.5% TES and 2.5% water was 
bubbled with the resin for 20 min, drained, and then rinsed with 2 x 20 mL TF A. The 
combined acidic solution was alternately concentrated under vacuum and repeatedly 
precipitated with water to remove TF A from solution. The solution was precipitated one 
last time and filtered over a sintered glass funnel (porosity 4), and dried to give 1.17 g of 49 
(71 % yield). HRFABMS showed MNa+ 637.2639 (C3J-i3s07N4Na required 637.2657). JH 
(Unity 300) and 13C NMR (XL300) spectral data ~hown in Table 4.5. 
4.3.2.1 Synthesis of Fmoc-Gly-Phe-Leu-Gly-Coumarin 
To 49 (30 mg, 0.0488 mmole) in dty pyridine was added 7-amino-4-methy1coumarin (50, 
9.4 mg, 0.0537 nmlole) and POCh (5.0 J..lL, 0.0537 mmole) with stirring for I hour. After 
removal of solvent, the residue was dissolved in MeOH and an analytical HPLC 
(phenomenex Cl8 colunm) performed (80% MeOHlHzO (0.05% TFA)) with elution ofthe 
product 51 at a retention time of 8.24 min compared to 49 at 6.38 min. Preparative HPLC 
on the Shimadzu LC-4A (Dynamax C18) of 51 with the same isocratic solvent mixture 
gave a retention time of 27 min for the product which was collected, dried and weighed 
(25.3 mg, 67%). HRESIMS gave MH+ 772.3341 (C44H46NSOS required 772.3346). IH 
(Unity 300) and 13C NMR (XL 300) spectral data shown in Table 4.6. 
4.3.2.3 Fmoc Removal to form H2N-Gly-Phe-Leu-Gly-Coumarin 
51 (25.3 mg, 0.0328 mmole) was dissolved in 20% piperidine/CH3CN (5 mL) and left for 
30 min and then evaporated to dryness. The residue was dissolved in DCM and 
cbromatographed on a silica column (60 x 5 mm) and washed initially with DCM (5 mL). 
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Elution with EtOAc (10 mL) yielded the Fmoc-piperidine adduct (ESIMS), followed by 
elution with MeOH (10 mL) which yielded the product (53, 16.8 mg, 93%). The IH NMR 
(Unity 300) spectrum in CD30D was assigned through comparison with 51. 
21 
o 12' 
H~ H 
N ~N 
. 4 N~ 8 13V,6 
114 
15 
H2N-Gly-Phe-Leu-Gly-coumarin (53) 
l' 
IH NMR (CD30D) () 0.91 (d, J=6.1 Hz, (H15)3 or (H16)3), () 0.95 (d, 6.1 Hz, (HI6)3 or 
(H15)3), () 1.52-1.71 (m, (HI3)2)' () 1.52-1.71 (m, H14), () 2.44 (s, (H11 ')3), () 2.96 (dd, 
J=8.1 and 14.3 Hz, H17a), () 3.16 (dd, J=5.7 and 14.3 Hz, H17b), () 3.47 (m, (Hll)2), () 
3.88 (d, J=17.1 Hz, H2a), () 4.J 4 (d, J=17.1 Hz, H2b), () 4.31 (t, J=6.3 Hz, H5), () 4.67 (t, 
J=5.8 Hz, H8), () 6.21 (s, H3'), () 7.15-7.23 (m, 2x HI9), 0 7.15-7.23 (m, 2x H20), () 7.1 
7.23 (m, H2l), () 7.66 (s, H5'), P 7.66 (s, H6'), () 7.76 (s, H8') amides were not observed 
4.3.3 Succinimide Activation of H2N-Gly-Phe-Leu-Gly-Counlarin 
This reaction was performed many times with a typical procedure for the succinimide 
activation shown below. To H2N-Gly-Phe-Leu-Gly-coumarin (53) in dry CH3CN was 
added DSC (54, 2 equiv.) and pyridine (2 equiv.). [Other reaction conditions attempted 
included a change of base (triethylamine, DIPEA), solvent (DMF, DCM) and performing 
the reaction tmder argon.] The reaction was monitored by TLC analysis (silica, 20% 
MeOH, EtOAc) and after 4 hours an increase in the Rr of the starting material from 0.2 to 
0.8 (UV, vanillin) was observed. The reaction mixture was dried, with a crude IH NMR 
spectrum typically showing the presence of a singlet at 2.8 ppm representing the four 
protons of the succinimide ring. An ESIMS analysis at this stage in general showed the 
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correct mass for the product. Purification of the crude sample was required but whatever 
method was used, such as column chromatography (silica, diol) or HPLC (CI8), the 
product degraded forming a mixture of compounds with the dominant species having a 
mass 26 Da higher than 53. The lH NMR spectrum of the 'purified' sample was generally 
a mixture, but a downfield shift in the a-proton of phenylalanine by 0.50 ppm and the ~­
protons by 0.16 ppm respectively was observable. A shift in the N-terminal glycine u-
protons of 0.22 ppm also suggested a change in the structure. Not enough material was 
available of sufficient purity to characterise by NMR spectroscopy although a structure was 
postulated (Figure 4.11). 
4.3.3.1 Chain Extension Reaction with Succininc Anhydride 
A sample of 53 (3.7 mg, 6.73xI0-3 mmole) was reacted with succinic anhydride (0.81 mg, 
8.08xlO-3 mmole) with DMAP (0.08 mg, 6.73xlO-4 mmole) in dry pyridine (1 mL). After 
24 hours the sample was dried and purified by preparative HPLC (Shimadzu LC-4A, 
Dynamax CI8, 40% CH3CN/lhO (0.05% TFA), 3.5 mL/min, 320 nm). An ESIMS 
analysis showed the correct mass (650 Da, MH') for succinic-Gly-Phe-Leu-Gly-coumarin 
and the product was immediately reacted with DSC (2 equiv.) and pyridine (2 equiv.) in 
CH3CN. LCMS analysis (Phenomenex CI8, 40% CH3CN/H20 (0.5% formic), 320 nm) 
showed formation of the product with the correct mass although a secondary peak also 
formed which represented a mass 26 Da higher than the starting material, succinic-Gly-
Phe-Leu-Gly-coumarin. Purification by preparative HPLC (Shimadzu LC-4A, Dynamax 
CI8, 40% CH3CN/H20 (0.05% TFA), 320 nm) produced primarily the compound of mass 
26 Da higher than the starting material. This was again unacceptable and this strategy was 
modified (section 4.3.4.2). 
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4.3.4.1 Adipic Anhydride Synthesis 
Adipic acid (5 gm, 0.034 mole) was dissolved in acetic anhydride (9.7 mL, 0.102 mole) 
and refluxed for 2 hours at 160°C under argon. The excess acetic anhydride and any acetic 
acid formed were distilled off at normal pressure. The liquid remaining solidified at room 
temperature and was distilled on a Kugelrohr (Biichi GKR-50) at approximately 180°C 
under vacuum. LREIMS on the Kratos MS80 found 128 Da (C6Hg0 3). 
adipic anhydride (55)· 
IH NMR (CDCh) 01.73 (m, 2x CH2), 0 2.50 (m, 2x CH2) 
4.3.4.2 Adipic Anhydride with HzN-Gly-Phe-Leu-Gly-Coumarin 
To 53 (5.6 mg, 0.0102 mmole) in CH3CN was added adipic anhydride (1.44 mg, 0.0112 
mmole) with stirring for 14 hours. After removal of solvent the sample was purified by 
preparative HPLC (Shimadzu LC-4A, Dynamax C 18, 50% CH3CN/fhO (0.05% TF A), 210 
um) with a retention time of 7.0 min for the starting material and 11.6 min for the product 
(56, 4.7 mg, 68%). ESIMS analysis gave 678.41 (MHl (C35fu~509 required 678.31). 
The lH NMR was recorded on the Unity 500 spectrometer. 
HO 
-;:::P' 21 
~ I 0 12' 
7 ~0~~ 
13~16 
114 
15 
adipic-Gly-Phe-Leu-Gly -coumarin (56) 
l' 
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lH NMR (CD30D) 00.92 (d, J=5.9 Hz, (HI5)3 or (HI6)3), 00.96 (d, J= 5.9 Hz, (HI6)3 or 
(HI5)3),o 1.49 (m, H14), 0 1.62-1.72 (m, (H13)2), 0 1.65 (m, (H24)2), 0 1.65 (m, (H25)2)' 
o 2.25 (m, (H23)2), 0 2.26 (m, (H26)2), 0 2.46 (s, (Hll ')3),02.99 (m, HI7a), 0 3.16 (m, 
H17b),o 3.76 (d, J=15.9 Hz, Hlla), 0 3.83 (d, J=15.9 Hz, Hllb), 0 3.91 (dd, J=6.3 and 
17.1 Hz, H2a), 04.14 (dd, J=6.3 and 17.1 Hz, H2b), 04.29 (m, H5), 0 4.62 (m, H8), 0 6.24 
(s, H3'), 0 7.20 (m, 2x HI9), 0 7.20 (m, 2x H20), 07.20 (m, H21), 07.69 (s, H5'), 0 7.71 
(s, H6'), 0 7.79 (s, H8'), amide protons were not observed. 
4.3.5 Activation of Adipic-Gly-Phe-Leu-Gly-Coumarin 
To 56 (2.5 mg, 3.69xlO-3 mmole) in DMF (500 j.1L) was added DCC (0.76 mg, 3.69xlO-3 
mmole) and NHS (0.45 mg, 3.69xlO-3 mmole). After 12 hours, preparative HPLC 
(Shimadzu LCAA, Dynamax C18, 45% CH3CNIH20 (0.05% TFA), 324 nm) separated the 
product with a retention time of 14.1 min. (57, 1.81 mg, 63%). ESIMS analysis found 
775.50 (MH+) (C39ILnN6011 required 775.32). 
4.3.6 Reaction ofCV-N with 57 
Dual reactions were carried out on two samples of CV-N (200 j.1g, 1.82xlO-5 mmole) in 
0.9% saline with NaHC03 (1.68 mg, 0.02 mmole, pH 8.2). To these was added 57 (0.352 
mg, 4.54xlO-4 mmole) in DMF (50 j.1L). The first sample was left for 15 min, 
chromatographed on a G25 column (400 x 10 mm) eluting with water at a flow rate of 0.9 
mLimin with monitoring at 276 run. The protein-containing fraction that eluted first was 
collected and analysed by LCMS (Zorbax C3, 280 nm). LCMS data shown in Figure 4.16 
and Figure 4.17. The second sample had a reaction time of 60 min with an identical 
analysis as above. LCMS data shown in Figure 4.18 and Figure 4.19. 
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4.4.1 Synthesis of Fmoc-Gly-Phe-Leu-Gly-Succinimidyl Ester 
Fmoc-Gly-Phe-Leu-Gly-OH (49, 1.12 mg, 1.82xlO-3 mmole) was dissolved in dry THF (2 
mL) with DCC (0.75 mg, 3.64x1O-3 mmole) and NHS (0.42 mg, 3.64xlO-3 mmole), flushed 
with argon, sealed, and left stirring at room temperature. Analytical HPLC analyses 
(Phenomenex C18 column, 60% CH3CNIH20 (0.05% TFA), 210 mll) showed progressive 
formation of the succinimidyl ester at a retention time of 9.2 min. After 14 hours, no sign 
of the starting material was visible by HPLC and the solution containing 60 was ready for 
addition of 28. 
4.4.2 Synthesis of Fmoc-Gly-Phe-Leu-Gly-Norhomohalichondrin B 
To the solution containing the activated ester 60, was added norhomohalichondrin B amine 
(28, 1.0 mg, 9.l6xlO-4 mmole) in dry THF. Aliquots (1 JlL) were removed for ESIMS 
analysis at various time intervals over 48 hours until complete disappearance of the 
halichondrin amine and formation of peaks (singly and doubly charged) representing the 
product (61). Preparative HPLC on the Shimadzu VP system (Phenomenex C18 column, 
85% CH3CN/H20, 210 nm) separated the product (61, retention time 8.4 min) which was 
collected and dried (0.80 mg, 52%). HRESIMS gave (MH2i+ 844.9344 ((C94H123Ns023)/2 
required 844.9304). 
4.4.3 Fmoc Removal frOiD 61 
61 was dissolved in 2% piperidine/CH3CN. for 30 min and the solvent and piperidine 
removed under vacuum. HRESIMS gave (MHl\fai+ 744.8842 ((C79H1l2Ns021Na)/2 
required 744.8874). 
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4.4.4 Adipic Anhydride Reaction with 62 
To the crude reaction mixture of 62 dissolved in CH3CN was added adipic anhydride 
(0.067 mg, 5.2lxlO-4 mmole) under argon. The reaction was monitored by ESIMS analysis 
with completion of the reaction by 26 hours. After drying under vacuum the sample was 
dissolved in minimal MeOH and chromatographed on a C18 cartridge (100 mg) pre-filled 
with water (-5 column volumes) above the packing material. After the sample had been 
diluted and rinsed through the cartridge in this way the column was washed with water (20 
column volumes). Washing with MeOH (10 column volumes) eluted 63 which was dried 
under vacuum (0.62 mg, 82% from 61). HRESIMS analysis gave (MNaz)z+ 819.9035 
((CgsH119NSOZ4NaZ)/2 required 819.9020). 
4.4.5 Activation of Adipic .. Gly .. Phe-Leu-Gly-Norhomohalichondrin B 
To 63 (0.62 mg, 3.89xlO-4 mmole) in dry CH3CN (0.6 mL) was added DCC (0.387 mg, 
1.88x10-3 mmole) and NHS (0.216 mg, 1.88xIO-3 mmole). An ESIMS injection after 48 
hours showed complete conversion to the succinimidyl ester (64). Purification by HPLC 
on the Shimadzu VP system (Phenomenex CI8 column, 65% CH3CNlHzO, 210 nm) 
separated the product (64) which was collected and dried (0.42 mg, 52%). ESIMS analysis 
gave (MNaz)z+ 868.82 ((Cs9H122N60Z6Naz)/2 required 868.41). 
4.4.6 Reaction of 64 with CV-N 
CV-N (15, 50 ~g, 4.54xlO-6 mmole) was dissolved in NaHC03 buffer (150 ~L, 0.1 M) and 
64 (0.153 mg, 9.08xlO-5 mmole) added in CH3CN (50 JlL). LCMS analysis (Zorbax C3) 
after 15 hours showed product formation but with CV -N (15) still present. A further 20 
equiv. of 64 (9.08xlO-s mmole) was added. LCMS analysis after a further 15 hours 
showed an increase in the relative size of the peak for the product. LCMS data shown in 
Figure 4.25. The reaction mixture was separated by HPLC using the same gradient profile 
and conditions as for LCMS, but with a change in the acid to 0.001% formic acid. 
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Work Described in Chapter 5 
5.2.1 Tbiolated-Lysozyme Reaction witb a Maleimide 
To the thiolated-lysozyme reaction mixture from section 3.4.1 was added maleimidobutyric 
acid (65, 0.128 mg, 6.99xl0-4 mmole) in reaction buffer (50 ilL, 0.1 M sodium borate, 
0.001 M EDTA, 0.15 M NaCl). ESIMS analysis after 5 min with the addition of formic 
acid to the analysis sample allowed observation of a significant concentration of product. 
ESIMS data shown in Figure 5.2. 
5.2.2 Tbiolated-CV-N Reaction with F-150 
To the thiolated-CV-N fonned in section 3.4.2.1 was added F-150 (66, 0.00776 mg, 
1.82xl0-5 mmole) in DMF (10 ilL). After 1 hour the reaction mixture was 
chromatographed on a G25 column (400 x 10 rum) eluting with water at a flow rate of 0.9 
mL/min with monitoring at 276 nrn. The protein containing fraction eluted at 6.7 min with 
the remainder of the lower molecular weight compounds eluting after 9 min. ESIMS 
analysis of the protein fraction revealed significant addition of F-150 (66) to CV-N (15). 
ESIMS data shown in Figure 5.4. 
5.3.1 Synthesis of Maleimido-Caproic-Gly-Pbe-Leu-Gly-Coumarin 
To H2N-Gly-Phe-Leu-Gly-coumarin (53, 2.0 mg, 3.64x1O-3 mmole) in DCM (0.5 mL, 3 
drops ofDMF for solubility) was added maleimido-caproic acid (67, 3.64x1O-3 mmole) and 
DCC (1.12 mg, 5.46x1O-3 rumole). TLC analysis (silica, 20% MeOHlEtOAc) after 20 
hours showed formation of a fluorescent spot (RFO.6, vanillin) more non-polar than the 
baseline starting material (53). After removal of solvent under vacuum the product was 
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dissolved in MeOH and purified by preparative HPLC (Shimadzu VP system, Phenomenex 
C18 column, 45% CH3CN/H20 (0.05% TFA)) with a retention time of 9.4 min (68, 1.04 
mg,38%). HRESIMS gave (MH+) 743.3424 (C39H47N609 required 743.3405). 
5.3.2 Thiolated-CV-N with 68 
To the thiolated-CV-N fOlmed in section 3.4.2.2 was added 68 (0.27 mg, 3.63xlO-4 mm01e) 
in DMF (20 ilL). After 2 hours the solution was concentrated under a flow of N2 and 
analysed by LCMS (Zorbax C3). The products eluted at 11.8 min representing thiolated-
CV-N with addition ofa single coumarin adduct (11,853 Da) and addition of two coumarin 
adducts (12,696 Da). 
5.4.1 Synthesis of Maleimido-Caproic-Gly-Phe-Leu-Gly-OH 
The method for SPPS of 69 was identical to that of 49 (section 4.3.1.2), but starting with 
0.118 meq. of Fmoc-Gly-resin. This required, in turn, 2 equiv. of each amino acid (0.237 
mmole), 2 equiv. of male imido caproic acid (67,50 mg, 0.237 mmole) with HBTU (90 mg, 
0.237 mmole), and 4 equiv. of DIPEA (93 ilL, 0.473 mmole) per coupling. Cleavage 
conditions and workup of the product was also identical to that of 69. The conect mass 
was noted by ESIMS analysis although analytical HPLC (Shimadzu VP system, 
Phenomenex C18 column, 60% MeOHlH20 (0.05% TFA)) indicated the presence of 
several minor impurities. Preparative HPLC using the same solvent mixture (Shimadzu 
LC-4A, Dynamax C18, 205 11111) purified the product (retention time 18 min, 8.2 mg). 
ESIMS (-ve mode, (MHn gave 584.24 Da (C29H3SNsOs required 584.28). IH NMR was 
recorded on the Unity 300. 
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maieimido-caproic-Gly-Phe-Leu-Gly-OH (69) 
IH NMR (CD30D) 80.92 (m, (HI5)3 or (HI6)3), 80.96 (m, (HI6)3 or (HI5)3), 8 1.13 (m, 
(H25)2), 8 1.34-1.55 (m, HI4), 8 1.34-1.55 (m, (H13)z), 8 1.34-1.55 (m, (H24)z), 8 1.34-
1.55 (m, (H26)2), 8 2.03 (m, (H23)z), 8 2.79 (m, HI7a), 8 2.99 (m, HI7b), 8 3.14 (m, 
(H27)2), 8 3.50-3.78(m, (Hll)i), 83.50-3.78 (m, (H2)2), 84.26 (m, H5), 8 4.45 (m, H8), 8 
6.61 (s, 2x H29), 8 7.07 (m, 2x HI9), 8 7.07 (m, 2x H20), 8 7.07 (m, H2I), amide protons 
were not observed. 
5.4.2 Synthesis of Maleimido-Caproic-Gly-Pbe-Leu-Gly-Toxin 
To 69 (1.07 mg, 1.83xlO,3 mrnoIe) in dry THF (1 rnL, 3 drops of dry DMF for dissolution) 
was added DCC (0.75 mg, 3.66xIO-3 rnmoIe) and NHS (0.42 mg, 3.66xlO-3 mmole) and 
the reaction left tmder argon. ESIMS analysis after 24 hours showed approximately 50% 
formation of the succinimidyl ester at which stage norhomohalichondrin B amine (28, I 
mg, 9 .16x 1 0-4 mmole) in CH3CN (1 00 ~) was added. ESIMS analysis after a total 
reaction time of 60 hours revealed complete disappearance of the toxin amine and 
formation of the desired product. Preparative HPLC (Shimadzu VP system, Phenomenex 
CI8 column, 25%-85% CH3CNIH20 over 20 min, 210 nm) purified the product (retention 
time 19.2 min) which was collected and dried. (71, 0.84 mg, 55%). HRESIMS gave 
(MNa2i+ 852.4125 (Cs9H122N6024Na2/2) required 852.4153). 
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5.5.1 Maleimide-Toxin Reaction with CV-N-Cys 
To CV-N-Cys (72, from LDDRD, 0.100 mg, 9.00xlO-6 mmole) in PBS buffer (274 j.lL) 
was added 71 (0.150 mg, 9.04xlO-5 mmo1e) in DMF (74 j.lL). LCMS analysis (Zorbax C3) 
after 24 hours indicated formation of approximately 15% product so the reaction was left 
for a further 24 hours at which time no perceivable increase in the yield was observed. 
Preparative HPLC (Shimadzu VP system, Zorbax C3 column, 20%-60% CH3CNIH20 
(0.001 % formic) over 20 min) separated the CV-N-Cys (retention time 9.5 min) from the 
CV-N-Cys-biolinker-toxin construct (retention time 12.4 min). LCMS data shown in 
Figure 5.S. 
5.5.2 Maleimide-Toxin Reaction with Thiolated-CV-N 
To the thiolated-CV-N (0.100 mg, 9.08xlO-6 mmole, in water) formed in section 3.4.2.3 
was added 71 (0.160 mg, 9.64xlO-5 mmole) in DMF (25 ilL). LCMS analysis after 90 min 
indicated the presence of both thiolated-CV-N and the male imide-toxin construct starting 
materials along with a small amount of product. The reaction was left for a further 24 
hours. LCMS analysis at this stage revealed no maleimide-toxin construct present so 
purification was by HPLC (Shimadzu VP system, Zorbax C3 column, 20%-60% 
CH3CN/H20 (0.001% fonnic) over 20 min). The CV-N-toxin eluted with a retention time 
of 12.9 min. LCMS data shown in Figure 5.9. 
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8.6 Work Described in Chapter 6 
Work in this chapter from sections' 6.3.1, 6.3.2 and 6.3.3 was carried out while a guest at 
the LDDRD, NCI, Frederick, Maryland, USA. 
ELISA and XTT assays were carried out as described in section 8.1 with the following 
modifications and changes described below. 
6.3.1 Initial ELISA Testing 
This ELISA was performed without the presence of gpl20 in the wells. The CV-N (15) or 
CV-N-conjugates were bound directly to the plate and the rest of the assay was 
accomplished as per the standard procedure. The response from the CV-N-conjugate 36 
was comparable to that of native CV-N (15) while 42 was much less effective at binding to 
gpl20 due to lack of protein material in the sample. 
Before addition of the substrate buffer the plates were read at 405 urn by the plate reader to 
ascertain if any contribution from the dye would interfere with the substrate-mediated 
colour change. The response from the samples was comparable to the background level of 
the B SA loaded cells therefore confinning no interference. As a side issue the plates were 
tested for an increasing fluorescence response as the concentration increased which was 
duly observed. 
6.3.2 ELISA Testing of and BODIPY CV-N-Conjugates 
The following data (Table 8.1) shows the volume 'and concentration of the CV-N-dye 
conjugates tested in the ELISA assay and the volume of sample used for the ELISA assay. 
The volunles for the ELISA assay were made up to 1,000 ilL with PBS to give standard 
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solutions at 5 ng/mL. These were subsequently diluted out for each well to give the 
amounts shown in Figure 6.2. 
Table 8.1 CV-N~dye conjugates for ELISA assay 
Samples Volume Concentration Volume for 
(mL) {J.lg/mL} ELlSA{~L} 
33 7.7 26.0 192 
34 5.0 40.0 125 
35 5.9 33.9 147 
36 6.2 32.3 154 
43 5.0 40.0 125 
44 7.0 28.6 175 
41 5.8 34.5 145 
1 
6.3.3 XTT Assay Testing of CV-N-Dye-Conjugates 
The same samples used above for the ELISA assay were also submitted for XTT assay 
analysis. 200 IJL aliquots of each were submitted at their respective concentrations and the 
ECso values obtained and scaled as below (Table 8.2). 
Table 8.2 CV-N~dye conjugate ECso values from XTT assay 
Samples Original EC50 High Test Corrected EC50 
{~g/mL} Cone. {~g/mL} (~g/mL) 
33 0.0015 1.73 0.0026 
34 0.0032 2.67 0.0085 
35 0.0024 2.26 0.0054 
36 0.0016 2.15 0.0034 
43 0.0024 2.67 0.0064 
44 0.0058 1.90 0.0110 
41 0.0390 2.30 0.0897 
42 0.6370 1.90 1.2133 
6.4.1 XTT Assay Testing of CV-N-Coumarin Conjugates 
Samples for this XTT assay were submitted at the same concentration as native CV~N (15, 
1.1 IJg/mL) providing ECso values in Table 6.2. 
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